Active agents for the treatment of metabolic disorders and non-alcoholic fatty liver disease and methods of use thereof - Patents.com
Acylated active agents are used to modulate metabolic markers and treat NAFLD and NASH, reducing liver enzymes and fibrosis, addressing the limitations of current treatments.
Patent Information
- Application Number
- JP2023184635
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-03
- Filing Date
- 2023-10-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-06-05
AI Technical Summary
There is a need for effective methods and compositions to manage metabolic disorders and treat non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), as current treatments like bariatric surgery and pharmacological interventions have limitations and risks.
The use of acylated active agents such as acylated catechin polyphenols, acylated carotenoids, acylated ellagic acid, and combinations of active agents like stilbenoids with ketone or preketone bodies, administered in compositions for modulating metabolic markers and treating NAFLD and NASH.
These agents effectively reduce liver enzymes like alanine and aspartate transaminase levels, decrease liver weight, and treat or reduce liver fibrosis, while improving metabolic markers in subjects with NAFLD and NASH.
Smart Images

Figure 0007592140000432 
Figure 0007592140000433 
Figure 0007592140000434
Abstract
Description
[Technical Field]
[0001] The present invention relates to compounds and methods of their medical use. [Background technology]
[0002] The increasing incidence of obesity has reached epidemic proportions in Western countries, and recently in developing countries as well. Obesity is associated with significant comorbidities, such as cardiovascular disease and type II diabetes. Bariatric surgery is a known treatment for obesity, but this treatment is associated with costs and risks. Pharmacological interventions are typically less effective and are often associated with adverse events.
[0003] Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease, affecting an estimated 12%–25% of people in the United States. The primary characteristic of NAFLD is the accumulation of fat (steatosis) in the liver. In NAFLD, fat accumulation is not associated with excessive alcohol consumption.
[0004] Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD. NASH is characterized by liver inflammation that can progress to scarring and irreversible liver damage. In its most severe form, NASH can progress to cirrhosis and liver failure.
[0005] There is a need for methods and compositions useful in managing metabolic disorders and / or treating NAFLD and NASH. Summary of the Invention [Means for solving the problem]
[0006] Generally, the present invention provides a method for treating a skin condition characterized by the inclusion of an acylated active agent (e.g., an acylated catechin polyphenol, an acylated carotenoid, an acylated ellagic acid, an acylated ellagic acid analog, an acylated ketone body or preketone body, an acylated stilbenoid, an acylated S-adenosyl-L-methionine, an acylated amino acid, an acylated bile acid, an acylated mesalamine, an acylated metformin, an acylated sugar, an acylated shikimic acid, an acylated vitamin, or an acylated hydroxybenzoic acid), a combination of active agents (e.g., a first agent is a stilbenoid, an acylated hydroxybenzoic acid ... and a combination of a ketone body, ...
[0007] In some embodiments, the present invention provides acylated active agents (e.g., acylated catechin polyphenols, acylated stilbenoids, acylated mesalamine, acylated sugars, acylated shikimic acid, and acylated hydroxybenzoic acids), combinations of active agents (e.g., stilbenoids and preketone bodies), compositions comprising them (e.g., in unit dosage forms), and methods of modulating metabolic markers in a subject or treating a metabolic disorder in a subject. In certain embodiments, the present invention provides acylated active agents (e.g., acylated stilbenoids, acylated carotenoids, acylated vitamins, acylated catechin polyphenols, acylated S-adenosyl-L-methionine, acylated bile acids, acylated amino acids, acylated metformin, acylated sugars, or acylated ketone bodies or preketone bodies), combinations of active agents (e.g., stilbenoids and preketone bodies), compositions comprising them (e.g., in unit dosage forms), and methods of modulating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) markers in a subject or treating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH) with or without fibrosis, fatty liver, or NASH with advanced fibrosis) in a subject.
[0008] In one aspect, a method is provided for modulating metabolic markers or non-alcoholic fatty liver disease markers in a subject in need thereof by administering an effective amount of an active agent to the subject. In a related aspect, a method is provided for treating metabolic disorders or non-alcoholic fatty liver disease in a subject in need thereof by administering an effective amount of an agent to the subject.
[0009] In some embodiments, the method is modulating a metabolic marker. In certain embodiments, the method is modulating a non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) marker.
[0010] In another embodiment, the method for adjusting metabolic markers or non-alcoholic fatty liver disease markers is provided in a subject who needs to do so by administering an effective amount of a first active agent and an effective amount of a second active agent to the subject.In another related embodiment, the method for treating metabolic disorders or non-alcoholic fatty liver disease is provided in a subject who needs to do so by administering an effective amount of a first active agent and an effective amount of a second active agent to the subject.
[0011] In some embodiments, the method is for treating a metabolic disorder. In certain embodiments, the method is for treating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis).
[0012] In some embodiments, the metabolic marker is for an obesity disorder, hi other embodiments, the metabolic marker is for type II diabetes, prediabetes, insulin resistance, metabolic syndrome, hypercholesterolemia, atherosclerosis, or hyperlipidemia.
[0013] In certain embodiments, the metabolic disorder is an obesity disorder. In certain embodiments, the metabolic disorder is type II diabetes, prediabetes, insulin resistance, metabolic syndrome, hypercholesterolemia, or hyperlipidemia.
[0014] In some embodiments, the total fat percentage, cellular fat, body mass index, weight gain rate, abdominal fat mass, white fat to brown fat ratio, level of lipogenesis, or level of fat storage is reduced after the administering step.
[0015] In certain embodiments, the subject is overweight. In further embodiments, the subject suffers from obesity. In still further embodiments, the subject suffers from severe obesity, morbid obesity, or super-obesity. In still further embodiments, the subject has a weight of at least 25 kg / m 2 , at least 28 kg / m 2 , at least 30 kg / m 2 , at least 35 kg / m 2, or at least 45 kg / m 2 He has a body mass index of .
[0016] In other embodiments, insulin, GLP-1, or PYY levels are increased after the administering step. In yet other embodiments, blood glucose or hemoglobin A1c levels are reduced after the administering step. In yet other embodiments, glucose tolerance is increased after the administering step.
[0017] In some embodiments, the method reduces the level of alanine transaminase in the subject's blood by at least 1% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more, e.g., up to 100%) relative to the level of alanine transaminase in the subject's blood before the administering step or relative to a control. In other embodiments, the method reduces the level of aspartate transaminase in the subject's blood by at least 1% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more, e.g., up to 100%) relative to the level of aspartate transaminase in the subject's blood before the administering step or relative to a control. In yet other embodiments, the method reduces the subject's liver weight by at least 1% relative to the subject's liver weight before the administering step or relative to a control. In further embodiments, the method treats or reduces liver fibrosis.
[0018] In yet a further embodiment, the subject has non-alcoholic fatty liver disease (e.g., the subject is diagnosed with non-alcoholic fatty liver disease). In yet a further embodiment, the subject has non-alcoholic steatohepatitis (e.g., the subject is diagnosed with non-alcoholic steatohepatitis).
[0019] In certain embodiments, the subject is a human. In certain embodiments, the subject is a cat or dog.
[0020] In some embodiments, the acylated active agent is an acylated stilbenoid, an acylated carotenoid, an acylated vitamin, an acylated catechin polyphenol, an acylated S-adenosyl-L-methionine, an acylated bile acid, an acylated amino acid, an acylated metformin, an acylated sugar, or an acylated ketone body or preketone body.
[0021] In some embodiments, the acylated active agent is an acylated stilbenoid. In further embodiments, the acylated stilbenoid is resveratrol, which has one, two, or three hydroxyl groups independently substituted with a group containing a fatty acid acyl, or a ketone or preketone body.
[0022] In yet a further embodiment, the acylated active agent is an acylated carotenoid. In yet a further embodiment, the acylated carotenoid is astaxanthin, having one or two hydroxyl groups independently substituted with a group comprising a fatty acid acyl, or a ketone or preketone body.
[0023] In certain embodiments, the acylated active agent is an acylated vitamin. In certain embodiments, the acylated vitamin is a tocopherol or tocotrienol having a hydroxyl group substituted with a fatty acid acyl group, or a group containing ketone bodies or preketone bodies. In other embodiments, the acylated vitamin is ascorbic acid having 1, 2, 3, or 4 hydroxyl groups independently substituted with a fatty acid acyl group, or a group containing ketone bodies or preketone bodies. In still other embodiments, the acylated vitamin is vitamin D having a hydroxyl group substituted with a fatty acid acyl group, or a group containing ketone bodies or preketone bodies. In still other embodiments, vitamin D is cholecalciferol.
[0024] In some embodiments, the active agent is acylated catechin polyphenol, acylated stilbenoid, acylated mesalamine, acylated sugar, acylated hydroxybenzoic acid or acylated shikimic acid.In certain embodiments, after oral administration to subject, the active agent can be hydrolyzed in the gastrointestinal tract of subject.In certain embodiments, the active agent releases at least one fatty acid.In further embodiments, the active agent is orally administered to subject.
[0025] In certain embodiments, the active agent is acylated mesalamine. In some embodiments, the active agent is acylated catechin polyphenol. In still further embodiments, the active agent is acylated stilbenoid. In further embodiments, the active agent is acylated hydroxybenzoic acid. In still further embodiments, the active agent is an acylated sugar. In certain embodiments, the active agent is acylated shikimic acid.
[0026] In other embodiments, the acylated stilbenoid, acylated catechin polyphenol, acylated mesalamine, acylated sugar, acylated hydroxybenzoic acid, or acylated shikimic acid comprises a fatty acid-containing group. In still other embodiments, the fatty acid-containing group is a monosaccharide (e.g., arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, and rhamnose) with one or more hydroxyl groups replaced with a fatty acid acyl group, a glucosinolate, a sugar alcohol, or a sugar acid. In certain embodiments, the fatty acid-containing group is a monosaccharide (e.g., arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, and rhamnose) with one or more hydroxyl groups replaced with a fatty acid acyl group, a sugar alcohol, or a sugar acid. In still other embodiments, the monosaccharide is L-arabinose, D-xylose, fructose, galactose, D-glucose, D-ribose, D-tagatose, L-fucose, or L-rhamnose (e.g., the monosaccharide is D-xylose). In further embodiments, the fatty acid-containing group is fatty acyl. In still further embodiments, the fatty acid is a short-chain fatty acid (e.g., acetyl, propionyl, or butyryl). In further embodiments, the short-chain fatty acid is acetyl. In certain embodiments, the short-chain fatty acid is butyryl.
[0027] In certain embodiments, the active agent (e.g., an acylated stilbenoid) comprises at least one group comprising a ketone body or a preketone body. In some embodiments, the active agent (e.g., an acylated stilbenoid) comprises at least one group comprising a preketone body. In further embodiments, the group comprising a ketone body or a preketone body is a group comprising a ketone body. In yet further embodiments, the group comprising a ketone body or a preketone body is a group comprising a preketone body.
[0028] In certain embodiments, the acylated active agent is an acylated catechin polyphenol. In certain embodiments, the acylated catechin polyphenol is epigallocatechin gallate, which has 1 to 8 hydroxyl groups independently substituted with a group including a fatty acid acyl, ketone body, or preketone body. In further embodiments, the acylated catechin polyphenol is silibinin, which has 1 to 5 hydroxyl groups independently substituted with a group including a fatty acid acyl, ketone body, or preketone body. In yet further embodiments, the acylated catechin polyphenol is a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof; During the ceremony, [ka] is a carbon-carbon single bond or a carbon-carbon double bond, Q is —CH— or —C(O)—; Each R 1 and each R 3 are independently H, halogen, or -OR A , phosphate, or sulfate, R 2 is H or -OR A and Each R A are independently H, optionally substituted alkyl, a monosaccharide, a sugar acid, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, phosphate, and sulfate; m is 0, 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4.
[0029] In further embodiments, each of n and m is independently 0, 1, 2, 3, or 4. In some embodiments, at least one R 1 -OR A In still further embodiments, each R A are independently H, optionally substituted alkyl, a monosaccharide, a sugar acid, a fatty acid containing group, a ketone or preketone body containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, a fatty acid containing group, a ketone or preketone body containing group, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, phosphate, and sulfate. A is a group that includes a fatty acid. In certain embodiments, at least one R A is a group containing a ketone or preketone body. A is benzoyl substituted with at least one group comprising a fatty acid. In a further embodiment, at least one R A is benzoyl substituted with at least one group comprising a ketone or preketone. A is a benzoyl substituted with at least one group that includes an amino acid metabolite.
[0030] In some embodiments, at least one R 1 -OR A and R A is a group containing a fatty acid or the compound contains at least one group containing a ketone body or a preketone body.
[0031] In certain embodiments, the acylated catechin polyphenol is a compound of formula (Ia). [ka]
[0032] In certain embodiments, the acylated catechin polyphenol is a compound of formula (Ib). [ka]
[0033] In a further embodiment, the acylated catechin polyphenol is a compound of formula (Ic). [ka]
[0034] In still further embodiments, the acylated catechin polyphenol is a compound of formula (Id). [ka]
[0035] In certain embodiments, the acylated catechin polyphenol is a compound of formula (If). [ka]
[0036] In still further embodiments, n is 2. In certain embodiments, m is 1. In certain embodiments, m is 2. In some embodiments, m is 3. In certain embodiments, each R 1 are independently -OR A In certain embodiments, each R 3 are independently H or -OR A In a further embodiment, R 2 is H or -OR A In still further embodiments, each R A is independently H, an optionally substituted alkyl, a group containing a fatty acid, or a group containing a ketone or preketone body.
[0037] In other embodiments, the acylated catechin polyphenol is a compound of formula (Ie): [ka] or a pharmaceutically acceptable salt thereof; In the formula, R 1A and R 1B each independently represents R 1 is as defined for R 3A , R 3B , and R 3C each independently represents R 3 is as defined for
[0038] In yet another embodiment, R 1A and R 1B each independently represents -OR A In yet another embodiment, R 3A , R 3B , and R 3C each independently represents -H, a halogen, or -OR A In some embodiments, R 2 is a group of the formula: [ka] where p is 1, 2, 3, or 4, and each R 4 are independently selected from the group consisting of H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone body, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, a phosphate, and a sulfate.
[0039] In certain embodiments, p is 3. In certain embodiments, each R 4 is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone, or an optionally substituted alkoxy. 2 is a group of the formula: [ka] R 4A , R 4B , and R 4C Each of R 4 is as defined for
[0040] In a further embodiment, R 4A , R 4B、 and R 4C is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone, or an optionally substituted alkoxy. A is independently H, optionally substituted alkyl, fatty acyl, or an optionally acylated monosaccharide.
[0041] In yet further embodiments, the active agent (e.g., acylated catechin polyphenol, acylated carotenoid, acylated ellagic acid, acylated ellagic acid analog, acylated ketone body or preketone body, acylated stilbenoid, acylated S-adenosyl-L-methionine, acylated amino acid, acylated bile acid, acylated mesalamine, acylated metformin, acylated sugar, acylated shikimic acid, acylated vitamin, or acylated hydroxybenzoic acid) comprises at least one fatty acyl (e.g., short-chain fatty acyl or medium-chain fatty acyl). In further embodiments, the active agent is an acylated catechin polyphenol, acylated stilbenoid, acylated mesalamine, acylated hydroxybenzoic acid, acylated sugar, or acylated shikimic acid. In certain embodiments, the at least one fatty acyl is a short-chain fatty acyl. In some embodiments, the short-chain fatty acyl is acetyl, propionyl, or butyryl. In certain embodiments, the short-chain fatty acyl is acetyl. In certain embodiments, the short-chain fatty acyl is butyryl. In further embodiments, the short-chain fatty acyl is propionyl. In still further embodiments, at least one fatty acyl is a medium-chain fatty acyl (e.g., octanoyl).
[0042] In some embodiments, the active agent is an acylated sugar (e.g., an acylated sugar comprising a monosaccharide core). In certain embodiments, the monosaccharide core is xylose, arabinose, rhamnose, fucose, glucosamine, tagatose, or ribose. In certain embodiments, the active agent is a monosaccharide having one or more hydroxyl groups substituted with alkyl, acyl, fatty acid-containing groups, ketone or preketone body-containing groups, or amino acid metabolite-containing groups.
[0043] In certain embodiments, the active agent is an acylated hydroxybenzoic acid (eg, an acylated hydroxybenzoic acid that includes gallic acid).
[0044] In some embodiments, the first active agent is a catechin polyphenol, a stilbenoid, a monosaccharide, a hydroxybenzoic acid, a shikimic acid, or mesalamine, and the second active agent is a ketone body or a preketone body. In certain embodiments, the first active agent is orally administered to the subject. In certain embodiments, the second active agent is orally administered to the subject. In further embodiments, the first and second active agents are administered separately to the subject (e.g., the first and second active agents are administered to the subject within 24 hours of each other). In still further embodiments, the first and second active agents are administered simultaneously to the subject (e.g., the first and second active agents are administered to the subject in the same unit dosage form). In other embodiments, the first active agent is a stilbenoid (e.g., resveratrol). In still other embodiments, the second active agent is a ketone body. In still other embodiments, the second active agent is a preketone body. In some embodiments, the molar ratio of the first active agent to the second active agent is from 1:1 to 1:10.
[0045] In another aspect, the present invention provides a composition (e.g., a pharmaceutical composition, a nutritional supplement composition, a food, a food additive, or a dietary supplement) comprising an active agent. In some embodiments, the composition is provided in a unit dosage form. In other embodiments, the active agent is an acylated catechin polyphenol, an acylated stilbenoid, an acylated mesalamine, an acylated hydroxybenzoic acid, an acylated shikimic acid, or an acylated sugar. In still other embodiments, the active agent is a combination of a first active agent and a second active agent, wherein the first active agent is a stilbenoid, a catechin polyphenol, a hydroxybenzoic acid, a shikimic acid, a monosaccharide, or mesalamine, and the second active agent is a ketone body or a preketone body.
[0046] In still other embodiments, the unit dosage form contains at least 0.5 g (e.g., at least 0.7 g, at least 1 g, or at least 2 g) of active pharmaceutical ingredient. In certain embodiments, the unit dosage form contains 10 g or less (e.g., 9 g or less, 8 g or less, 7 g or less, 6 g or less, 5 g or less) of active pharmaceutical ingredient. In certain embodiments, the unit dosage form contains 0.5 to 10 g (e.g., 0.7 to 10 g, 1 to 10 g, 2 to 10 g, 0.5 to 9 g, 0.7 to 9 g, 1 to 9 g, 2 to 9 g, 0.5 to 8 g, 0.7 to 8 g, 1 to 8 g, 2 to 8 g, 0.5 to 7 g, 0.7 to 7 g, 1 to 7 g, 2 to 7 g, 0.5 to 6 g, 0.7 to 6 g, 1 to 6 g, 2 to 6 g, 0.5 to 5 g, 0.7 to 5 g, 1 to 10 g, or 2 to 5 g) of active pharmaceutical ingredient.
[0047] In some embodiments, the unit dosage form is a pharmaceutical unit dosage form. In further embodiments, the unit dosage form is a nutritional supplement dosage form. In yet further embodiments, the unit dosage form is a single serving of food.
[0048] In still further embodiments, the active agent is an acylated catechin polyphenol. In some embodiments, the active agent is an acylated stilbenoid (e.g., acylated resveratrol). In certain embodiments, the active agent is an acylated mesalamine. In certain embodiments, the active agent is an acylated hydroxybenzoic acid (e.g., an acylated hydroxybenzoic acid containing gallic acid). In further embodiments, the active agent is an acylated sugar (e.g., an acylated sugar containing a monosaccharide core, such as xylose, arabinose, rhamnose, fucose, glucosamine, tagatose, or ribose (e.g., xylose, arabinose, rhamnose, fucose, glucosamine, or tagatose)). In still further embodiments, the active agent is an acylated shikimic acid.
[0049] In other embodiments, the acylated stilbenoid, acylated catechin polyphenol, or acylated mesalamine comprises a group containing a fatty acid. In still other embodiments, the group containing a fatty acid is a monosaccharide (e.g., arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, and rhamnose) with one or more hydroxyl groups substituted with a fatty acid acyl group, a glucosinolate, a sugar alcohol, or a sugar acid. In certain embodiments, the group containing a fatty acid is a monosaccharide (e.g., arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, and rhamnose) with one or more hydroxyl groups substituted with a fatty acid acyl group, a sugar alcohol, or a sugar acid. In still other embodiments, the monosaccharide is L-arabinose, D-xylose, fructose, galactose, D-glucose, D-ribose, D-tagatose, L-fucose, or L-rhamnose (e.g., the monosaccharide is D-xylose). In further embodiments, the fatty acid-containing group is fatty acyl. In still further embodiments, the fatty acid is a short-chain fatty acid (e.g., acetyl, propionyl, or butyryl). In further embodiments, the short-chain fatty acid is acetyl. In certain embodiments, the short-chain fatty acid is butyryl.
[0050] In certain embodiments, the active agent (e.g., an acylated stilbenoid) comprises at least one group comprising a ketone body or a preketone body. In some embodiments, the active agent (e.g., an acylated stilbenoid) comprises at least one group comprising a preketone body. In further embodiments, the group comprising a ketone body or a preketone body is a group comprising a ketone body. In yet further embodiments, the group comprising a ketone body or a preketone body is a group comprising a preketone body.
[0051] In still further embodiments, the acylated catechin polyphenol is a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof; During the ceremony, [ka] is a carbon-carbon single bond or a carbon-carbon double bond, Q is —CH— or —C(O)—; Each R 1 and each R 3 are independently H, halogen, or -OR A , phosphate, or sulfate, R 2 is H or -OR A and Each R A are independently H, optionally substituted alkyl, a monosaccharide, a sugar acid, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, phosphate, and sulfate; m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, or 4.
[0052] In some embodiments, at least one R 1 -OR A and R A is a group comprising a fatty acid, a group comprising a ketone body or a preketone body, or a group comprising an amino acid metabolite, or the compound comprises at least one group comprising a fatty acid, a group comprising a ketone body or a preketone body, or a group comprising an amino acid metabolite. 1 -OR A and R A is a group containing a fatty acid or the compound contains at least one group containing a ketone body or a preketone body.
[0053] In certain embodiments, the acylated catechin polyphenol is a compound of formula (Ia). [ka]
[0054] In certain embodiments, the acylated catechin polyphenol is a compound of formula (Ib). [ka]
[0055] In a further embodiment, the acylated catechin polyphenol is a compound of formula (Ic). [ka]
[0056] In still further embodiments, the acylated catechin polyphenol is a compound of formula (Id). [ka]
[0057] In certain embodiments, the acylated catechin polyphenol is a compound of formula (If). [ka]
[0058] In still further embodiments, n is 2. In certain embodiments, m is 1. In certain embodiments, m is 2. In some embodiments, m is 3. In certain embodiments, each R 1 are independently -OR A In certain embodiments, each R 3 are independently H or -OR A In a further embodiment, R 2 is H or -OR A In still further embodiments, each R A is independently H, an optionally substituted alkyl, a group containing a fatty acid, or a group containing a ketone or preketone body.
[0059] In other embodiments, the acylated catechin polyphenol is a compound of formula (Ie): [ka] or a pharmaceutically acceptable salt thereof; In the formula, R 1A and R 1B each independently represents R 1 is as defined for R 3A , R 3B , and R 3C each independently represents R 3 is as defined for
[0060] In yet another embodiment, R 1A and R 1B each independently represents -OR A In yet another embodiment, R 3A , R 3B , and R 3C each independently represents -H, a halogen, or -ORA In some embodiments, R 2 is a group of the formula: [ka] where p is 1, 2, 3, or 4, and each R 4 are independently selected from the group consisting of H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone body, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, a phosphate, and a sulfate.
[0061] In certain embodiments, p is 3. In certain embodiments, each R 4 is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone, or an optionally substituted alkoxy. 2 is a group of the formula: [ka] R 4A , R 4B , and R 4C Each of R 4 is as defined for
[0062] In a further embodiment, R 4A , R 4B、 and R 4C is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone or preketone, or an optionally substituted alkoxy. A is independently H, optionally substituted alkyl, fatty acyl, or an optionally acylated monosaccharide.
[0063] In yet further embodiments, the acylated catechin polyphenol comprises at least one fatty acyl (e.g., short-chain fatty acyl). In some embodiments, the short-chain fatty acyl is acetyl, propionyl, or butyryl. In certain embodiments, the short-chain fatty acyl is acetyl. In certain embodiments, the short-chain fatty acyl is butyryl.
[0064] In some embodiments, the active agent is a combination of a stilbenoid or catechin polyphenol and a ketone body or a preketone body. In certain embodiments, the molar ratio of the stilbenoid or catechin polyphenol to the ketone body or a preketone body is 1:1 to 1:10. In certain embodiments, the active agent is a combination of a stilbenoid and a ketone body or a preketone body. In further embodiments, the active agent is a combination of a stilbenoid and a preketone body. In still further embodiments, the stilbenoid is resveratrol.
[0065] In another aspect, the present invention provides an acylated stilbenoid of the structure: [ka] During the ceremony, n is 1, 2, 3, or 4; m is 1, 2, 3, or 4; Each R 1 is independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; Each R 2 is independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; each fatty acid-containing group is independently a monosaccharide having 1, 2, 3, or 4 hydroxyls substituted with a fatty acyl; However, at least one R 1 or at least one R 2is a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite.
[0066] In certain embodiments, n is 1. In certain embodiments, m is 2. In further embodiments, the acylated stilbenoid is a compound of the following structure: [ka]
[0067] In still further embodiments, at least one R 1 is a group comprising a fatty acid. In still further particular embodiments, at least one R 1 is a group containing a ketone or preketone body. In certain embodiments, at least one R 1 is a group that includes an amino acid metabolite. In certain embodiments, at least one R 2 is a group that comprises a fatty acid. In some embodiments, at least one R 2 is a group containing a ketone or preketone body. In a further embodiment, at least one R 2 is a group containing amino acid metabolites.
[0068] In yet another aspect, the present invention provides a compound and a composition (for example, a pharmaceutical composition or a nutritional supplement composition) comprising the compound.The compound of the present invention is the compound described herein, for example, acylated catechin polyphenol, acylated carotenoid, acylated ellagic acid, acylated ellagic acid analog, acylated ketone body or preketone body, acylated stilbenoid, acylated S-adenosyl-L-methionine, acylated amino acid, acylated bile acid, acylated mesalamine, acylated metformin, acylated sugar, acylated shikimic acid, acylated vitamin, or acylated hydroxybenzoic acid.
[0069] definition The term "active agent," as used herein, refers to an acylated active agent, a catechin polyphenol, a stilbenoid, a ketone body, a preketone body, or a fatty acid.
[0070] The term "combination of active agents" as used herein refers to a combination regimen comprising a first active agent and a second active agent. The first active agent can be, for example, catechin polyphenols, stilbenoids, mesalamine, hydroxybenzoic acid, shikimic acid, or monosaccharides. The second active agent can be, for example, ketone bodies or preketone bodies. Non-limiting examples of combinations of active agents include stilbenoids (e.g., resveratrol) and preketone bodies (e.g., 1,3-butanediol). The first and second active agents can be administered together (e.g., in the same dosage form) or separately (e.g., within 24 hours of each other).
[0071] The term "acyl," as used herein, refers to a chemical substituent of formula -C(O)-R, where R is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl. Optionally substituted acyl is acyl optionally substituted as described herein for each group R. Furthermore, acyl can be a chemical substituent selected from the group consisting of a fatty acid-containing group, a ketone body or preketone body-containing group, an amino acid metabolite-containing group, mesalamine acyl, and retinoic acid acyl. Non-limiting examples of acyl include fatty acid acyl (e.g., short-chain fatty acid acyl (e.g., acetyl)), benzoyl (e.g., optionally substituted benzoyl), ketone body acyl, preketone body acyl, sugar acid acyl (e.g., aldonyl, uronyl, urosonyl), amino acid acyl, and amino acid metabolite acyl.
[0072] The term "acylated active agent," as used herein, refers to a compound containing two or more agents linked via ester bond(s), amide bond(s), carbonate linker(s), carbamate linker(s), and / or glycosidic bond(s). Non-limiting examples of acylated active agents include acylated catechin polyphenols, acylated carotenoids, acylated ellagic acid, acylated ellagic acid analogs, acylated ketone or preketone bodies, acylated stilbenoids, acylated S-adenosyl-L-methionine, acylated amino acids, acylated bile acids, acylated mesalamine, acylated metformin, acylated shikimic acid, acylated sugars, acylated vitamins, or acylated hydroxybenzoic acids.
[0073] The term "acylated S-adenosyl-L-methionine," as used herein, refers to S-adenosyl-L-methionine in which at least one hydroxyl group has been replaced with the substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a group comprising a fatty acid, a group comprising a ketone body or preketone body, and a group comprising an amino acid metabolite, provided that at least one R is a group comprising a fatty acid, a group comprising a ketone body or preketone body, or a group comprising an amino acid metabolite.
[0074] The term "acylated amino acid," as used herein, refers to an amino acid in which at least one alcohol hydroxyl group, if present, or amino group is replaced with a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite. Non-limiting examples of acylated amino acids include L-alanine, which has an amino group replaced with a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite.
[0075] The term "acylated bile acid," as used herein, refers to a bile acid in which at least one hydroxyl group has been replaced with the substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a fatty acid-containing group, a ketone or preketone body-containing group, and an amino acid metabolite-containing group, provided that at least one R is a fatty acid-containing group, a ketone or preketone body-containing group, or an amino acid metabolite-containing group. Non-limiting examples of acylated bile acids include ursodeoxycholic acid or obeticholic acid, which have one or two alcohol hydroxyl groups independently substituted with acyl, alkyl, a ketone or preketone body-containing group, or an amino acid metabolite-containing group, provided that at least one hydroxyl group is replaced with a fatty acid-containing group, a ketone or preketone body-containing group, or an amino acid metabolite-containing group.
[0076] The term "acylated carotenoid," as used herein, refers to a carotenoid in which at least one hydroxyl group has been replaced with the substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a fatty acid-containing group, a ketone or preketone body-containing group, and an amino acid metabolite-containing group, provided that at least one R is a ketone or preketone body-containing group or an amino acid metabolite-containing group. Non-limiting examples of acylated carotenoids include astaxanthin, which has one or both hydroxyl groups independently replaced with an acyl, alkyl, a ketone or preketone body-containing group, or an amino acid metabolite-containing group, provided that at least one hydroxyl is replaced with a fatty acid-containing group, a ketone or preketone body-containing group, or an amino acid metabolite-containing group.
[0077] The term "acylated catechin polyphenols" as used herein refers to substituted compounds having a core of formula (A): [ka] or a multimer thereof, or a salt thereof, wherein the substituents are independently -OR A , -OCOO-R A , -NHR B , oxo, halogen, optionally substituted C 1-20 Alkyl, optionally substituted C 2-20 Alkenyl, optionally substituted thioalkyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfenyl, optionally substituted alkylsulfinyl, optionally substituted thioaryl, optionally substituted arylthioalkyl, optionally substituted thioalkenyl, dialkylamino, sulfate, phosphate, ascorbic acid, optionally substituted heterocyclyl, nitro, amino acid, C of amino acid 1-6 esters, optionally acylated monosaccharides, and optionally acylated sugar acids, and each R A are independently H, optionally substituted alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, a group containing an amino acid metabolite, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxyl, halogen, a group containing a fatty acid, a group containing a ketone body or preketone body, a group containing an amino acid metabolite, optionally substituted alkoxy, and optionally substituted alkyl; R B is independently H or optionally substituted alkyl; the carbon-carbon bond connecting carbon 2 and carbon 3 in formula (A) is a single bond or a double bond; The multimer comprises a total of two or three cores of formula (A), each core independently substituted as described above; The two adjacent centers in the core (A) are groups -(O) q -L 1 -L 2 -, where q is 0 or 1, and L 1is an optionally substituted alkylene, an optionally substituted alkenylene, or an optionally substituted heterocyclylene; L 2 is a covalent bond, an optionally substituted heterocyclylene, or an optionally substituted cycloalkylene; However, at least one of the 5th, 6th, 7th, and 8th positions must be -OR. A where R A is a fatty acid-containing group, a ketone or preketone body-containing group, an amino acid metabolite-containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxyl, halogen, a fatty acid-containing group, a ketone or preketone body-containing group, optionally substituted alkoxy, and optionally substituted alkyl; The replacement compound is provided that it contains at least one fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group.
[0078] The term "acylated catechin polyphenol" also refers to a catechin polyphenol in which at least one hydroxyl group is independently replaced with a substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a fatty acid-containing group, a ketone or preketone body-containing group, and an amino acid metabolite-containing group, provided that at least one R is a fatty acid-containing group, a ketone or preketone body-containing group, or an amino acid metabolite-containing group. Non-limiting examples of acylated catechin polyphenols include epigallocatechin gallate, which has 1 to 8 hydroxyl groups independently substituted with acyl, alkyl, a fatty acid-containing group, or a ketone or preketone body-containing group, provided that at least one hydroxyl is replaced with a fatty acid-containing group or a ketone or preketone body-containing group. For example, an acylated catechin polyphenol can be a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, [ka] is a carbon-carbon single bond or a carbon-carbon double bond, Q is —CH— or —C(O)—; Each R 1 and each R 3 are independently H, halogen, or -OR A , phosphate, or sulfate, R 2 is H or -OR A and Each R A are independently H, optionally substituted alkyl, a monosaccharide, a sugar acid, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, phosphate, and sulfate; Each of n and m is independently 0, 1, 2, 3, or 4.
[0079] The term "acylated ellagic acid" as used herein refers to a compound of the following structure: [ka] or, or a salt thereof, In the formula, each R A are independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, and each R B are independently H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, provided that at least one R A and / or at least one RB is, if present, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite.
[0080] The term "acylated ellagic acid analogs," as used herein, refers to compounds of the following structure: [ka] or a salt thereof, During the ceremony, R 2 , R 3 , and R 4 each independently represents H or -OR A and R 6 is H or -(CO)-R 5B and R 1A is H or -OR A and R 5A is -OH or -OR B or R 1A and R 5A combine to form -O-, R 1B is H or -OR A and R 5B is absent, -OH, or -OR B or R 1B and R 5B combine to form -O-, Each R A are independently H, O protecting groups, alkyl, acyl, fatty acid containing groups, ketone body or preketone body containing groups, or amino acid metabolite containing groups; Each R B are independently H, O protecting groups, alkyl, fatty acid-containing groups, ketone or preketone body-containing groups, or amino acid metabolite-containing groups; However, at least one R A and / or at least one R Bis a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite.
[0081] The term "acylated hydroxybenzoic acid" as used herein refers to a compound of the following formula: [ka] or a salt thereof, During the ceremony, n is 1, 2, or 3; Each R 1 is independently H, acyl, alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; R 2 is H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, However, the compound must contain at least one fatty acid-containing group, ketone body or preketone body-containing group, or amino acid metabolite-containing group. Non-limiting examples of acylated hydroxybenzoic acids include gallic acid in which one, two, or three of the phenolic hydroxyls are independently replaced with a group containing a fatty acid, a group containing a ketone or preketone body, or a group containing an amino acid metabolite.
[0082] The term "acylated mesalamine," as used herein, refers to mesalamine in which one H in one or more of -NH, -OH, or -COOH is replaced with acyl, a fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group, provided that the acylated mesalamine contains at least one fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group. In some embodiments, the acylated mesalamine is a compound of formula (II): [ka] During the ceremony, R1 is H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, R 2 is H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, Each R 3 are independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite, or both R 3 The groups combine to form: [ka]
[0083] Acylated mesalamine contains at least one fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group.
[0084] The term "acylated metformin," as used herein, refers to metformin in which at least one nitrogen is substituted with an acyl, alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite, provided that at least one R is a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite.
[0085] The term "acylated shikimic acid" as used herein refers to a compound of the following formula: [ka] or a salt thereof, During the ceremony, Each R 1 is independently H, acyl, alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; R 2 is a group containing H, alkyl, or fatty acid, However, the compound must contain at least one fatty acid-containing group, ketone body or preketone body-containing group, or amino acid metabolite-containing group.
[0086] The term "acylated stilbenoid," as used herein, refers to a stilbenoid in which one, two, three, four, or five hydroxyl groups have been replaced with the substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a group comprising a fatty acid, a group comprising a ketone body or preketone body, or a group comprising an amino acid metabolite, provided that at least one R is a group comprising a fatty acid, a group comprising a ketone body or preketone body, or a group comprising an amino acid metabolite.
[0087] The term "acylated sugar" as used herein refers to a monosaccharide or glucosinolate having one or more hydroxyls substituted with alkyl, acyl, fatty acid-containing groups, ketone or preketone body-containing groups, or amino acid metabolite-containing groups. A monosaccharide-based acylated sugar is an acylated monosaccharide. A glucosinolate-based acylated sugar is an acylated glucosinolate. Preferably, the acylated sugar is an acylated monosaccharide. The monosaccharide is present in the form of a pyranose or furanose. Preferably, the monosaccharide is present in the form of a pyranose. The monosaccharide may be an aldose or ketose. Non-limiting examples of monosaccharides are arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, glucosamine, and rhamnose. In some embodiments, the monosaccharide is L-arabinose, D-xylose, fructose, galactose, D-glucose, D-ribose, D-tagatose, L-fucose, or L-rhamnose. Preferably, the monosaccharide is xylose, arabinose, rhamnose, fucose, glucosamine, or tagatose. The monosaccharide may contain an anomeric carbon bonded to -OR, where R is H, alkyl, acyl, or a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite.
[0088] The term "acylated vitamin," as used herein, refers to a vitamin in which at least one hydroxyl is independently replaced with a substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a group comprising a fatty acid, a group comprising a ketone or preketone body, and a group comprising an amino acid metabolite, provided that at least one R is a group comprising a fatty acid or a group comprising a ketone or preketone body. Non-limiting examples of acylated vitamins include tocopherols (e.g., α-tocopherol, β-tocopherol, γ-tocopherol, or δ-tocopherol), tocotrienols, or vitamin D (e.g., cholecalciferol) having a hydroxyl replaced with a group comprising a fatty acid, a group comprising a ketone or preketone body, or a group comprising an amino acid metabolite. A non-limiting example of an acylated vitamin is ascorbic acid having 1, 2, 3, or 4 hydroxyl groups substituted with acyl, alkyl, fatty acid-containing groups, and ketone or preketone body-containing groups, provided that at least one R is a fatty acid-containing group, a ketone or preketone body-containing group, or an amino acid metabolite-containing group.
[0089] The term "acyloxy," as used herein, represents a chemical substituent of formula -OR, where R is acyl. An optionally substituted acyloxy is an acyloxy optionally substituted as described herein for acyl.
[0090] The term "alcohol oxygen atom," as used herein, refers to an alcohol oxygen atom in which one valence is attached to a first carbon atom and another valence is attached to a second carbon atom, and the first carbon atom is not sp 3 The hybridized carbon atom is the sp carbon of the carbonyl group. 3 -hybridized carbon atom or sp 2 - is a hybridized carbon atom.
[0091] The term "aldonyl," as used herein, refers to a monovalent substituent that is an aldonic acid in which a carboxylate hydroxyl has been replaced in its valence.
[0092] The term "alkanoyl," as used herein, refers to a chemical substituent of formula -C(O)-R, where R is alkyl. An optionally substituted alkanoyl is an alkanoyl optionally substituted as described herein for alkyl.
[0093] The term "alkoxy" as used herein refers to a chemical substituent of formula -OR, where R is, unless otherwise specified, C 1-6 An optionally substituted alkoxy is an alkoxy group optionally substituted as defined herein for alkyl.
[0094] The term "alkenyl," as used herein, represents an acyclic monovalent, straight- or branched-chain hydrocarbon group containing one, two, or three carbon-carbon double bonds. When unsubstituted, an alkenyl has 2 to 22 carbons, unless otherwise specified. In certain preferred embodiments, when unsubstituted, an alkenyl has 2 to 12 carbon atoms (e.g., 1 to 8 carbons). Non-limiting examples of alkenyl groups include ethenyl, prop-1-enyl, prop-2-enyl, 1-methylethenyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylprop-1-enyl, 2-methylprop-1-enyl, and 1-methylprop-2-enyl. Alkenyl groups can be optionally substituted as defined herein for alkyl.
[0095] The term "alkenylene," as used herein, refers to a straight or branched chain alkenyl group in which one hydrogen has been removed, thereby making the group divalent. Non-limiting examples of alkenylene groups include ethene-1,1-diyl, ethene-1,2-diyl, prop-1-ene-1,1-diyl, prop-2-ene-1,1-diyl, prop-1-ene-1,2-diyl, prop-1-ene-1,3-diyl, prop-2-ene-1,1-diyl, prop-2-ene-1,2-diyl, but-1-ene-1,1-diyl, but-1-ene-1,2-diyl, but-1-ene-1,3-diyl, but-1-ene-1,4-diyl, but-2-ene-1,1-diyl, but-2-ene-1,2-diyl, but-2-ene-1,3-diyl, but-2-ene-1,4-diyl, but- buta-1,2-diene-1,3-diyl, buta-1,2-diene-1,4-diyl, buta-1,3-diene-1,1-diyl, buta-1,3-diene-1,2-diyl, buta-1,3-diene-1,1-diyl, buta-1,2-diene-1,3-diyl, buta-1,2-diene-1,4-diyl, buta-1,3-diene-1,1-diyl, buta-1,3-diene-1,2-diyl, buta-1,3-diene-1,3-diyl, buta-1,3-diene-1,4-diyl, buta-1,3-diene-2,3-diyl, buta-2,3-diene-1,1-diyl, and buta-2,3-diene-1,2-diyl. Optionally substituted alkenylene is alkenylene optionally substituted as described herein for alkyl.
[0096] The term "alkyl," as used herein, when unsubstituted, refers to an acyclic, straight- or branched-chain saturated hydrocarbon group having 1 to 22 carbons (e.g., 1 to 20 carbons), unless otherwise specified. In certain preferred embodiments, alkyl, when unsubstituted, has 1 to 12 carbons (e.g., 1 to 8 carbons). Alkyl groups are exemplified by methyl; ethyl; n- and isopropyl; n-, sec-, iso-, and tert-butyl; neopentyl, and the like, and can be optionally substituted, where valence allows, with one, two, three, or, in the case of alkyl groups of two or more carbon atoms, four or more substituents independently selected from the group consisting of alkoxy; acyloxy; alkylsulfenyl; alkylsulfinyl; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; halo; heterocyclyl; heteroaryl; heterocyclylalkyl; heteroarylalkyl; heterocyclyloxy; heteroaryloxy; hydroxy; nitro; thioalkyl; thioalkenyl; thioaryl; thiol; silyl; cyano; oxo (=O); thio (=S); and imino (=NR'), where R' is H, alkyl, aryl, or heterocyclyl. Each of the substituents may itself be unsubstituted or, where valence allows, substituted with unsubstituted substituent(s) as defined herein for each respective group.
[0097] The term "alkylene," as used herein, refers to a saturated divalent hydrocarbon group that is a straight-chain or branched-chain saturated hydrocarbon in which two valencies replace two hydrogen atoms. Non-limiting examples of alkylene groups include methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-1,1-diyl, propane-2,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, butane-1,1-diyl, and butane-2,2-diyl, butane-2,3-diyl. Optionally substituted alkylene is optionally substituted alkylene as described herein for alkyl.
[0098] The term "alkylsulfenyl," as used herein, represents a group of formula -S-(alkyl). An optionally substituted alkylsulfenyl is an alkylsulfenyl optionally substituted as described herein for alkyl.
[0099] The term "alkylsulfinyl," as used herein, represents a group of the formula -S(O)-(alkyl). Optionally substituted alkylsulfinyl is alkylsulfinyl optionally substituted as described herein for alkyl.
[0100] The term "alkylsulfonyl," as used herein, represents a group of formula -S(O)-(alkyl). An optionally substituted alkylsulfonyl is an alkylsulfonyl optionally substituted as described herein for alkyl.
[0101] The term "amide bond," as used herein, refers to a covalent bond between the nitrogen atom of a carbonyl group and a carbon atom that is further bonded to another carbon atom.
[0102] The term "amino acid" as used herein refers to proline, taurine, or a compound having an amino group and a carboxylate or sulfonate group separated by an optionally substituted alkylene or an optionally substituted arylene. Amino acids are small molecules with a molecular weight of <900 g / mol (preferably <500 g / mol). Preferably, when the linker is alkylene, the linker can be optionally substituted as described herein for alkyl. In some embodiments, the optionally substituted alkylene is alkylene substituted with one or two groups, independently selected from hydroxyl, thiol, amino, guanidine, carbamoylamino, imidazolyl, indolyl, -SeH, oxo, 4-hydroxyphenyl, phenyl, or -SMe. Non-limiting examples of amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, selenocysteine, serine, threonine, tyrosine, tryptophan, ornithine, citrulline, aminobenzoic acid, and taurine.
[0103] The term "amino acid metabolite," as used herein, refers to a proteinogenic amino acid in which the α-amino group is replaced with -OH or -H, the 1-carboxyl group is replaced with H, the α-(CHNH) group is replaced with a carbonyl, the α-amino group and β-hydrogen atom are replaced with a double bond, or the 1-carboxyl group is replaced with a hydroxyl and the α-(CHNH) group is replaced with a carbonyl. Non-limiting examples of amino acid metabolites include indole-3-acetic acid, indole-3-propionic acid, 3-(indol-3-yl)-acrylic acid, indole-3-pyruvic acid, and 3-(indol-3-yl)-2-hydroxypropionic acid.
[0104] The term "acyl amino acid metabolite," as used herein, refers to an amino acid metabolite in which the carboxylate --OH is replaced with a valency.
[0105] The term "aryl," as used herein, refers to a monocyclic, bicyclic, or polycyclic carbocyclic ring system having one or two aromatic rings. Aryl groups can contain 6 to 10 carbon atoms. All atoms in an unsubstituted carbocyclic aryl group are carbon atoms. Non-limiting examples of carbocyclic aryl groups include phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl, and the like. Aryl groups can be unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, acyloxy, amino, aryl, aryloxy, azido, cycloalkyl, cycloalkoxy, halo, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, heterocyclyloxy, heteroaryloxy, hydroxy, nitro, thioalkyl, thioalkenyl, thioaryl, thiol, silyl, and cyano. Each of the substituents may itself be unsubstituted or may be substituted with unsubstituted substituent(s) as defined herein for each respective group.
[0106] The term "arylalkyl," as used herein, refers to an alkyl group substituted with an aryl group. An optionally substituted arylalkyl is an arylalkyl in which the aryl and alkyl portions can be optionally substituted as in the individual groups described herein.
[0107] The term "arylene" as used herein refers to a divalent group that is an aryl group in which one hydrogen atom is replaced by a valence. As described herein for aryl, arylene can be optionally substituted. Non-limiting examples of arylene include phenylene (e.g., 1,2-phenylene, 1,3-phenylene, and 1,4-phenylene).
[0108] The term "aryloxy" as used herein refers to the group -OR, where R is aryl. The aryloxy can be an optionally substituted aryloxy. The optionally substituted aryloxy is an aryloxy optionally substituted as described herein for aryl.
[0109] The term "bile acid" as used herein refers to a compound of the formula: [ka] During the ceremony, R 1 is hydroxyl, R 2 and R 3 each is independently H or hydroxy; R 4 is H or alkyl, R 5 is hydroxyl, -NH-CH(R A )-COOH, or aminosulfonic acid, R A is the side chain of a proteinogenic amino acid, if present. Non-limiting examples of bile acids include: [ka] Examples include: When a bile acid is acylated, one or more of the hydroxyl groups in the bile acid are independently replaced with a fatty acid acyl-containing group or a ketone or preketone-containing group.
[0110] The term "bile acid acyl," as used herein, refers to a monovalent group that is a bile acid having a carboxylate where the --OH is replaced with a valence.
[0111] The term "carbamate linker," as used herein, refers to a linker having a group R 1 -(CO)-R 2 In the formula, R 1is the bond to the alcohol or phenol oxygen atom, and R 2 is the bond to the nitrogen atom.
[0112] The term "carbonate linker," as used herein, refers to a linker having a group R 1 -C(O)-R 2 In the formula, R 1 is the bond to the first alcohol or phenol oxygen atom, and R 2 is the bond to the second alcohol or phenol oxygen atom.
[0113] The term "carbonyl," as used herein, refers to the divalent group --C(O)--.
[0114] The term "carboxylate," as used herein, refers to a -COOH group or salts thereof.
[0115] The term "carotenoid" as used herein refers to a compound of the formula: [ka] During the ceremony, R 1 teeth, [ka] and R 2 teeth, [ka] ,,or is.
[0116] Non-limiting examples of carotenoids include: [ka] When a carotenoid is acylated, one or both of the hydroxyl groups in the carotenoid are independently substituted with a fatty acid acyl-containing group or a ketone or preketone-containing group.
[0117] The term "catechin polyphenols" as used herein refers to compounds of the formula: [ka] During the ceremony, [ka] is a carbon-carbon single bond or a carbon-carbon double bond, Q is —CH— or —C(O)—; Each R 1 and each R 3 are independently H, halogen, or -OR A , phosphate, or sulfate, R 2 is H or -OR A and Each R A are independently H, optionally substituted alkyl, monosaccharide, sugar acid, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, optionally substituted alkyl, optionally substituted alkoxy, monosaccharide, sugar acid, phosphate, and sulfate; m is 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4. Preferably, n and m are each independently 1, 2, 3, or 4. Non-limiting examples of catechin polyphenols include epigallocatechin gallate. When catechin polyphenols are acylated, one or more of the hydroxyl groups in the catechin polyphenols are independently substituted with a group containing a fatty acid or a group containing a ketone or preketone body.
[0118] "C x-yAs used herein, the phrase "x" indicates that the named group immediately following the phrase, when unsubstituted, contains a total of x to y carbon atoms. If the group is a composite group (e.g., arylalkyl), C x-y indicates that the portion of the name immediately following that expression, if unsubstituted, contains a total of x to y carbon atoms. For example, (C 6-10 -aryl)-C 1-6 -Alkyl is a group in which the aryl portion, if unsubstituted, contains a total of 6 to 10 carbon atoms, and the alkyl portion, if unsubstituted, contains a total of 1 to 6 carbon atoms.
[0119] The term "cycloalkyl," as used herein, unless otherwise specified, refers to a cyclic alkyl group having 3 to 10 carbons (e.g., C-C 10Cycloalkyl). Cycloalkyl groups can be monocyclic or bicyclic. Bicyclic cycloalkyl groups can be bicyclo[pq0]alkyl-type groups, where p and q are each independently 1, 2, 3, 4, 5, 6, or 7, provided that the sum of p and q is 2, 3, 4, 5, 6, 7, or 8. Alternatively, bicyclic cycloalkyl groups can include bridged cycloalkyl structures, e.g., bicyclo[pqr]alkyl, where r is 1, 2, or 3, and p and q are each independently 1, 2, 3, 4, 5, or 6, provided that the sum of p, q, and r is 3, 4, 5, 6, 7, or 8. A cycloalkyl group may be a spirocyclic group, e.g., spiro[pq]alkyl, where each of p and q is independently 2, 3, 4, 5, 6, or 7, provided that the sum of p and q is 4, 5, 6, 7, 8, or 9. Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-bicyclo[2.2.1.]heptyl, 2-bicyclo[2.2.1.]heptyl, 5-bicyclo[2.2.1.]heptyl, 7-bicyclo[2.2.1.]heptyl, and decalinyl. A cycloalkyl group can be unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, acyloxy, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, amino, aryl, aryloxy, azido, cycloalkyl, cycloalkoxy, halo, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, heterocyclyloxy, heteroaryloxy, hydroxy, nitro, thioalkyl, thioalkenyl, thioaryl, thiol, silyl, cyano, oxo (=O), thio (=S), imino (=NR'), where R' is H, alkyl, aryl, or heterocyclyl (e.g., optionally substituted cycloalkyl). Each of the substituents can itself be unsubstituted or substituted with the unsubstituted substituent(s) defined herein for each respective group.
[0120] The term "cycloalkylene," as used herein, is a divalent group that is a cycloalkyl group in which one hydrogen atom is replaced by a valence. An optionally substituted cycloalkylene is a cycloalkylene that is optionally substituted as described herein for cycloalkyl.
[0121] The term "cycloalkoxy" as used herein refers to the group -OR, where R is cycloalkyl. Optionally substituted cycloalkoxy is cycloalkoxy optionally substituted as described herein for cycloalkyl.
[0122] The term "dialkylamino," as used herein, refers to the group --NR.sub.2, where each R is independently alkyl.
[0123] The terms "ellagic acid" and "ellagic acid analogs," as used herein, collectively refer to compounds of the following structure: [ka] During the ceremony, R 2 , R 3 , and R 4 each independently represents H or -OR A and R 6 is H or -(CO)-R 5B and R 1A is H or -OR A and R 5A is -OH or -OR A or R 1A and R 5A combine to form -O-, R 1B is H or -OR A and R 5B is absent, -OH, or -OR A or R 1Band R 5B combine to form -O-, Each R A are independently H or O protecting groups. When ellagic acid or its analogs are present in acylated ellagic acid or acylated ellagic acid analogs, one to all of the hydroxyls in ellagic acid or its analogs are replaced with fatty acid-containing groups. The term "ellagic acid analogs" refers to compounds and groups of the above structure that are not ellagic acid. The term "ellagic acid" is used to refer to the following two compounds: [ka] or refers to these compounds within the structure of a complex.
[0124] Non-limiting examples of ellagic acid analogs include urolithin A, urolithin B, urolithin C, urolithin D, urolithin E, and urolithin M5.
[0125] The term "ester bond," as used herein, refers to a covalent bond between an alcoholic or phenolic oxygen atom and a carbonyl group further attached to a carbon atom.
[0126] The term "fatty acid," as used herein, refers to short-chain fatty acids, medium-chain fatty acids, long-chain fatty acids, very-long-chain fatty acids, or unsaturated analogs thereof, or phenyl-substituted analogs thereof. Short-chain fatty acids contain 1 to 6 carbon atoms, medium-chain fatty acids contain 7 to 13 carbon atoms, and long-chain fatty acids contain 14 to 22 carbon atoms. Fatty acids may be saturated or unsaturated. Unsaturated fatty acids contain 1, 2, 3, 4, 5, or 6 carbon-carbon double bonds. Preferably, the carbon-carbon double bonds in unsaturated fatty acids have Z stereochemistry.
[0127] The term "fatty acyl," as used herein, refers to a fatty acid in which the hydroxyl group is replaced with a valence.
[0128] The term "fatty acyloxy," as used herein, refers to the group --OR, where R is fatty acyl.
[0129] The term "glycosidic bond," as used herein, refers to the covalent bond between an oxygen atom and the anomeric carbon atom in a monosaccharide or sugar acid having an anomeric carbon atom.
[0130] The terms "amino acid metabolite-containing group" and "amino acid metabolite-containing group," when used interchangeably herein, refer to a monovalent substituent that includes at least one amino acid metabolite within its structure and has a valency on the carbonyl or anomeric carbon atom. The amino acid metabolite-containing group is attached to the core via a carbonate linker, a carbamate linker, an ester bond, a glycosidic bond, or an amide bond. The amino acid metabolite-containing group can be a group selected from the group consisting of a monosaccharide, a ketone body, a preketone body, an aldonyl, a uronyl, a urosonyl, and an amino acid metabolite acyl, wherein each hydroxyl in the monosaccharide, the ketone body, the preketone body, the aldonyl, the urosonyl, and the urosonyl is optionally and independently replaced with an amino acid metabolite acyl.
[0131] The terms "fatty acid-containing group" and "fatty acid-containing group," when used interchangeably herein, refer to a monovalent substituent that contains at least one fatty acid within its structure and has a valency on the carbonyl or anomeric carbon atom. The fatty acid-containing group is attached to the core via a carbonate linker, a carbamate linker, an ester bond, a glycosidic bond, or an amide bond. The fatty acid-containing group can be a group selected from the group consisting of a monosaccharide, a ketone body, a preketone body, an aldonyl, a uronyl, a urosonyl, and a fatty acyl, wherein each hydroxyl in the monosaccharide, the ketone body, the preketone body, the aldonyl, the urosonyl, and the urosonyl is optionally and independently replaced with a fatty acyl.
[0132] The terms "ketone or preketone containing group" and "ketone or preketone containing group," when used interchangeably herein, refer to a monovalent substituent that contains at least one ketone and / or at least one preketone within its structure and has a valency on the carbonyl or anomeric carbon atom. The ketone or preketone containing group is attached to the core via a carbonate linker, an ester bond, or a glycosidic bond. The ketone or preketone containing group can be a group selected from the group consisting of a monosaccharide, a ketone, an aldonyl, a uronyl, a urosonyl, and a -C(O)-R, where R is a preketone or ketone, and each hydroxyl in the monosaccharide, ketone, preketone, aldonyl, uronyl, and urosonyl is optionally and independently replaced with an acyl or a ketone, and the hydroxyl group, if present, is optionally replaced with an acyl.
[0133] The term "halogen," as used herein, refers to a halogen selected from bromine, chlorine, iodine, and fluorine.
[0134] The term "heteroaryl," as used herein, refers to a monocyclic 5-, 6-, 7-, or 8-membered ring system, or a fused or bridged bicyclic, tricyclic, or tetracyclic ring system containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and at least one of the rings is aromatic. Non-limiting examples of heteroaryl groups include benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl, imidazolyl, indolyl, isoindazolyl, isoquinolinyl, isothiazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrrolyl, pyridinyl, pyrazinyl, pyrimidinyl, quinazolinyl, quinolinyl, thiadiazolyl (e.g., 1,3,4-thiadiazole), thiazolyl, thienyl, triazolyl, tetrazolyl, dihydroindolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, etc. The terms bicyclic, tricyclic, and tetracyclic heteroaryl include at least one ring having at least one heteroatom as described above and at least one aromatic ring. For example, a ring having at least one heteroatom can be fused to one, two, or three carbocyclic rings, such as an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring. Examples of fused heteroaryls include 1,2,3,5,8,8a-hexahydroindolizine, 2,3-dihydrobenzofuran, 2,3-dihydroindole, and 2,3-dihydrobenzothiophene. Heteroaryl can be optionally substituted with 1, 2, 3, 4, or 5 substituents, which are independently selected from alkyl, alkenyl, alkoxy, acyloxy, aryloxy, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, amino, arylalkoxy, cycloalkyl, cycloalkoxy, halogen, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heterocyclyloxy, heteroaryloxy, hydroxyl, nitro, thioalkyl, thioalkenyl, thioaryl, thiol, cyano, ═O, —NR, —COOR A, and -CON(R B )2, wherein each R is independently hydrogen, alkyl, acyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl; A is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl, where each R B is independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl. Each of the substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group.
[0135] The term "heteroaryloxy," as used herein, refers to the structure -OR, where R is a heteroaryl. The heteroaryloxy can be optionally substituted as defined for heteroaryl.
[0136] The term "heterocyclyl," as used herein, unless otherwise specified, refers to a monocyclic, bicyclic, tricyclic, or tetracyclic non-aromatic ring system having fused or bridged 4-, 5-, 6-, 7-, or 8-membered rings, wherein the ring system contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Non-aromatic 5-membered heterocyclyls have zero or one double bond, non-aromatic 6- and 7-membered heterocyclyl groups have zero to two double bonds, and non-aromatic 8-membered heterocyclyl groups have zero to two double bonds and / or zero or one carbon-carbon triple bond. Heterocyclyl groups, unless otherwise specified, have a carbon number of 1 to 16 carbon atoms. Some heterocyclyl groups can have up to 9 carbon atoms. Non-aromatic heterocyclyl groups include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, pyridazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, thiazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyranyl, dihydropyranyl, dithiazolyl, etc. The term "heterocyclyl" also refers to heterocyclic compounds having bridged polycyclic structures in which one or more carbon and / or heteroatoms bridge two non-adjacent members of a monocyclic ring, such as quinuclidine, tropane, or diaza-bicyclo[2.2.2]octane. The term "heterocyclyl" includes bicyclic, tricyclic, or tetracyclic groups in which any of the above heterocyclic rings is fused to one, two, or three carbocyclic rings, such as a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another heterocyclic ring. Examples of fused heterocyclyls include 1,2,3,5,8,8a-hexahydroindolizine, 2,3-dihydrobenzofuran, 2,3-dihydroindole, and 2,3-dihydrobenzothiophene.Heterocyclyl groups can be unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents, which are independently alkyl, alkenyl, alkoxy, acyloxy, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, aryloxy, amino, arylalkoxy, cycloalkyl, cycloalkoxy, halogen, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heterocyclyloxy, heteroaryloxy, hydroxyl, nitro, thioalkyl, thioalkenyl, thioaryl, thiol, cyano, ═O, ═S, —NR2, —COOR. A , and -CON(R B )2, wherein each R is independently hydrogen, alkyl, acyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl; A is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl, where each R B is independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, or heteroaryl.
[0137] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, the heterocyclyl and alkyl portions of which are optionally substituted as described for heterocyclyl and alkyl, respectively.
[0138] The term "heterocyclylene," as used herein, refers to a heterocyclyl in which one hydrogen atom is replaced by a valence. An optionally substituted heterocyclylene is a heterocyclylene optionally substituted as described herein for heterocyclyl.
[0139] The term "heterocyclyloxy" as used herein refers to the structure -OR, in which R is a heterocyclyl. The heterocyclyloxy can be optionally substituted as described for heterocyclyl.
[0140] The term "hydroxybenzoic acid" as used herein refers to a compound of the following structure: [ka] or a salt thereof, During the ceremony, n is 1, 2, or 3; Each R 1 are independently H or alkyl; R 2 is H or alkyl. Non-limiting examples of hydroxybenzoic acids include gallic acid.
[0141] The terms "hydroxyl" and "hydroxy", when used interchangeably herein, refer to -OH. A hydroxyl substituted with an acyl is an acyloxy. A protected hydroxyl is a hydroxyl in which the hydrogen atom has been replaced with an O-protecting group.
[0142] The term "hydroxymethyl," as used herein, refers to a -CHOH group.
[0143] The term "ketone body," as used herein, refers to (i) β-hydroxybutyric acid or acetoacetic acid, or (ii) a group that is β-hydroxybutyric acid or acetoacetic acid, in which at least one hydroxyl hydrogen atom is replaced with a valence, or in which the carboxylate -OH is replaced with a valence.
[0144] The term "ketone acyl," as used herein, refers to a ketone in which the carboxylate --OH group has been replaced with a valence.
[0145] The term “alpha-lipoic acid acyl,” as used herein, refers to a monovalent group of the following formula: [ka]
[0146] The term "metabolic marker" as used herein refers to an observable indicator of the presence, absence, or risk of metabolic disorder. The level of a metabolic marker can be directly or inversely correlated with obesity status. Non-limiting examples of metabolic markers include total fat percentage, cellular fat, weight gain rate, abdominal fat mass, subcutaneous fat mass, inguinal fat mass, epididymal fat mass, white fat to brown fat ratio, cholesterol (e.g., high-density lipoprotein (HDL) or low-density lipoprotein (LDL)) level, and triglyceride level. In some embodiments, the metabolic marker is total fat percentage, cellular fat, weight gain rate, abdominal fat mass, white fat to brown fat ratio, cholesterol (e.g., high-density lipoprotein (HDL) or low-density lipoprotein (LDL)) level, and triglyceride level. Body mass index can be used to assess total fat percentage. Abdominal fat can be assessed by measuring waist circumference. The ratio of white to brown fat can be determined, for example, by measuring miRNA-92a levels using the techniques and methods described in Chen et al., Nat. Commun., 7:11420. 18 F-fludeoxyglucose positron emission tomography / computed tomography, e.g., using the techniques and methods described in Gerngrob et al., J. Nucl. Med., 58:1104-1110, 2017, and magnetic resonance imaging, e.g., using the techniques and methods described in Chen et al., J. Nucl. Med., 54:1584-1587, 2013, can be evaluated.
[0147] The term “4-methyl-1,3-dioxan-2-yl,” as used herein, refers to a monovalent group of the formula: [ka] In the formula, R 1 is an arbitrarily substituted C 1-6 It is alkyl (eg, methyl).
[0148] The term "modulate," as used herein, refers to an observable change in the level of a marker in a subject, as measured using techniques and methods known in the art for measuring markers. Modulating the level of a marker in a subject can result in a change of at least 1% compared to before administration (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more compared to before administration, e.g., up to 100% compared to before administration). In some embodiments, modulating is increasing the level of the marker in a subject. The increase in marker level in the subject can result in an increase of at least 1% relative to pre-administration (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more relative to pre-administration, e.g., up to 100% relative to pre-administration). In other embodiments, modulating is decreasing the level of the marker in the subject. The decrease in marker levels in a subject may result in at least a 1% decrease relative to pre-administration (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more relative to pre-administration, e.g., up to 100% relative to pre-administration). In embodiments in which a parameter increases or decreases (or is reduced) in a subject after administering a composition described herein, the increase or decrease may occur and / or be detectable within a period of time after administration (e.g., within 6 hours, 24 hours, 3 days, 1 week or more), and may occur and / or be detectable after one or more administrations (e.g., after 2, 3, 4, 5, 6, 7, 8, 9, 10 or more administrations as part of a dosing regimen for the subject).
[0149] The term "non-alcoholic fatty disease marker" as used herein refers to an observable indicator of the presence or absence of non-alcoholic fatty disease (e.g., non-alcoholic steatohepatitis).The level of non-alcoholic disease marker can be directly or inversely correlated with the state of non-alcoholic disease.Non-limiting examples of non-alcoholic disease markers include alanine transaminase level (ALT), aspartate transaminase level (AST), gamma-glutamyltransferase level, liver weight, and fibrosis marker.Alanine transaminase level, aspartate transaminase level, gamma-glutamyltransferase level, and fibrosis marker can be measured in blood samples from subjects using methods known in the art.Non-alcoholic fatty disease markers can be evaluated using non-invasive tests, imaging tests, and biopsies. Liver fibrosis can be assessed invasively via liver biopsy or, alternatively, noninvasively via imaging techniques, such as a composite score / algorithm of serum markers (Fibrotest, Hepatscore, Fibrometet FIB-4 score, NAFLDD fibrosis score), or transient elastography, magnetic resonance elastography, acoustic radiation force impulse, and sonography (Almpanis, Z., Annals of Gastroenterology, 29:1-9, 2016). The BAAT is a global clinical score that can be used to identify subjects who would benefit from a liver biopsy for the evaluation of subjects with nonalcoholic fatty liver disease (e.g., nonalcoholic steatohepatitis). The BAAT combines body mass index, age, ALT, and serum triglycerides. Additionally, acoustic radiation force impulse can be used to measure liver stiffness, which correlates with fibrosis scoring. Magnetic resonance imaging (MRI) is also used to identify liver density and liver fat fraction, and liver stiffness can be measured by MR elastography (Neuman et al., J. Pharm. Pharm. Sci., 19:8-24, 2016).
[0150] The term "oxo," as used herein, represents a divalent oxygen atom (eg, the structure of an oxo can be shown as ═O).
[0151] The term "phenolic oxygen atom," as used herein, refers to a divalent oxygen atom in a compound structure, where one valence of the phenolic oxygen atom is attached to a first carbon atom and the other valence is attached to a second carbon atom, and the first carbon atom is attached to a sp 2 - hybridized carbon atom and the second carbon atom is sp 3 -hybridized carbon atom or sp 2 - is a hybridized carbon atom.
[0152] The term "phosphate," as used herein, refers to the -OPO(OH)2 group or salts thereof.
[0153] The term "preketone body," as used herein, refers to a group that is (i) a ketone body having a hydroxymethyl in place of the carboxylate, or (ii) a ketone body having a hydroxymethyl in place of the carboxylate, where at least one hydroxyl is replaced with -OR, where R is a valence. The term "preketone body," as used herein, refers to a group that is (4-methyl-1,3-dioxan-2-yl)-(alkylene) n -CO-R A wherein n is 0 or 1, and R A is -OH when the preketone body is not part of an acylated active agent, or is a valency when the preketone body is part of a group that includes the preketone body (e.g., preketone body acyl). Non-limiting examples of preketone bodies are butane-1,3-diol or 4-hydroxybutan-2-one.
[0154] The term "preketone acyl," as used herein, refers to a preketone in which the carboxylate --OH group has been replaced with a valence.
[0155] The term "protecting group," as used herein, refers to a group intended to prevent a hydroxy, amino, or carbonyl from participating in one or more undesired reactions during chemical synthesis. The term "O-protecting group," as used herein, refers to a group intended to prevent a hydroxy or carbonyl group from participating in one or more undesired reactions during chemical synthesis. The term "N-protecting group," as used herein, refers to a group intended to prevent a nitrogen-containing (e.g., amino or hydrazine) group from participating in one or more undesired reactions during chemical synthesis. Commonly used O-protecting groups and N-protecting groups are described in Greene, "Protective Groups in Organic Synthesis," 3, incorporated herein by reference. rd Edition (John Wiley & Sons, New York, 1999). Exemplary O-protecting and N-protecting groups include alkanoyl, aryloyl, or carbamyl groups, such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, t-butyldimethylsilyl, tri-isopropylsilyloxymethyl, 4,4′-dimethoxytrityl, isobutyryl, phenoxyacetyl, 4-isopropylphenoxyacetyl, dimethylformamidino, and 4-nitrobenzoyl.
[0156] Exemplary O-protecting groups for protecting carbonyl-containing groups include, but are not limited to, acetals, acylals, 1,3-dithianes, 1,3-dioxanes, 1,3-dioxolanes, and 1,3-dithiolanes.
[0157] Other O-protecting groups include, but are not limited to, substituted alkyl, aryl, and aryl-alkyl ethers (e.g., trityl; methylthiomethyl; methoxymethyl; benzyloxymethyl; siloxymethyl; 2,2,2-trichloroethoxymethyl; tetrahydropyranyl; tetrahydrofuranyl; ethoxyethyl; 1-[2-(trimethylsilyl)ethoxy]ethyl; 2-trimethylsilylethyl; t-butyl ether, p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, benzyl, p-methoxybenzyl, and nitrobenzyl). , silyl ethers (e.g., trimethylsilyl; triethylsilyl; triisopropylsilyl; dimethylisopropylsilyl; t-butyldimethylsilyl; t-butyldiphenylsilyl; tribenzylsilyl; triphenylsilyl; and diphenylmethylsilyl); carbonates (e.g., methyl, methoxymethyl, 9-fluorenylmethyl; ethyl; 2,2,2-trichloroethyl; 2-(trimethylsilyl)ethyl; vinyl, allyl, nitrophenyl; benzyl; methoxybenzyl; 3,4-dimethoxybenzyl; and nitrobenzyl).
[0158] Other N-protecting groups include, but are not limited to, chiral auxiliaries such as protected or unprotected D, L, or D,L-amino acids, such as alanine, leucine, phenylalanine, etc.; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl; benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p carbamate-forming groups such as (-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl; aryl-alkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl; and silyl groups such as trimethylsilyl. Useful N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
[0159] The term "stilbenoid," as used herein, refers to trans-stilbene, when not acylated, substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy (e.g., methoxy) and hydroxyl. Non-limiting examples of stilbenoids include resveratrol, pterostilbene, rhapontigenin, pinostilbene, oxyresveratrol, 4-methoxyresveratrol, and piceatannol. When the stilbenoid is acylated, one or both of the hydroxyl groups in the stilbenoid are independently substituted with a group containing a fatty acid acyl or a group containing a ketone or preketone body.
[0160] The term "subject" as used herein refers to a human or non-human animal (e.g., a mammal) that suffers from or is at risk of a disease, disorder, or condition, as determined by a qualified professional (e.g., a doctor or nurse), with or without clinical examination known in the art of a sample(s) from the subject.Non-limiting examples of disease, disorder, and condition include metabolic disorders, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis (e.g., NASH with or without fibrosis, fatty liver, or NASH with advanced fibrosis), as described herein.Diagnosis can be performed by techniques and methods known in the art. Subjects to be treated according to the methods of the present invention may have undergone standard testing (e.g., testing of blood liver enzyme (e.g., alanine transaminase or aspartate transaminase) levels, liver weight, blood triglyceride and / or cholesterol levels, body fat content, and / or glucose tolerance and / or insulin resistance), or may have been identified as being at high risk without such testing due to the presence of one or more risk factors.
[0161] The term "sugar acid," as used herein, refers to a monosaccharide in its linear form in which one or both terminal positions are oxidized to a carboxylic acid. There are four types of sugar acids: aldonic acid, ulosonic acid, uronic acid, and aldaric acid. Any of these four sugar acids can be used in the acylated catechin polyphenols disclosed herein. Non-limiting examples of sugar acids include gluconic acid.
[0162] The term "sugar acid acyl," as used herein, refers to a monovalent group that is a sugar acid having a carboxylate where the --OH is replaced with a valence.
[0163] The term "sulfate," as used herein, refers to the group -OSO3H or salts thereof.
[0164] The term "thioalkenyl," as used herein, refers to the group -SR, where R is alkenyl. An optionally substituted thioalkenyl is an optionally substituted thioalkenyl as described herein for alkenyl.
[0165] The term "thioalkyl," as used herein, refers to the group -SR, where R is alkyl. An optionally substituted thioalkyl is an optionally substituted thioalkyl as described herein for alkyl.
[0166] The term "thioaryl" as used herein refers to the group -SR, where R is aryl. Optionally substituted thioaryl is thioaryl optionally substituted as described herein for aryl.
[0167] "Treatment" and "treating," as used herein, refer to the medical management of a subject with the intent to ameliorate, enhance, stabilize, prevent, or cure a disease, disorder, or condition. This term includes active treatment (treatment directed at ameliorating the disease, disorder, or condition), causal treatment (treatment directed at the cause of the associated disease, disorder, or condition), palliative treatment (treatment aimed at alleviating the symptoms of the disease, disorder, or condition), preventative treatment (treatment directed at minimizing or partially or completely preventing the occurrence of the associated disease, disorder, or condition), and supportive treatment (treatment used to complement other therapies).
[0168] The term "trimethylglycine acyl," as used herein, refers to a monovalent group of the formula: [ka]
[0169] The term "urosonyl," as used herein, refers to a monovalent substituent that is urosonic acid with the carboxylate hydroxyl replaced in its valence.
[0170] The term "uronyl," as used herein, refers to a monovalent substituent that is a uronic acid in which the carboxylate hydroxyl has been replaced in valence.
[0171] The term "vitamin," as used herein, refers to tocopherols (e.g., α-tocopherol, β-tocopherol, γ-tocopherol, or δ-tocopherol), tocotrienols, vitamin D (e.g., cholecalciferol), and ascorbic acid. When a vitamin is acylated, one or more of the hydroxyl groups in the vitamin are independently replaced with a fatty acid acyl-containing group or a ketone or preketone body-containing group.
[0172] The compounds described herein, unless otherwise indicated, include isotopically enriched compounds (e.g., deuterated compounds), tautomers, and all stereoisomers and conformational isomers (e.g., enantiomers, diastereomers, E / Z isomers, atropisomers, etc.), as well as racemates and mixtures of different ratios of enantiomers or diastereomers thereof, or mixtures of any of the foregoing forms and salts (e.g., pharmaceutically acceptable salts).
[0173] Other features and advantages of the invention will be apparent from the drawings, the detailed description, and the claims. [Brief explanation of the drawings]
[0174] [Figure 1] 1 is a graph showing the percent weight change for three animal cohorts: (1) untreated animals receiving a high-fat diet, (2) animals receiving epigallocatechin octaacetate gallate (EGCG-8A) in addition to a high-fat diet, and (3) animals receiving rosiglitazone in addition to a high-fat diet. [Figure 2] 1 is a diagram showing glucose tolerance levels in three animal cohorts: (1) untreated animals receiving a high-fat diet, (2) animals receiving rosiglitazone with a high-fat diet, and (3) animals receiving epigallocatechin octaacetate gallate (EGCG-8A) with a high-fat diet. [Figure 3] Figure 1 shows the adiposity scores of mice divided into the following cohorts: (ND) normal diet group, (HFD) high-fat diet group, (HFD + acetate) high-fat diet group administered with acetic acid, (HFD + EGCG) high-fat diet group administered with epigallocatechin gallate, (HFD + acetate + EGCG) high-fat diet group administered with a combination of epigallocatechin gallate and acetic acid, (HFD + EGCG-8A) high-fat diet group administered with epigallocatechin gallate octaacetate, and (HFD + rosiglitazone) high-fat diet group receiving rosiglitazone. [Figure 4]Figure 1 shows the balloon degeneration scores of mice divided into the following cohorts: (ND) normal diet group, (HFD) high-fat diet group, (HFD + acetate) high-fat diet group administered with acetic acid, (HFD + EGCG) high-fat diet group administered with epigallocatechin gallate, (HFD + acetate + EGCG) high-fat diet group administered with a combination of epigallocatechin gallate and acetic acid, (HFD + EGCG-8A) high-fat diet group administered with epigallocatechin gallate octaacetate, and (HFD + rosiglitazone) high-fat diet group receiving rosiglitazone. [Figure 5-1] Figure 4 (ND) shows images from histological analysis of livers from the normal diet group. [Figure 5-2] Images from histological analysis of livers from the (HFD) high-fat diet group in Figure 4. [Figure 5-3] Figure 4 shows images from histological analysis of livers from the high-fat diet group administered acetate (HFD + acetate). [Figure 5-4] Figure 4 shows images from histological analysis of livers from the high-fat diet group administered epigallocatechin gallate (HFD+EGCG). [Figure 5-5] Figure 4 shows images from histological analysis of livers from the high-fat diet group administered a combination of epigallocatechin gallate and acetate (HFD + acetate + EGCG). [Figure 5-6] Figure 4 shows images from histological analysis of livers from the high-fat diet group administered epigallocatechin octaacetate gallate (HFD+EGCG-8A). [Figure 5-7] Figure 4 (HFD + rosiglitazone) shows images from histological analysis of livers from the high-fat diet group receiving rosiglitazone. [Figure 6]1 is a diagram showing abdominal fat levels for five animal cohorts: (none) control animals, (BHB) animals receiving β-hydroxybutyrate, (resveratrol + BH) animals receiving a combination of resveratrol and β-hydroxybutyrate, (butanediol) animals receiving 1,3-butanediol, and (resveratrol + butanediol) animals receiving resveratrol and 1,3-butanediol. [Figure 7] 1 is a diagram showing triglyceride levels for five animal cohorts: (none) control animals, (BHB) animals receiving β-hydroxybutyrate, (resveratrol + BH) animals receiving a combination of resveratrol and β-hydroxybutyrate, (butanediol) animals receiving 1,3-butanediol, and (resveratrol + butanediol) animals receiving resveratrol and 1,3-butanediol. [Figure 8] 1 is a diagram showing cholesterol levels in five animal cohorts: (none) control animals, (BHB) animals receiving β-hydroxybutyrate, (resveratrol + BH) animals receiving a combination of resveratrol and β-hydroxybutyrate, (butanediol) animals receiving 1,3-butanediol, and (resveratrol + butanediol) animals receiving resveratrol and 1,3-butanediol. [Figure 9] 1 is a diagram showing the daily food intake of five animal cohorts: (none) control animals, (BHB) animals receiving β-hydroxybutyrate, (resveratrol + BH) animals receiving a combination of resveratrol and β-hydroxybutyrate, (butanediol) animals receiving 1,3-butanediol, and (resveratrol + butanediol) animals receiving resveratrol and 1,3-butanediol. [Figure 10]Graph showing steatosis scores of FATZO mice divided into the following cohorts: (None) control group, (BHB) β-hydroxybutyrate group, (Resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (Butanediol) 1,3-butanediol group, (Resveratrol + Butanediol) resveratrol and 1,3-butanediol combination group, and (Obeticholic Acid) obeticholic acid group. [Figure 11] Graph showing lobular inflammation scores for FATZO mice divided into the following cohorts: (None) control group, (BHB) β-hydroxybutyrate group, (Resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (Butanediol) 1,3-butanediol group, (Resveratrol + Butanediol) resveratrol and 1,3-butanediol combination group, and (Obeticholic Acid) obeticholic acid group. [Figure 12] Graph showing balloon degeneration scores of FATZO mice divided into the following cohorts: (None) control group, (BHB) β-hydroxybutyrate group, (Resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (Butanediol) 1,3-butanediol group, (Resveratrol + Butanediol) resveratrol and 1,3-butanediol combination group, and (Obeticholic Acid) obeticholic acid group. [Figure 13] Graph showing fibrosis scores of FATZO mice divided into the following cohorts: (None) control group, (BHB) β-hydroxybutyrate group, (Resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (Butanediol) 1,3-butanediol group, (Resveratrol + Butanediol) resveratrol and 1,3-butanediol combination group, and (Obeticholic Acid) obeticholic acid group. [Figure 14]Graph showing liver weights of FATZO mice divided into the following cohorts: (None) control group, (BHB) β-hydroxybutyrate group, (Resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (Butanediol) 1,3-butanediol group, (Resveratrol + Butanediol) resveratrol and 1,3-butanediol combination group, and (Obeticholic Acid) obeticholic acid group. [Figure 15] 1 is a graph showing alanine transaminase blood levels in FATZO mice divided into the following cohorts: (none) control group, (BHB) β-hydroxybutyrate group, (resveratrol + BHB) resveratrol and β-hydroxybutyrate combination group, (butanediol) 1,3-butanediol group, (resveratrol + butanediol) resveratrol and 1,3-butanediol combination group, and (obeticholic acid) obeticholic acid group. [Figure 16] FIG. 1 is a graph showing an HPLC trace of 1,3-butanediol produced by cleavage of compound 78 in simulated intestinal fluid. [Figure 17] 1 is a scheme outlining the study described in Example 15. Abbreviations are as follows: QD means once daily, BIW means twice weekly, BW means body weight, FI means food intake, WI means water intake, ALT means alanine transaminase, AST means aspartate transaminase, TG means triglycerides, TC means total cholesterol, HP means hydroxyproline, HE means hematoxylin and eosin, PSR means picrosirius red, IHC means immunohistochemistry, Gal-3 means galectin-3, Col1a1 means collagen 1a1, and α-SMA means alpha-smooth muscle actin. [Figure 18-1] Figure 1 shows hepatic collagen 1a1 (Col1a1) in liver biopsies taken 4 weeks prior to the start of the study in Example 15. Values expressed as mean of n=12-13 + SEM. Single-factor linear model with Dunnett's test. No difference was observed compared to the control group at a significance level of 0.05. [Figure 18-2] 1 is a graph showing individual hepatic collagen 1a1 (Col1a1) in liver biopsies taken 4 weeks prior to the start of the study in Example 15. Points represent individual measurements. Boxes indicate the location of the mean (center line) and SEM (top and bottom). [Figure 19-1] Figure 1 shows absolute body weight throughout the study period. Values expressed as mean, n = 10-13 + SEM. No statistical analysis was performed. [Figure 19-2] Figure 1 shows absolute body weights at the end of the study. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05, ***: P<0.001 compared to control. [Figure 20-1] Figure 1 shows the relative body weight (BW) throughout the study period. Values are expressed as mean, n=10-12 + SEM. No statistical analysis was performed. [Figure 20-2] Figure 1 shows relative body weight (BW) at the end of the study. Values expressed as mean of n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05, ***: P<0.001 compared to control. [Figure 21-1] Figure 1 shows a diagram of daily food intake during weeks 1 and 2 of the study. Values are expressed as mean, n=11-13 + SEM. No statistical analysis was performed. [Figure 21-2] Figure 1 shows cumulative food intake during weeks 1 and 2 of the study. Values expressed as mean, n=10-12 + SEM. No statistical analysis was performed. [Figure 22] Figure 1 shows weekly food intake measured twice weekly during weeks 3-8 of the study. Values expressed as mean, n=11-13 + SEM. No statistical analysis was performed. [Figure 23-1] Figure 1 is a diagram showing daily fluid intake during treatment during weeks 1 and 2 of the study. Values expressed as mean, n=10-12 + SEM. No statistical analysis was performed. [Figure 23-2] Figure 1 shows cumulative fluid intake during weeks 1 and 2 of the study. Values expressed as mean, n=9-12 + SEM. No statistical analysis was performed. [Figure 24]Figure 1 shows weekly fluid intake (measured over 24 hours) measured twice weekly during weeks 3-8 of the study. Values are expressed as mean, n=10-12 + SEM. No statistical analysis was performed. [Figure 25-1] Figure 1 shows plasma alanine transaminase (ALT) at terminal time. Values expressed as mean of n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05, **: P<0.01, ***: P<0.001 compared with control. [Figure 25-2] Figure 1 shows plasma aspartate transaminase (AST) at terminal time. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05, **: P<0.01, ***: P<0.001 compared with control. [Figure 26-1] Figure 1 shows plasma triglycerides (TG) at terminal time. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. *: P<0.05, ***: P<0.001 compared with control. [Figure 26-2] Figure 1 shows plasma total cholesterol (TC) at end of life. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. **: P<0.01 compared with control. [Figure 27-1] Figure 1 shows total intestinal weight (including contents) at terminal stage. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. **: P<0.01, ***: P<0.001 compared to control. [Figure 27-2] Figure 1 shows liver weight at terminal. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. *: P<0.05 compared with control. [Figure 28-1] Figure 1 shows relative liver triglycerides (TG) at terminal time. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared with control. [Figure 28-2]Figure 1 shows total liver triglycerides (TG) at terminal time. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. **: P<0.01, ***: P<0.001 compared to control. [Figure 29-1] Figure 1 shows relative liver total cholesterol (TC) at end of life. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared with control. [Figure 29-2] Figure 1 shows total liver cholesterol (TC) at terminal. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. **: P<0.01 compared with control. [Figure 30-1] Figure 1 shows relative liver hydroxyproline (HP) at terminal. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared with control. [Figure 30-2] Figure 1 shows total liver hydroxyproline (HP) at terminal. Values expressed as mean, n=11-13+SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared with control. [Figure 31-1] This is an image of liver morphology (HE staining of liver) at the end of Group 1 (magnification 20x, scale bar = 100 μm). [Figure 31-2] This is an image of liver morphology (HE staining of liver) at the end of group 2 (magnification 20x, scale bar = 100 μm). [Figure 31-3] This is an image of liver morphology (HE staining of liver) at the end of group 3 (magnification 20x, scale bar = 100 µm). [Figure 31-4] This is an image of liver morphology (HE staining of liver) at the end of group 4 (magnification 20x, scale bar = 100 µm). [Figure 31-5] This is an image of liver morphology (HE staining of liver) at the end of group 5 (magnification 20x, scale bar = 100 μm). [Figure 31-6] This is an image of liver morphology (HE staining of liver) at the end of Group 6 (magnification 20x, scale bar = 100 µm). [Figure 31-7] This is an image of liver morphology (HE staining of liver) at the end of Group 7 (magnification 20x, scale bar = 100 µm). [Figure 31-8] This is an image of liver morphology (HE staining of liver) at the end of group 8 (magnification 20x, scale bar = 100 µm). [Figure 32-1] Images of liver morphology (picrosirius red staining of liver) at terminal stage in Group 1 (20x magnification, scale bar = 100 μm). [Figure 32-2] Images of liver morphology (picrosirius red staining of liver) at terminal stage in Group 2 (20x magnification, scale bar = 100 μm). [Figure 32-3] Images of liver morphology (picrosirius red staining of liver) at terminal stage in Group 3 (20x magnification, scale bar = 100 μm). [Figure 32-4] Images of liver morphology (picrosirius red staining of liver) at the end of group 4 (20x magnification, scale bar = 100 μm). [Figure 32-5] Figure 1 shows images of liver morphology (picrosirius red staining of liver) at the end of group 5 (20x magnification, scale bar = 100 µm). [Figure 32-6] 10 shows images of liver morphology (picrosirius red staining of liver) at the end of Group 6 (20x magnification, scale bar = 100 μm). [Figure 32-7] Figure 1 shows images of liver morphology (picrosirius red staining of liver) at the end of group 7 (20x magnification, scale bar = 100 µm). [Figure 32-8] Figure 1 shows images of liver morphology (picrosirius red staining of liver) at the end of group 8 (20x magnification, scale bar = 100 µm). [Figure 33-1]Graph showing a summary of histopathological scoring (fibrosis stage) of biopsies before and after the study. For each group, the number of animals with a post-study score higher (worsened), the same, or lower (improved) compared to the pre-study score is indicated by the height of the bar. For each compound group, the significance of the number of animals with a lower score relative to the appropriate vehicle was assessed using Fisher's exact test, followed by correction for multiple comparisons using the Bonferroni method. ***: P<0.001 when compared to control. [Figure 33-2] Graph showing a summary of histopathological scoring (NAFLD activity score) of biopsies before and after the study. For each group, the number of animals with a post-study score higher (worsened), the same, or lower (improved) compared to the pre-study score is indicated by the height of the bar. For each compound group, the significance of the number of animals with a lower score relative to the appropriate vehicle was assessed using Fisher's exact test, followed by correction for multiple comparisons using the Bonferroni method. ***: P<0.001 when compared to control. [Figure 34-1] 1 is a diagram summarizing the fibrosis stage results. For each animal, the change from pre-study to post-study biopsy is indicated by a line. The points for each scoring step have been slightly shifted to allow for visual separation of the animals; this is for visualization purposes only and does not reflect any difference in scores. [Figure 34-2] 1 is a diagram summarizing the results of the NAFLD activity score. For each animal, the change from pre-study to post-study biopsy is shown as a line. The points at each scoring step have been slightly shifted to allow for visual separation of the animals; this is for visualization purposes only and does not reflect any difference in scores. [Figure 35-1]Graph showing a summary of the NAFLD activity score (steatosis score) showing individual scores for steatosis, lobular inflammation, and ballooning of biopsies before and after the study. For each group, the number of animals with a post-study score higher (worsened), the same, or lower (improved) than the pre-study score is indicated by the height of the bar. One-tailed Fisher's exact test with Bonferroni correction. *: P<0.05 compared to control. [Figure 35-2] Graph showing summary of NAFLD activity score (lobular inflammation) showing individual scores for steatosis, lobular inflammation, and ballooning of biopsies before and after the study. For each group, the number of animals with a post-study score higher (worsened), the same, or lower (improved) compared to the pre-study score is indicated by the height of the bar. One-tailed Fisher's exact test with Bonferroni correction. *: P<0.05 compared to control. [Figure 35-3] Graph showing a summary of the NAFLD activity score (hepatocellular ballooning), showing individual scores for steatosis, lobular inflammation, and ballooning of biopsies before and after the study. For each group, the number of animals with a higher (worsened), the same, or lower (improved) post-study score compared to the pre-study score is indicated by the height of the bar. One-tailed Fisher's exact test with Bonferroni correction. *: P<0.05 compared to control. [Figure 36-1] 1 is a diagram summarizing the steatosis score results. For each animal, the change from pre-study to post-study biopsy is shown as a line. The points of each scoring step have been slightly shifted to allow for visual separation of the animals; this is for visualization purposes only and does not reflect any differences in scores. [Figure 36-2] 1 is a diagram summarizing the inflammation score results. For each animal, the change from pre-study to post-study biopsy is shown as a line. The points for each scoring step have been slightly shifted to allow for visual separation of the animals; this is for visualization purposes only and does not reflect any difference in scores. [Figure 36-3]1 is a diagram summarizing the results of the ballooning score. For each animal, the change from pre-study to post-study biopsy is shown as a line. The points of each scoring step have been slightly shifted to allow for visual separation of the animals; this is for visualization purposes only and does not reflect any difference in score. [Figure 37-1] 10 shows images showing crude detection of tissue at low magnification (first step in histological quantitative evaluation). [Figure 37-2] 10 is an image showing detection of steatosis (pink) and tissue (blue) at high magnification. [Figure 38-1] Figure 1 shows terminal relative hepatic steatosis quantified by morphometry. Values expressed as mean of n=11-13 + SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared to control. [Figure 38-2] Figure 1 shows terminal total hepatic steatosis quantified by morphometry. Values expressed as mean of n=11-13 + SEM. Single-factor linear model with Dunnett's test. **: P<0.01, ***: P<0.001 compared to control. [Figure 38-3] Figure 1 shows lipid droplet size quantified by morphometry. Values expressed as mean of n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05, ***: P<0.001 compared to control. [Figure 39-1] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at terminal time in Group 1 (20x magnification, scale bar = 100 μm). [Figure 39-2] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at terminal time in Group 2 (20x magnification, scale bar = 100 μm). [Figure 39-3] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at the end of Group 3 (20x magnification, scale bar = 100 μm). [Figure 39-4]1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at terminal time in Group 4 (20x magnification, scale bar = 100 μm). [Figure 39-5] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at the end of Group 5 (20x magnification, scale bar = 100 μm). [Figure 39-6] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at the end of Group 6 (20x magnification, scale bar = 100 μm). [Figure 39-7] 1 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at the end of Group 7 (20x magnification, scale bar = 100 μm). [Figure 39-8] 10 shows liver morphology (livers stained with anti-type I collagen (Southern Biotech, Cat. No. 1310-01)) at the end of Group 8 (20x magnification, scale bar = 100 μm). [Figure 40-1] 10 shows images showing crude detection of tissue at low magnification (first step in histological quantitative evaluation). [Figure 40-2] 10 is an image showing detection of collagen 1A1 (green) and tissue (red) at high magnification. [Figure 41-1] Figure 1 shows terminal relative collagen 1A1 (Col1a1) quantified by morphometry. Values expressed as mean, n = 11–13 + SEM. Single-factor linear model with Dunnett's test. No difference was observed compared to the control group at a significance level of 0.05. [Figure 41-2] Figure 1 shows terminal total collagen 1A1 (Col1a1) quantified by morphometry. Values expressed as mean, n = 11–13 + SEM. Single-factor linear model with Dunnett's test. No difference was observed compared to the control group at a significance level of 0.05. [Figure 42-1]Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of Group 1 (20x magnification, scale bar = 100 μm). [Figure 42-2] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 2 (20x magnification, scale bar = 100 μm). [Figure 42-3] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 3 (20x magnification, scale bar = 100 μm). [Figure 42-4] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of Group 4 (20x magnification, scale bar = 100 μm). [Figure 42-5] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 5 (20x magnification, scale bar = 100 μm). [Figure 42-6] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 6 (20x magnification, scale bar = 100 μm). [Figure 42-7] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 7 (20x magnification, scale bar = 100 μm). [Figure 42-8] Image of liver morphology (livers stained with anti-α-smooth muscle actin (anti-α-SMA), AbCam, catalog number ab124964) at the end of group 8 (20x magnification, scale bar = 100 μm). [Figure 43-1] 10 shows images showing crude detection of tissue at low magnification (first step in histological quantitative evaluation). [Figure 43-2] Images showing detection of α-SMA (green) and tissue (red) at high magnification. [Figure 44-1] Figure 1 shows terminal relative alpha-smooth muscle actin (a-SMA) quantified by morphometry. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. **: P<0.01 compared to control. [Figure 44-2] Figure 1 shows terminal total alpha-smooth muscle actin (a-SMA) quantified by morphometry. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. ***: P<0.001 compared to control. [Figure 45-1] 1 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, catalog number 125402) at terminal time in Group 1 (20x magnification, scale bar = 100 μm). [Figure 45-2] 10 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, catalog number 125402) at terminal time in Group 2 (20x magnification, scale bar = 100 μm). [Figure 45-3] FIG. 11 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 3 (20x magnification, scale bar = 100 μm). [Figure 45-4] 10 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 4 (20x magnification, scale bar = 100 μm). [Figure 45-5] FIG. 11 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 5 (20x magnification, scale bar = 100 μm). [Figure 45-6] 10 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 6 (20x magnification, scale bar = 100 μm). [Figure 45-7] FIG. 11 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 7 (20x magnification, scale bar = 100 μm). [Figure 45-8] FIG. 11 shows images of liver morphology (livers stained with anti-galectin-3, Biolegend, Cat. No. 125402) at terminal time in Group 8 (20x magnification, scale bar = 100 μm). [Figure 46-1] 10 shows images showing crude detection of tissue at low magnification (first step in histological quantitative evaluation). [Figure 46-2] 10 is an image showing detection of galectin-3 (green) and tissue (red) at high magnification. [Figure 47-1] Figure 1 shows terminal relative galectin-3 quantified by morphometry. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. *: P<0.05 compared to control. [Figure 47-2] Figure 1 shows terminal total galectin-3 quantified by morphometry. Values expressed as mean, n=11-13 + SEM. Single-factor linear model with Dunnett's test. **: P<0.01 compared to control. [Figure 48-1] Images showing liver morphology in DIO-NASH controls. Steatosis is assessed according to the NASH CRN (Clinical Research Network) scoring criteria, which evaluate the number of hepatocytes containing lipid droplets regardless of the size of the lipid vacuoles. In DIO-NASH vehicles, lipid vacuoles are typically large. Lipid vacuoles are present in more than 66% of all hepatocytes in both animal groups, resulting in a 3-point score. In contrast, image analysis quantifying the steatosis area fraction or biochemical analysis of liver lipids shows a smaller fraction of lipid in elafibranor-treated animals (20x magnification, scale bar = 100 μm). [Figure 48-2]Images showing liver morphology in elafibranor-treated animals. Steatosis is assessed according to the NASH CRN (Clinical Research Network) scoring criteria, which evaluates the number of hepatocytes containing lipid droplets, regardless of the size of the lipid vacuoles. In elafibranor-treated animals, the vacuoles are smaller. Lipid vacuoles are present in more than 66% of all hepatocytes in both animal groups, resulting in a 3-point scale. In contrast, image analysis quantifying the steatosis area fraction or biochemical analysis of liver lipids shows a smaller fraction of lipid in elafibranor-treated animals (20x magnification, scale bar = 100 µm). [Figure 49-1] This image shows liver fibrosis (picrosirius red-stained slide) in a DIO-NASH control with high-end collagen 1a1 (Col1a1) analysis. When assessing fibrosis according to the Brunt scoring criteria, fibrosis is assessed based on its localization. In DIO-NASH, vehicle animals have fibrosis localized to the sinusoids and portal tracts without bridging. In Elfibranor-treated animals, fibrosis is more subtle but still localized to both the sinusoids and portal tracts without bridging. In contrast, image analysis quantifying fibrosis area fraction shows a smaller fraction of fibrosis in this Elfibranor-treated animal (10x magnification, scale bar = 200 μm). [Figure 49-2] This image shows liver fibrosis (picrosirius red-stained slide) in an Elafibranor-treated animal in low-end Col1a1 analysis. When assessing fibrosis according to the Brunt scoring criteria, fibrosis is assessed based on its localization. In DIO-NASH, fibrosis in vehicle animals is localized to the sinusoids and portal tracts without bridging. In Elfibranor-treated animals, fibrosis is more subtle but still localized to both the sinusoids and portal tracts without bridging. In contrast, image analysis quantifying fibrosis area fraction shows a smaller fraction of fibrosis in this Elafibranor-treated animal (10x magnification, scale bar = 200 μm). DETAILED DESCRIPTION OF THE INVENTION
[0175] The present invention provides a method for treating a skin condition characterized by the inclusion of an acylated active agent (e.g., an acylated catechin polyphenol, an acylated carotenoid, an acylated ellagic acid, an acylated ellagic acid analog, an acylated ketone body or preketone body, an acylated stilbenoid, an acylated S-adenosyl-L-methionine, an acylated amino acid, an acylated bile acid, an acylated mesalamine, an acylated metformin, an acylated sugar, an acylated shikimic acid, an acylated vitamin, or an acylated hydroxybenzoic acid), a combination of active agents (e.g., a combination of active agents wherein a first agent is a stilbenoid, a catechin polyphenol, an acylated carotenoid ...ellagic acid analog, an acylated ketone body or preketone body, an acylated stilbenoid, an acylated S-adenosyl-L-methionine, an acylated amino acid, an acylated bile acid, an acylated mesalamine, an acylated metformin, an acylated sugar, an acylated shikimic acid, an acylated vitamin, or an acylated hydroxybenzoic acid), a The present invention provides a method for regulating metabolic markers or non-alcoholic fatty liver disease markers in a subject or treating metabolic disorders or non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) in a subject, a composition comprising the compound (e.g., a unit dosage form), and a method for treating metabolic disorders or non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) in a subject. Without wishing to be bound by theory, it is believed that the acylated active agent of the present invention cooperates with or acts on behalf of the subject's microbiota.
[0176] As described herein, it has been unexpectedly observed that the compounds and combination therapies of the present invention exhibit in vivo activity for regulating metabolic markers or treating metabolic disorders (e.g., obesity, type II diabetes, prediabetes, insulin resistance, metabolic syndrome, hypercholesterolemia, atherosclerosis, or hyperlipidemia). Surprisingly, it has been found that administering an acylated catechin polyphenol (e.g., epigallocatechin-3-octagallate acetate) to a subject can induce weight loss, even when the subject eats a high-fat diet. Surprisingly, it has been found that administering an acylated catechin polyphenol results in superior activity compared to administering the same dose of the acylated catechin polyphenol components as separate compounds.
[0177] The components of acylated catechin polyphenols (e.g., short-chain fatty acyl (e.g., acetyl) and epigallocatechin gallate) can act synergistically to regulate metabolic markers, for example, when hydrolyzed in the GI tract of a subject receiving the acylated catechin polyphenols. The components of acylated catechin polyphenols (e.g., short-chain fatty acyl (e.g., acetyl) and epigallocatechin gallate) can act synergistically to treat metabolic disorders, for example, when hydrolyzed in the GI tract of a subject receiving the acylated catechin polyphenols.
[0178] As described herein, compounds and combination therapies of the present invention have been unexpectedly observed to exhibit activity in vivo for modulating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) markers or treating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH) with or without fibrosis, fatty liver, NASH with advanced fibrosis). For example, FATZO mice (a disease model of NAFLD / NASH) administered the exemplary combination of stilbenoids and ketone bodies or preketone bodies exhibited statistically significant reductions in steatosis, liver weight, and liver enzymes (e.g., alanine transaminase (ALT) levels) relative to FATZO mice not receiving stilbenoids and ketone bodies or preketone bodies. In another study described herein, test mice administered an acylated active agent disclosed herein (e.g., epigallocatechin octaacetate gallate) exhibited statistically significant improvements in liver histology (e.g., reduced steatosis and reduced ballooning).
[0179] Moreover, surprisingly, the compounds and combination therapies disclosed herein can exhibit synergistic activity for modulating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) markers or treating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH) with or without fibrosis, fatty liver, NASH with advanced fibrosis). For example, as described herein, FATZO mice administered the exemplary combination of stilbenoids and preketone bodies exhibited greater reduction in steatosis than mice administered obeticholic acid, an agent under investigation for the treatment of NAFLD / NASH.
[0180] Advantageously, the acylated active agents disclosed herein can have excellent organoleptic properties (e.g., palatability). This provides an important advantage because individual components (e.g., acetic acid or epigallocatechin gallate) can exhibit less desirable organoleptic properties (e.g., palatability). Improved organoleptic properties facilitate oral administration, which is particularly advantageous for the delivery of high unit doses (e.g., unit doses of 0.5 g or greater).
[0181] The present invention also provides combinations of active agents.
[0182] Surprisingly, the compounds and combination therapies disclosed herein can exhibit synergistic activity for regulating metabolic disorder markers or treating metabolic disorders. For example, as described herein, FATZO mice administered with the exemplary combination of stilbenoids and preketone bodies exhibited reduced abdominal fat, blood triglycerides, and blood cholesterol compared to a control group of FATZO mice not administered with the exemplary combination.
[0183] Acylated active agents The acylated active agents disclosed herein are acylated catechin polyphenols, acylated carotenoids, acylated ellagic acid, acylated ellagic acid analogs, acylated ketone bodies or preketone bodies, acylated stilbenoids, acylated S-adenosyl-L-methionine, acylated amino acids, acylated bile acids, acylated mesalamine, acylated metformin, acylated hydroxybenzoic acids, acylated shikimic acid, acylated vitamins, or acylated sugars.
[0184] Typically, an "acylated active agent" comprises two or more agents linked via ester bond(s), amide bond(s), carbonate linker(s), carbamate linker(s), and / or glycosidic bond(s). For example, an acylated active agent may comprise a core (e.g., a catechin polyphenol, a stilbenoid, shikimic acid, a hydroxybenzoic acid, a monosaccharide, or a glucosinolate), which may be substituted with one or more substituents independently selected from the group consisting of alkyl, acyl, fatty acid-containing groups (e.g., short-chain or medium-chain fatty acids), and ketone or preketone body-containing groups.
[0185] The acylated active agent disclosed herein may, for example, comprise at least one group comprising a fatty acid. The fatty acid-containing group may, for example, be a fatty acid (e.g., short-chain fatty acid or medium-chain fatty acid), a monosaccharide having one or more hydroxyl groups substituted with a fatty acyl (e.g., short-chain fatty acid or medium-chain fatty acid), or a sugar acid (e.g., aldonic acid) having one or more alcohol hydroxyl groups substituted with a fatty acyl (e.g., short-chain fatty acid or medium-chain fatty acid).
[0186] The acylated active agents disclosed herein may, for example, comprise at least one group comprising a ketone body or a preketone body. The group comprising a ketone body or a preketone body may, for example, comprise a ketone body optionally having a hydroxyl group optionally substituted with an acyl (e.g., a fatty acyl (e.g., a short-chain fatty acyl or a medium-chain fatty acyl)); a preketone body optionally having a hydroxyl group optionally substituted with an acyl (e.g., a fatty acyl (e.g., a short-chain fatty acyl or a medium-chain fatty acyl)); a monosaccharide having one or more hydroxyl groups substituted for the ketone body acyl and / or the preketone body acyl (each ketone body acyl and preketone body acyl). The ketone body acyl may optionally have a hydroxyl group optionally replaced with a fatty acyl (e.g., a short-chain fatty acyl or a medium-chain fatty acyl), or a sugar acid (e.g., an aldonic acid or a uronic acid) having one or more alcohol hydroxyl groups replaced with a ketone body acyl and / or a preketone body acyl (each ketone body acyl and preketone body acyl optionally has a hydroxyl group optionally replaced with a fatty acyl (e.g., a short-chain fatty acyl or a medium-chain fatty acyl)). A group containing a ketone body or a preketone body may, for example, be a group containing a ketone body. A group containing a ketone body may, for example, be a group containing a preketone body. A group containing a ketone body comprises at least one ketone body residue. A group containing a preketone body comprises at least one preketone body residue.
[0187] The acylated active agent disclosed herein may, for example, comprise at least one group comprising an amino acid metabolite. The group comprising an amino acid metabolite may, for example, be an amino acid metabolite group (e.g., an amino acid metabolite acyl). The group comprising an amino acid metabolite may, for example, be an amino acid metabolite acyl. Alternatively, the amino acid metabolite may be a preketone body having a hydroxyl group replaced with an amino acid metabolite acyl; a monosaccharide having one or more hydroxyl groups replaced with an amino acid metabolite acyl (each amino acid metabolite acyl optionally having a hydroxyl group replaced with a fatty acyl (e.g., short-chain or medium-chain fatty acyl), and one or more remaining hydroxyls on the monosaccharide, if present, are optionally replaced with a fatty acyl (e.g., short-chain or medium-chain fatty acyl); or a sugar acid (e.g., an aldonic acid or uronic acid) having one or more alcohol hydroxyl groups replaced with an amino acid metabolite acyl (each amino acid metabolite acyl optionally having a hydroxyl group replaced with a fatty acyl (e.g., short-chain or medium-chain fatty acyl), and one or more remaining hydroxyls on the sugar acid, if present, are optionally replaced with a fatty acyl (e.g., short-chain or medium-chain fatty acyl). The group comprising an amino acid metabolite includes at least one amino acid metabolite residue.
[0188] In certain embodiments, the group may be a monovalent group of the formula: [ka] During the ceremony, L is absent, a carbamate linker, or a carbonate linker; group A is a fatty acyl, a ketone body, a preketone body, a monosaccharide, a sugar acid, or a glucosinolate (e.g., group A is a fatty acyl, a ketone body, a preketone body, a monosaccharide, or a sugar acid); each R is independently a ketone body optionally having a hydroxyl group optionally replaced with an acyl (e.g., a fatty acyl), a preketone body optionally having a hydroxyl group optionally replaced with an acyl (e.g., a fatty acyl), an amino acid metabolite acyl optionally having a hydroxyl group optionally replaced with an acyl (e.g., a fatty acyl), or an acyl; m is an integer from 0 to the total number of available hydroxyl groups in group A (e.g., 1, 2, 3, 4, or 5); however, When group A has a valency on a non-glycosidic alcohol oxygen atom, L is a carbonate or carbamate linker; Provided that when group A has a valence on the carbonyl carbon atom, L is absent.
[0189] When the group of formula (B) is a group containing a fatty acid, the group of formula (B) contains at least one fatty acid. When the group of formula (B) is a group containing a ketone body or a preketone body, the group contains at least one ketone body or a preketone body. When the group of formula (B) is a group containing an amino acid metabolite, the group of formula (B) contains at least one amino acid metabolite.
[0190] In some embodiments, the fatty acid(s) are short chain fatty acyl (e.g., butyryl). In certain embodiments, the fatty acid(s) of the fatty acid-containing group are medium chain fatty acyl (e.g., octanoyl).
[0191] Non-limiting examples of fatty acid-containing groups include: [ka] are listed, During the ceremony, R is H, -CH3, or -CH2OR FA and Each R FA is independently H or a fatty acyl (e.g., a short chain fatty acyl or a medium chain fatty acyl); However, at least one R FAis a fatty acyl (e.g., a short-chain fatty acyl or a medium-chain fatty acyl).
[0192] Non-limiting examples of groups containing ketone bodies include: [ka] are listed, In the formula, R A is H or alkyl, and R FA is a fatty acyl and has one R Me is methyl, and the remaining R Me is H.
[0193] Acylated catechin polyphenols The acylated catechin polyphenols of the present invention are substituted compounds having a core of formula (A): [ka] or a multimer thereof, or a salt thereof, wherein the substituents are independently -OR A , -OCOO-R A , -NHR B , oxo, halogen, optionally substituted C 1-20 Alkyl, optionally substituted C 2-20 Alkenyl, optionally substituted thioalkyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfenyl, optionally substituted alkylsulfinyl, optionally substituted thioaryl, optionally substituted arylthioalkyl, optionally substituted thioalkenyl, dialkylamino, sulfate, phosphate, ascorbic acid, optionally substituted heterocyclyl, nitro, amino acid, C of amino acid 1-6 esters, optionally acylated monosaccharides, and optionally acylated sugar acids, and each R Aare independently H, optionally substituted alkyl, a fatty acid-containing group, a ketone or preketone-containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxyl, halogen, a fatty acid-containing group, a ketone or preketone-containing group, optionally substituted alkoxy, and optionally substituted alkyl; R B is independently H or optionally substituted alkyl; the carbon-carbon bond connecting carbon 2 and carbon 3 in formula (A) is a single bond or a double bond; The multimer comprises a total of two or three cores of formula (A), each core independently substituted as described above; The two adjacent centers in the core (A) are groups -(O) q -L 1 -L 2 -, where q is 0 or 1, and L 1 is an optionally substituted alkylene, an optionally substituted alkenylene, or an optionally substituted heterocyclylene; L 2 is a covalent bond, an optionally substituted heterocyclylene, or an optionally substituted cycloalkylene.
[0194] In some embodiments, at least one of positions 5, 6, 7, and 8 is -OR A where R A is a fatty acid-containing group, a ketone or preketone body-containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxyl, halogen, a fatty acid-containing group, a ketone or preketone body-containing group, optionally substituted alkoxy, and optionally substituted alkyl. In some embodiments, the compound of Formula (A) comprises at least one fatty acid-containing group or at least one ketone or preketone body-containing group.
[0195] The acylated catechin polyphenols of the present invention may be catechin polyphenols in which one or more hydroxyl groups are independently replaced with -OR, where each R is independently selected from the group consisting of acyl, alkyl, a fatty acid-containing group, and a ketone body or preketone body-containing group, provided that at least one R is a fatty acid-containing group or a ketone body or preketone body-containing group.
[0196] The acylated catechin polyphenols are compounds of formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, [ka] is a carbon-carbon single bond or a carbon-carbon double bond, Q is —CH— or —C(O)—; Each R 1 and each R 3 are independently H, halogen, or -OR A , phosphate, or sulfate, R 2 is H or -OR A and Each R A are independently H, optionally substituted alkyl, a monosaccharide, a sugar acid, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, or benzoyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of H, hydroxy, halogen, a fatty acid containing group, a ketone body or preketone body containing group, an amino acid metabolite containing group, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, phosphate, and sulfate; m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, or 4.
[0197] Preferably, each of n and m is independently 0, 1, 2, 3, or 4. More preferably, each of n and m is independently 1, 2, 3, or 4.
[0198] In some embodiments, the compound comprises at least one group comprising a fatty acid, or at least one group comprising a ketone body or a preketone body. 1 -OR A where R A is a group comprising a fatty acid. In certain embodiments, the compound of formula (I) comprises at least one group comprising a ketone body or a preketone body. In further embodiments, the compound comprises at least one group comprising a ketone body or a preketone body. In yet further embodiments, the compound comprises at least one group comprising a preketone body.
[0199] In certain embodiments, [ka] is a carbon-carbon single bond. In certain embodiments, Q is —CH—.
[0200] In some embodiments, the acylated catechin polyphenol is of formula (Ia): [ka]
[0201] In certain embodiments, the acylated catechin polyphenol is of formula (Ib): [ka]
[0202] In certain embodiments, the acylated catechin polyphenol is of formula (Ic): [ka]
[0203] In a further embodiment, the acylated catechin polyphenol is of formula (Id): [ka]
[0204] In certain embodiments, the acylated catechin polyphenol is a compound of formula (If). [ka]
[0205] In still further embodiments, n is 2. In certain embodiments, m is 1. In certain embodiments, m is 2. In some embodiments, m is 3. In certain embodiments, each R 1 are independently -OR A In certain embodiments, each R 3 are independently H or -OR A In a further embodiment, R 2 is H or -OR A In still further embodiments, each R A are independently H, optionally substituted alkyl, a group containing a fatty acid, or a group containing a ketone or preketone body.
[0206] In some embodiments, R 2 is a group of the formula: [ka] where p is 1, 2, 3, or 4, and each R 4 are independently selected from the group consisting of H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone body or a preketone body, a group containing an amino acid metabolite, optionally substituted alkyl, optionally substituted alkoxy, a monosaccharide, a sugar acid, a phosphate, and a sulfate.
[0207] In certain embodiments, p is 3. In certain embodiments, R 4 is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone body or preketone body, a group containing an amino acid metabolite, or an optionally substituted alkoxy.
[0208] In some embodiments, the acylated catechin polyphenol is of formula (Ie): [ka]
[0209] In certain embodiments, R 1A and R 1B each independently represents -OR A In certain embodiments, R 3A , R 3B , and R 3C each independently represents -H, a halogen, or OR A is.
[0210] In a further embodiment, R 2 is a base of the formula: [ka]
[0211] In still further embodiments, R 4A , R 4B、 and R 4C is independently H, hydroxy, halogen, a group containing a fatty acid, a group containing a ketone body or preketone body, a group containing an amino acid metabolite, or an optionally substituted alkoxy.
[0212] In some embodiments, each R A is independently H, optionally substituted alkyl, fatty acyl, or an optionally acylated monosaccharide.
[0213] In certain embodiments, the acylated catechin polyphenol comprises at least one fatty acyl (e.g., a short-chain fatty acyl (e.g., the short-chain fatty acyl is acetyl, propionyl, or butyryl)). In certain embodiments, the acylated catechin polyphenol comprises at least one ketone body. In certain embodiments, the acylated catechin polyphenol comprises at least one preketone body. In further embodiments, the acylated catechin polyphenol comprises at least one amino acid metabolite.
[0214] Acylated Stilbenoids The acylated stilbenoid herein may be a stilbenoid in which one, two, three, four, or five hydroxyl groups are independently replaced with the substituent -OR, where each R is independently selected from the group consisting of acyl, alkyl, a fatty acid-containing group, and a ketone or preketone-containing group, provided that at least one R is a fatty acid-containing group or a ketone or preketone-containing group. When the stilbenoid is not acylated, it is a trans-stilbene substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy (e.g., methoxy) and hydroxyl. Non-limiting examples of stilbenoids include resveratrol, pterostilbene, rhapontigenin, pinostilbene, oxyresveratrol, 4-methoxyresveratrol, and piceatannol. When the stilbenoid is acylated, one or both of the hydroxyl groups in the stilbenoid are independently replaced with a group containing a fatty acid acyl or a group containing a ketone or preketone.In some embodiments, the acylated stilbenoid is acylated resveratrol.In further embodiments, the acylated stilbenoid is acylated piceatannol.
[0215] Acylated Mesalamine The acylated mesalamine of the present invention may be mesalamine in which one or more of -NH, -OH, or -COOH are replaced with acyl, a fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group, provided that the acylated mesalamine contains at least one fatty acid-containing group, a ketone body or preketone body-containing group, or an amino acid metabolite-containing group. The fatty acid-containing group, the ketone body or preketone body-containing group, or the amino acid metabolite-containing group is bonded to mesalamine via a glycosidic bond, an ester bond, an amide bond, a carbonate linker, or a carbamate linker. In some embodiments, the fatty acid-containing group, the ketone body or preketone body-containing group, or the amino acid metabolite-containing group is bonded to mesalamine via a glycosidic bond. In certain embodiments, the acylated mesalamine contains a ketone body or preketone body-containing group. In further embodiments, the acylated mesalamine comprises a group that includes a fatty acid (e.g., a short chain fatty acyl (e.g., the short chain fatty acyl is acetyl, propionyl, or butyryl) or a medium chain fatty acyl (e.g., octanoyl)). In some embodiments, the acylated mesalamine is a compound of formula (II): [ka] During the ceremony, R 1 is H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, R 2 is H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, Each R 3 are independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite, or both R 3 The groups combine to form: [ka]
[0216] In some embodiments, the acylated mesalamine comprises at least one group comprising a fatty acid. In certain embodiments, the acylated mesalamine comprises at least one group comprising a ketone body or a preketone body. In further embodiments, the acylated mesalamine comprises at least one group comprising an amino acid metabolite.
[0217] In yet a further embodiment, R 1 is a group containing H, alkyl, acyl, or fatty acid; R 2 is a group containing H, alkyl, or fatty acid, Each R 3 are independently H, alkyl, acyl, or fatty acid containing groups, or both R 3 The groups combine to form: [ka]
[0218] Acylated ellagic acid and acylated ellagic acid analogs Acylated ellagic acid comprises an ellagic acid core with one or more hydroxyls replaced with acyl (e.g., fatty acyl). Acylated ellagic acid analogs comprise an ellagic acid analog core with one or more hydroxyls replaced with acyl (e.g., fatty acyl).
[0219] Acylated ellagic acid is a compound having the following structure: [ka] or a salt thereof, In the formula, each R A are independently H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, and each R Bare independently H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, provided that at least one R A and / or at least one R B is, if present, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite.
[0220] Acylated ellagic acid analogs are compounds of the following structure: [ka] or a salt thereof, During the ceremony, R 2 , R 3 , and R 4 each independently represents H or -OR A and R 6 is H or -(CO)-R 5B and R 1A is H or -OR A and R 5A is -OH or -OR B or R 1A and R 5A combine to form -O-, R 1B is H or -OR A and R 5B is absent, -OH, or -OR B or R 1B and R 5B combine to form -O-, Each R A are independently H, O protecting groups, alkyl, acyl, fatty acid containing groups, ketone body or preketone body containing groups, or amino acid metabolite containing groups; Each R B are independently H, O protecting groups, alkyl, fatty acid-containing groups, ketone or preketone body-containing groups, or amino acid metabolite-containing groups; However, at least one RA and / or at least one R B is a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite.
[0221] Non-limiting examples of ellagic acid analogs include urolithin A, urolithin B, urolithin C, urolithin D, urolithin E, and urolithin M5.
[0222] Acylated hydroxybenzoic acids Acylated active agents include, for example, acylated hydroxybenzoic acids of the following structure: [ka] or a salt thereof, During the ceremony, n is 1, 2, or 3; Each R 1 is independently H, acyl, alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; R 2 is H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, provided that the compound contains at least one group containing a fatty acid, at least one group containing a ketone body or preketone body, or a group containing an amino acid metabolite.
[0223] Non-limiting examples of acylated hydroxybenzoic acids include gallic acid in which one, two, or three of the phenolic hydroxyls are independently replaced with a group containing a fatty acid, a group containing a ketone or preketone body, or a group containing an amino acid metabolite.
[0224] Acylated sugars The acylated active agent may be, for example, an acylated sugar. The acylated sugar may be a monosaccharide having one or more hydroxyl groups substituted with alkyl, acyl, fatty acid-containing groups, ketone or preketone bodies, or amino acid metabolites. The monosaccharide is present in the form of a pyranose or furanose. Preferably, the monosaccharide is present in the form of a pyranose. The monosaccharide may be an aldose or ketose. Non-limiting examples of monosaccharides include arabinose, xylose, fructose, galactose, glucose, ribose, tagatose, fucose, and rhamnose. In some embodiments, the monosaccharide is L-arabinose, D-xylose, fructose, galactose, D-glucose, D-ribose, D-tagatose, L-fucose, or L-rhamnose. Preferably, the monosaccharide is xylose, arabinose, rhamnose, fucose, glucosamine, or tagatose. The monosaccharide may contain an anomeric carbon bonded to -OR, where R is H, alkyl, acyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite. Preferably, R is an alkyl or a group containing a fatty acid. Alternatively, R is an alkyl or a group containing an amino acid metabolite.
[0225] Acylated Shikimic Acid Acylated active agents include, for example, acylated shikimic acid of the following structure: [ka] or a salt thereof, During the ceremony, Each R 1 is independently H, acyl, alkyl, a group containing a fatty acid, a group containing a ketone body or preketone body, or a group containing an amino acid metabolite; R 2 is H, alkyl, a group containing a fatty acid, a group containing a ketone body or a preketone body, or a group containing an amino acid metabolite, provided that the compound contains at least one group containing a fatty acid, at least one group containing a ketone body or preketone body, or a group containing an amino acid metabolite.
[0226] combination The present invention also provides a combination regimen comprising a first active agent and a second active agent (e.g., as a method or unit dosage form). The first active agent can be, for example, a stilbenoid, a catechin polyphenol, a carotenoid, a bile acid, an amino acid, a hydroxybenzoic acid, a shikimic acid, a monosaccharide, or mesalamine, metformin, a vitamin, or S-adenosyl-L-methionine. The second active agent can be, for example, a ketone body or preketone body, a nuclear receptor modulator (e.g., a PPAR agonist (including alpha, delta / beta, gamma, and heterodimers thereof), an FXR agonist, a thyroid hormone receptor 1β agonist), a GLP1R agonist, or an ACC1 inhibitor. In some embodiments, the first active agent is a stilbenoid (e.g., resveratrol). In further embodiments, the second active agent is a preketone body (e.g., 1,3-butanediol). The first and second active agents may act synergistically to regulate metabolic markers or treat metabolic disorders. The first and second active agents may act synergistically to regulate nonalcoholic fatty liver disease markers or treat nonalcoholic fatty liver disease (e.g., nonalcoholic steatohepatitis). The first and second active agents may be provided in a dose ratio of, for example, 2:1 to 1:20 (e.g., 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:8, 1:1 to 1:3, 1:2 to 1:20, 1:2 to 1:10, 1:2 to 1:8, 1:2 to 1:3, 1:3 to 1:20, 1:3 to 1:10, or 1:3 to 1:8).
[0227] method The acylated active agents and active agent combinations described herein can be used to treat metabolic disorders in subjects in need thereof. Additionally or alternatively, the acylated active agents and active agent combinations described herein can be used to prepare metabolic markers in subjects in need thereof.
[0228] Western diets, high in fat and refined carbohydrates, are associated with weight gain, leading to obesity and the risk of metabolic syndrome, type 2 diabetes, prediabetes, insulin resistance, hypercholesterolemia, and hyperlipidemia. Consumption of these diets can lead to the accumulation of fat in adipose tissue and liver. This can lead to changes in the gut microbiota and elevated levels of related markers. In susceptible individuals, these diet-dependent changes can lead to full-blown diabetes. Type 2 diabetes can cause cardiovascular and ocular diseases, which can result in blindness, peripheral vascular insufficiency, heart disease, and premature death. Dietary changes also correlate with changes in the gut microbiota, a condition known as dysbiosis. Correcting gut dysbiosis can lead to weight loss and improved glucose tolerance, potentially negating many of the harmful effects of an unhealthy diet in the long term. Metabolites of the human gut microbiota, such as short-chain fatty acids (SFCAs), can produce favorable metabolic effects in the human host. In some cases, these molecules may act by binding to short-chain fatty acid receptors. In other cases, benefit may be produced through mechanisms such as peroxisome proliferator-activated receptor gamma (PPAR-gamma) or histone deacetylase inhibition (HDACi).
[0229] A method of treating a metabolic disorder in a subject in need thereof can include administering to the subject in need thereof an acylated active agent (e.g., a pharmaceutical or nutraceutical composition comprising the acylated active agent). In some embodiments, the components of the acylated active agent (e.g., a short-chain fatty acyl (e.g., acetyl) or amino acid metabolite and epigallocatechin gallate or quercetin) can act synergistically to treat the metabolic disorder in a subject in need thereof.
[0230] Alternatively, a method for treating a metabolic disorder in a subject in need thereof can include administering a first active agent (e.g., a pharmaceutical or nutraceutical composition comprising the first active agent) and a second active agent (e.g., a pharmaceutical or nutraceutical composition comprising the second active agent) to the subject in need thereof. In certain embodiments, the first active agent and the second active agent (e.g., resveratrol and preketone bodies) can act synergistically to treat a metabolic disorder in a subject in need thereof. In some embodiments, the first active agent (e.g., a stilbenoid or catechin polyphenol) is co-administered with the second active agent (e.g., a preketone body, a ketone body, or a fatty acid). The first and second active agents can be administered simultaneously. In certain embodiments, the second active agent can be administered before (for example, within 12 hours, within 24 hours, within 3 days, or within 1 week) the administration of the first active agent, simultaneously therewith, or after (for example, within 12 hours, within 24 hours, within 3 days, or within 1 week).When the first active agent and the second active agent are administered simultaneously, the two agents can be administered in separate unit doses or the same unit dose.Preferably, the first active agent is a stilbenoid (for example, resveratrol).Preferably, the second active agent is a preketone body.
[0231] Non-limiting examples of metabolic disorders include obesity, metabolic syndrome, type II diabetes, prediabetes, insulin resistance, hypercholesterolemia, atherosclerosis, and hyperlipidemia.
[0232] A method for modulating a metabolic marker in a subject in need thereof can include administering to the subject an acylated active agent (e.g., a pharmaceutical or nutraceutical composition comprising an acylated active agent). In some embodiments, components of the acylated active agent (e.g., a short-chain fatty acyl (e.g., acetyl) or amino acid metabolite and a catechin polyphenol (e.g., epigallocatechin gallate or quercetin)) can act synergistically to modulate a metabolic marker in a subject in need thereof.
[0233] Alternatively, the method for regulating metabolic markers in a subject in need thereof can include administering a combination of active agents (e.g., a first active agent and a second active agent) to the subject.In certain embodiments, the first active agent and the second active agent (e.g., resveratrol and preketone bodies) can act synergistically to regulate metabolic markers in a subject in need thereof.
[0234] Non-limiting examples of metabolic markers include markers for obesity, type II diabetes, prediabetes, insulin resistance, metabolic syndrome, hypercholesterolemia, and hyperlipidemia.Obesity markers include, for example, total fat percentage, cellular fat, body mass index, weight gain rate, abdominal fat mass, subcutaneous fat mass, inguinal fat mass, epididymal fat mass, the ratio of white fat to brown fat, the level of lipogenesis, and the level of fat storage.When administered to a subject in need of administration, the acylated active agent or combination of active agents described herein can reduce total fat percentage, cellular fat, body mass index, weight gain rate, abdominal fat mass, the ratio of white fat to brown fat, the level of lipogenesis, or the level of fat storage.Markers for type II diabetes, prediabetes, insulin resistance, metabolic syndrome, hypercholesterolemia, and hyperlipidemia include, for example, insulin level, GLP-1 level, PYY level, blood glucose level, hemoglobin A1c level, glucose tolerance level, cholesterol (e.g., HDL or LDL) level, and blood triglyceride level. When administered to a subject in need thereof, the acylated active agents or combinations of active agents described herein can increase insulin levels, GLP-1 levels, or PYY levels. Additionally or alternatively, when administered to a subject in need thereof, the acylated active agents or combinations of active agents described herein can reduce blood glucose levels or hemoglobin A1c levels. Additionally or alternatively, when administered to a subject in need thereof, the acylated active agents or combinations of active agents described herein can increase the subject's glucose tolerance. Additionally or alternatively, when administered to a subject in need thereof, the acylated active agents or combinations of active agents described herein can reduce blood cholesterol (e.g., LDL) levels. Additionally or alternatively, when administered to a subject in need thereof, the acylated active agents or combinations of active agents described herein can reduce blood triglyceride levels.In some embodiments, components of an acylated active agent (e.g., a short chain fatty acyl (e.g., acetyl) or amino acid metabolite and a catechin polyphenol (e.g., epigallocatechin gallate or quercetin)) may act synergistically to modulate metabolic markers, for example, when hydrolyzed in the GI tract of a subject receiving the acylated active agent. In some embodiments, active agents in an active agent combination (e.g., a stilbenoid (e.g., resveratrol) and a preketone body) may act synergistically to modulate metabolic markers upon administration to a subject.
[0235] The markers described herein can be measured using methods known in the art.For example, glucose tolerance can be evaluated using the oral glucose tolerance test (OGTT) described in MedlinePlus (medlineplus.gov).In this test, the subject drinks a liquid containing a predetermined amount of glucose (typically 75g of glucose), and then blood glucose levels are measured 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, and 180 minutes after glucose administration.Insulin sensitivity can be measured using insulin clamp, for example, as described in Farrnini and Mari, J.Hypertens.,16:895-906,1998.Lipogenesis can be measured using hepatic de novo lipogenesis test, for example, as described in Rabol et al., Proc.Nat.Acad.Sci,108:13705-13709,2011. This study evaluates the incorporation of deuterium into plasma very low density lipoprotein triglycerides (VLDL) during administration of deuterium-labeled water.
[0236] The acylated active agents and active agent combinations disclosed herein can be used in methods for treating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH) with or without fibrosis, fatty liver, NASH with advanced fibrosis) in a subject in need thereof. Additionally or alternatively, the acylated active agents and active agent combinations disclosed herein can be used in methods for modulating non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis) markers in a subject in need thereof.
[0237] Typically, a method for treating NAFLD (e.g., NASH) or modulating a NAFLD (e.g., NASH) marker involves administering an acylated active agent or combination of active agents disclosed herein to a subject in need thereof (e.g., a subject diagnosed with or suffering from NAFLD (e.g., NASH)). In some embodiments, the components of an acylated active agent (e.g., a short-chain fatty acyl (e.g., acetyl) or amino acid metabolite and a catechin polyphenol (e.g., epigallocatechin gallate or quercetin)) can act synergistically to treat NAFLD (e.g., NASH) in a subject in need thereof. In certain embodiments, a first active agent and a second active agent (e.g., resveratrol and preketone bodies) can act synergistically to treat NAFLD (e.g., NASH) in a subject in need thereof. In certain embodiments, components of an acylated active agent (e.g., a short-chain fatty acyl (e.g., acetyl) or amino acid metabolite and a catechin polyphenol (e.g., epigallocatechin gallate or quercetin)) may act synergistically to regulate NAFLD markers in a subject in need thereof. In further embodiments, a first active agent and a second active agent (e.g., resveratrol and preketone bodies) may act synergistically to regulate NAFLD markers in a subject in need thereof.
[0238] In some embodiments, the methods reduce the level of alanine transaminase in the subject's blood by at least 1% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more, e.g., up to 99% or 100%) relative to the level of alanine transaminase in the subject's blood prior to the administering step. Certain methods disclosed herein can reduce the level of alanine transaminase in the subject's blood to a level considered normal for a subject (e.g., a human), with normal levels of alanine transaminase in human blood typically ranging from 7 to 56 units / L. In certain embodiments, the methods reduce the level of aspartate transaminase in the subject's blood by at least 1% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 98% or more, e.g., up to 99% or 100%) relative to the level of aspartate transaminase in the subject's blood prior to the administering step. Certain methods disclosed herein can reduce the level of aspartate transaminase in the subject's blood to a level considered normal for a subject (e.g., a human), where normal levels of aspartate transaminase in human blood are typically 10-40 units / L. In certain embodiments, the methods reduce the subject's liver weight by at least 1% relative to the subject's liver weight prior to the administering step.
[0239] The methods described herein may include administering multiple active agents (e.g., stilbenoids, carotenoids, vitamins, catechin polyphenols, S-adenosyl-L-methionine, bile acids, or metformin, for example, in combination with preketone bodies, ketone bodies, or fatty acids). In some embodiments, a first agent (e.g., a stilbenoid, carotenoid, vitamin, catechin polyphenol, S-adenosyl-L-methionine, bile acids, or metformin) is co-administered with a second agent (e.g., a preketone body, ketone body, or fatty acid). The first and second agents may be administered simultaneously. In certain embodiments, the second agent may be administered prior to (e.g., within 12 hours, within 24 hours, within 3 days, or within 1 week), simultaneously with, or after (e.g., within 12 hours, within 24 hours, within 3 days, or within 1 week) the administration of the first agent. When the first and second agents are administered simultaneously, the two agents can be administered in separate unit doses or the same unit dose. Preferably, the first agent is a stilbenoid (e.g., resveratrol). Preferably, the second agent is a preketone body.
[0240] Pharmaceutical and Nutraceutical Compositions The active agents disclosed herein (e.g., acylated active agents or active agents intended for combination regimens, e.g., stilbenoids and preketone bodies) may be formulated into pharmaceutical or nutraceutical compositions for administration to a human subject in a biologically compatible form suitable for in vivo administration. Typically, the pharmaceutical or nutraceutical composition includes an active agent described herein and a physiologically acceptable excipient (e.g., a pharmaceutically acceptable excipient).
[0241] The active agents described herein can also be used in free acid / free base form, salt form, zwitterion form, or solvate form. All forms are within the scope of the present invention. The active agents, their salts, zwitterions, solvates, or pharmaceutical or nutraceutical compositions thereof can be administered to a subject in various forms depending on the selected route of administration, as will be understood by those skilled in the art. The active agents described herein may be administered, for example, orally, parenterally, bucally, sublingually, nasally, rectally, via patch, pump, or transdermally, and the pharmaceutical or nutraceutical compositions are formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transdermal, nasal, pulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may also be administered by continuous infusion over a selected period of time.
[0242] For human use, the active agents disclosed herein can be administered alone or mixed with pharmaceutical or nutraceutical carriers selected according to the intended route of administration and standard pharmaceutical practice.Therefore, pharmaceutical compositions and nutraceutical compositions for use according to the present invention can be formulated in a standard manner using one or more physiologically acceptable carriers, including excipients and adjuvants that facilitate the processing of the active agents disclosed herein into pharmaceutically usable formulations.
[0243] The present disclosure also includes pharmaceutical and nutraceutical compositions, which may contain one or more physiologically acceptable carriers. In preparing the pharmaceutical or nutraceutical compositions of the present invention, the active ingredient is typically mixed with an excipient, diluted by an excipient, or enclosed within a carrier, such as a capsule, sachet, paper, or other container. When an excipient serves as a diluent, the excipient may be a solid, semi-solid, or liquid material (e.g., normal saline) that serves as a vehicle, carrier, or medium for the active ingredient. Thus, the composition may be in the form of a tablet, powder, troche, sachet, cachet, elixir, suspension, emulsion, solution, syrup, and soft and hard gelatin capsules. As is known in the art, the type of diluent may vary depending on the intended route of administration. The resulting composition may contain additional agents, such as preservatives. The nutraceutical composition may be administered enterally (e.g., orally). The nutraceutical composition may be a nutritional oral formulation (e.g., a tablet, powder, troche, sachet, cachet, elixir, suspension, emulsion, solution, syrup, or soft or hard gelatin capsule), a food additive (e.g., a food additive as defined in 21 CFR § 170.3), a food (e.g., a food for specific food use as defined in 21 CFR § 105.3), or a dietary supplement (e.g., where the active agent is a dietary ingredient (e.g., as defined in 21 USC § 321(ff))). The active agent may be used for nutritional supplement applications and may be used as a food additive or as a food. Non-limiting examples of compositions containing the active agent of the present invention are a bar, a drink, a shake, a powder, an additive, a gel, or a chew.
[0244] Excipients or carriers are selected based on the mode and route of administration. Suitable pharmaceutical carriers and pharmaceutical necessities for use in pharmaceutical formulations are described in Remington: The Science and Practice of Pharmacy, 21, a reference well known in the art. st Ed.,Gennaro,Ed.,Lippencott Williams & Wilkins (2005), and USP / NF (United The excipients are listed in the US Pharmacopeia and the National Formulary. Examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methylcellulose. The formulation may further include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. Other exemplary excipients are listed in Handbook of Pharmaceutical Excipients, 6 th Edition, Rowe et al., Eds., Pharmaceutical Press (2009).
[0245] These pharmaceutical and nutraceutical compositions can be manufactured in a conventional manner, for example, by conventional mixing, dissolving, granulating, dragee-making, pulverizing, emulsifying, encapsulating, entrapping, or lyophilizing processes. Methods known in the art for preparing formulations are described, for example, in Remington: The Science and Practice of Pharmacy, 21 st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2005), and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York. Appropriate formulation depends on the selected route of administration. The formulation and preparation of such compositions are known to those skilled in the art of pharmaceutical formulations and nutraceutical formulations. In the preparation of the formulation, the active agent can be milled to provide an appropriate particle size before combining with other ingredients. If the active agent is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active agent is substantially water-soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, for example, about 40 mesh.
[0246] dose The dosage of the active agent or its pharmaceutically acceptable salt or prodrug, or its pharmaceutical composition or nutraceutical composition used in the methods described herein can vary depending on many factors, such as the pharmacodynamic properties of the active agent, the mode of administration, the recipient's age, health condition and weight, the nature and severity of symptoms, the frequency of treatment, and the type of concomitant treatment, if any, and the clearance rate of the active agent in the treated subject.Those skilled in the art can determine the appropriate dosage based on the above factors.The active agent used in the methods described herein can be initially administered at a suitable dosage, which can be adjusted as needed depending on clinical response.In general, the suitable daily dosage of the active agent disclosed herein is the amount of the active agent that is the minimum dosage effective to produce a therapeutic effect.Such an effective dosage generally depends on the above factors.
[0247] The active agents disclosed herein may be administered to a subject in a single dose or multiple doses. When multiple doses are administered, the doses may be separated from each other by, for example, 1 to 24 hours, 1 to 7 days, or 1 to 4 weeks. The active agents may be administered according to a schedule, or the active agents may be administered without a predetermined schedule. For any particular subject, specific dosing regimens should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the composition.
[0248] The active agent may be provided in a unit dosage form, which in some embodiments may be an oral unit dosage form (e.g., a tablet, capsule, suspension, liquid solution, powder, crystal, troche, sachet, cachet, elixir, syrup, etc.) or a single serving of food (e.g., the active agent may be included as a food additive or dietary supplement). In certain embodiments, the unit dosage form is designed for administration of at least one active agent disclosed herein, wherein the total amount of the active agent(s) administered is between 0.1 g and 10 g (e.g., between 0.5 g and 9 g, between 0.5 g and 8 g, between 0.5 g and 7 g, between 0.5 g and 6 g, between 0.5 g and 5 g, between 0.5 g and 1 g, between 0.5 g and 1.5 g, between 0.5 g and 2 g, between 0.5 g and 2.5 g, between 1 g and 1.5 g, between 1 g and 2 g, between 1 g and 2.5 g, between 1.5 g and 2 g, between 1.5 g and 2.5 g, or between 2 g and 2.5 g). When the administered active agents are provided as a combination of active agents, the total amount can be, for example, 0.1 g to 10 g (e.g., 0.5 g to 9 g, 0.5 g to 8 g, 0.5 g to 7 g, 0.5 g to 6 g, 0.5 g to 5 g, 0.5 g to 1 g, 0.5 g to 1.5 g, 0.5 g to 2 g, 0.5 g to 2.5 g, 1 g to 1.5 g, 1 g to 2 g, 1 g to 2.5 g, 1.5 g to 2 g, 1.5 g to 2.5 g, or 2 g to 2.5 g). In other embodiments, the active agent is taken at a rate of 0.1 g to 10 g per day (e.g., 0.5 g to 9 g, 0.5 g to 8 g, 0.5 g to 7 g, 0.5 g to 6 g, 0.5 g to 5 g, 0.5 g to 1 g, 0.5 g to 1.5 g per day, 0.5 g to 2 g per day, 0.5 g to 2.5 g per day, 1 g to 1.5 g per day, 1 g to 2 g per day, 1 g to 2.5 g per day, 1.5 g to 2 g per day, 1.5 g to 2.5 g per day, or 2 g to 2.5 g per day).When the administered active agents are provided as a combination of active agents, the total daily dose may be 0.1 g to 10 g per day (e.g., 0.5 g to 9 g, 0.5 g to 8 g, 0.5 g to 7 g, 0.5 g to 6 g, 0.5 g to 5 g, 0.5 g to 1 g, 0.5 g to 1.5 g per day, 0.5 g to 2 g per day, 0.5 g to 2.5 g per day, 1 g to 1.5 g per day, 1 g to 2 g per day, 1 g to 2.5 g per day, 1.5 g to 2 g per day, 1.5 g to 2.5 g per day, or 2 g to 2.5 g per day) or more. The appropriate amount and dosing regimen is ultimately determined by the attending physician. An effective amount of an active agent disclosed herein may be, for example, a total daily dose of any of the acylated active agents or combinations of active agents described herein, for example, 0.5 g to 10 g (e.g., 0.5 to 5 g). Alternatively, the dosage can be calculated using the subject's body weight. Preferably, if the daily dosage exceeds 5 g / day, the dosage of the active agent can be divided into two or three daily administration events.
[0249] In the methods of the present invention, the period over which multiple doses of an active agent disclosed herein are administered to a subject can vary. For example, in some embodiments, doses of an active agent are administered to a subject over a period of 1 to 7 days, 1 to 12 weeks, or 1 to 3 months. In other embodiments, the active agent is administered to a subject over a period of, for example, 4 to 11 months or 1 to 30 years. In still other embodiments, the active agent disclosed herein is administered to a subject at the onset of symptoms. In any of these embodiments, the amount of active agent administered can vary over the administration period. If the active agent is administered daily, administration can occur, for example, once, twice, three times, or four times per day.
[0250] formulation The active agent described herein can be administered to the subject in unit dosage form with pharmaceutically acceptable diluent, carrier or excipient.Conventional pharmaceutical practice can be adopted to provide suitable formulation or composition for administering the active agent to the subject suffering from disorder.Administration can be started before the subject shows symptoms.
[0251] Exemplary administration routes of the active agent disclosed herein or its pharmaceutical composition or nutraceutical composition used in the present invention include oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intraarterial, intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, and topical administration.It is desirable that the active agent be administered together with a physiologically acceptable carrier (e.g., a pharmaceutically acceptable carrier).Pharmaceutical preparations of the active agent disclosed herein, formulated for the treatment of the disorders described herein, are also part of the present invention.In some preferred embodiments, the active agent disclosed herein is administered to a subject orally.In other preferred embodiments, the active agent disclosed herein is administered to a subject topically.
[0252] Oral administration formulation Pharmaceutical and nutraceutical compositions contemplated by the present invention include those formulated for oral administration ("oral unit dosage forms"), which may be in the form of, for example, a tablet, capsule, liquid solution or suspension, powder, or liquid or solid crystals, containing the active ingredient(s) in a mixture with a physiologically acceptable excipient (e.g., a pharmaceutically acceptable excipient). These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugars, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate), granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid), binders (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol), and lubricants, glidants, and antiadherents (e.g., magnesium stearate, zinc stearate, stearic acid, silica, hydrogenated vegetable oils, or talc). Other physiologically acceptable excipients (eg, pharmaceutically acceptable excipients) can be colorants, flavoring agents, plasticizers, humectants, buffering agents, and the like.
[0253] Formulations for oral administration may also be provided as chewable tablets, hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate, or kaolin), or soft gelatin capsules in which the active ingredient is mixed with an aqueous or oily medium, such as peanut oil, liquid paraffin, or olive oil. Powders, granules, and pellets may be prepared using the ingredients described above under tablets and capsules in a conventional manner, for example, using a mixer, fluidized bed apparatus, or spray drying apparatus.
[0254] Controlled-release compositions for oral use may be constructed to release the active agent by controlling the dissolution and / or diffusion of the active drug substance. Any of a number of strategies can be pursued to achieve a controlled release versus time profile and target plasma concentration. In one example, controlled-release is obtained by appropriately selecting various formulation parameters and components, including, for example, various types of controlled-release compositions and coatings. Examples include single- or multi-unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. In certain embodiments, the composition includes a biodegradable, pH- and / or temperature-sensitive polymer coating.
[0255] Dissolution or diffusion controlled release can be achieved by suitable coating of tablet, capsule, pellet, or granule formulations of the active agent or by incorporating the active agent into a suitable matrix. The controlled release coating may comprise one or more of the coating materials described above and / or, for example, shellac, beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glycerol palmitostearate, ethylcellulose, acrylic resin, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinylpyrrolidone, polyethylene, polymethacrylate, methyl methacrylate, 2-hydroxymethacrylate, methacrylate hydrogel, 1,3-butylene glycol, ethylene glycol methacrylate, and / or polyethylene glycol. In controlled-release matrix formulations, the matrix material may further comprise, for example, hydrated methylcellulose, carnauba wax, and stearyl alcohol, Carbopol 934, silicone, glyceryl tristearate, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene, and / or halogenated fluorocarbons.
[0256] Liquid forms into which the active agents and compositions of the present invention can be incorporated for oral administration include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical and nutraceutical vehicles.
[0257] Oral administration formulation The dosage for oral or sublingual administration is usually 0.1-500 mg per administration, as needed. In practice, a doctor will determine the actual dosage regimen that is most suitable for each individual subject, and the dosage will vary depending on the age, weight, and response of the specific subject. The dosages above are average cases, but there are individual cases where higher or lower dosages are beneficial, and such cases are also within the scope of the present invention.
[0258] For oral administration, the compositions may take the form of tablets, lozenges, etc., formulated in a conventional manner. Liquid drug formulations suitable for use with nebulizers and liquid spray devices and electrohydrodynamic (EHD) aerosol devices generally contain an active agent disclosed herein together with a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is preferably a liquid, such as alcohol, water, polyethylene glycol, or a perfluorocarbon. Optionally, another material may be added to alter the aerosol properties of the solution or suspension of the active agent disclosed herein. Desirably, this material is a liquid, such as an alcohol, glycol, polyglycol, or fatty acid. Other methods for formulating liquid drug solutions or suspensions suitable for use in aerosol devices are known to those skilled in the art (see, e.g., U.S. Pat. Nos. 5,112,598 and 5,556,611, which are incorporated herein by reference).
[0259] Formulations for nasal and inhaled administration Active agent can be formulated for nasal administration.The composition for nasal administration is preferably formulated as aerosol, drop, gel and powder.The formulation can be provided in single or multiple dose form.In case of dropper or pipette, administration can be achieved by administering a suitable, predetermined amount of solution or suspension to the subject.In case of spray, it can be achieved by a metered atomizing spray pump.
[0260] The active agent may further be formulated for aerosol administration, particularly to the respiratory tract via inhalation, including intranasal administration. Active agents for nasal or inhaled administration generally have a small particle size, e.g., on the order of 5 microns or less. Such a particle size can be obtained by means known in the art, for example, by micronization. The active ingredient is provided in a pressurized pack containing a suitable propellant, e.g., a chlorofluorocarbon (CFC), such as dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide, or other suitable gas. The aerosol may conveniently further contain a surfactant, e.g., lecithin. The dosage of the drug may be controlled by a metered valve. Alternatively, the active ingredient may be provided in the form of a dry powder, e.g., a powder mix of the active agent in a suitable powder base, such as lactose, starch and starch derivatives, e.g., hydroxypropylmethylcellulose, and polyvinylpyrrolidine (PVP). The powder carrier forms a gel in the nasal cavity. The powder composition may be presented in unit dose form in capsules or cartridges, for example, gelatin or blister packs from which the powder may be administered by means of an inhaler.
[0261] Aerosol formulations typically contain a solution or fine suspension of an active substance in a physiologically acceptable aqueous or non-aqueous solvent, and are usually provided in a sterile form in a sealed container in single or multiple doses, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container can be a unitary dispensing device, such as a single-dose nasal inhaler or aerosol dispenser with a metered valve intended for disposal after use. When the unit dosage form comprises an aerosol dispenser, it contains a propellant, which can be, for example, compressed air or a compressed gas such as an organic propellant, e.g., fluorochlorohydrocarbon. The aerosol unit dosage form can also take the form of a pump atomizer.
[0262] Parenteral administration formulations The active agents described herein for use in the methods of the present invention can be administered in pharmaceutically acceptable parenteral (e.g., intravenous or intramuscular) formulations described herein. Pharmaceutical formulations may also be administered parenterally (intravenously, intramuscularly, subcutaneously, etc.) in unit dosage forms or formulations containing standard, non-toxic pharmaceutically acceptable carriers and adjuvants. In particular, formulations suitable for parenteral administration include aqueous or non-aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient. Also included are aqueous or non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. For example, to prepare such compositions, the active agents disclosed herein may be dissolved or suspended in a parenterally acceptable liquid vehicle. Among acceptable vehicles and solvents that may be employed are water, appropriate amounts of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and water adjusted to a suitable pH by adding isotonic sodium chloride solution. The aqueous formulation may further include one or more preservatives, such as, for example, methyl, ethyl, or n-propyl p-hydroxybenzoate. Additional information regarding parenteral formulations can be found, for example, in the United States Pharmacopeia-National Formulary (USP-NF), which is incorporated herein by reference.
[0263] The parenteral formulation may be any of the five general types of preparations identified by the USP-NF as suitable for parenteral administration. (1) "drug injection" liquid preparations that are drug substances (e.g., active agents disclosed herein or solutions thereof); (2) "Injectable Drug" drug substance (e.g., an active drug disclosed herein) as a dry solid mixed with a sterile vehicle suitable for parenteral administration as an injection; (3) "Drug Injectable Emulsion" a liquid preparation of a drug substance (e.g., an active agent disclosed herein) dissolved or dispersed in a suitable emulsion vehicle; (4) "Drug Injectable Suspensions" liquid preparations of drug substances (e.g., active agents disclosed herein) suspended in a suitable liquid medium; and (5) "Drug for Injectable Suspension" Drug substance (e.g., an active agent disclosed herein) as a dry solid mixed with a sterile vehicle suitable for parenteral administration as a drug injectable suspension.
[0264] Exemplary formulations for parenteral administration include solutions of active agents prepared in water, suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can be prepared in glycerol, liquid polyethylene glycol, DMSO, and mixtures thereof with or without alcohol, and in oils. Under normal conditions of storage and use, these preparations may contain preservatives to prevent the growth of microorganisms. Standard procedures and ingredients for the selection and preparation of suitable formulations can be found, for example, in Remington: The Science and Practice of Pharmacy, 21 st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2005), and The United States Pharmacopeia: The National Formulary (USP 36 NF31), published in 2013.
[0265] Formulations for parenteral administration may contain, for example, excipients such as sterile water or saline, polyalkylene glycols such as polyethylene glycol, plant-derived oils, or hydrogenated naphthalene. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the active agent or the release of bioactive agents within the active agent. Other potentially useful parenteral delivery systems for active agents include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Inhalation formulations may contain excipients such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate, and deoxycholate, or may be oily solutions for administration in the form of nasal drops or as a gel.
[0266] Parenteral formulations may be formulated for immediate release of the active agent or for sustained / extended release. Examples of formulations for parenteral release of the active agent include aqueous solutions, powders for reconstitution, co-solvent solutions, oil / water emulsions, suspensions, oil-based solutions, liposomes, microspheres, and polymer gels.
[0267] Preparation of acylated active agents Acylated active agents can be prepared using synthetic methods and reaction conditions known in the art.Optimal reaction conditions and reaction times can vary depending on the reactants used.Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions can be selected by those skilled in the art.
[0268] Ester Preparation Strategy #1 (Acylation) [ka] In Scheme 1, a polyphenol compound, Compound 1 (where n is an integer from 1 to 15), is treated with an acylating agent, Compound 2, in a suitable solvent, optionally in the presence of a catalyst. Suitable catalysts include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to Compound 2. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. Suitable acylating agents, regardless of symmetric or asymmetric, include acyl chlorides, acyl fluorides, acyl bromides, and carboxylic acid anhydrides. Suitable acylating agents may be generated in situ by pre-reacting a carboxylic acid with an activating agent, such as EDC or EEDQ. The acylating agent can be used in an amount ranging from 0.5 to 15 equivalents relative to Compound 1.
[0269] The product, compound 3, can be purified by methods known to those skilled in the art.
[0270] Ester Preparation Strategy #2 (Acylation) In some cases, polyphenol compound 1 may contain a functional group Y that must remain unreacted during ester formation. In this case, it is appropriate to protect the functional group Y in the polyphenol compound from acylation. This functional group may be an amino group, a hydroxyl group, or another functional group having a labile hydrogen atom attached to a heteroatom. Such polyphenol esters can be prepared according to Scheme 2. [ka]
[0271] In step 1 of scheme 2, compound 1, a polyphenol compound containing a functional group Y having a labile hydrogen that requires protection, is treated with a protecting reagent such as BOC anhydride, benzyloxycarbonyl chloride, FMOC chloride, benzyl bromide, etc., in a suitable solvent, optionally in the presence of a catalyst, to obtain compound 2, scheme 2. Compound 2 can be purified by methods known to those skilled in the art.
[0272] In step 2 of Scheme 2, compound 2 is treated with an acylating agent, compound 3, in a suitable solvent, optionally in the presence of a catalyst. Suitable catalysts include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to compound 2. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. Suitable acylating agents include acyl chlorides, acyl fluorides, acyl bromides, and carboxylic acid anhydrides, regardless of symmetric or asymmetric reactions. A suitable acylating agent may be generated in situ by pre-reacting a carboxylic acid with an activating agent, such as EDC or EEDQ. The acylating agent can be used in an amount ranging from 0.5 to 15 equivalents relative to compound 3. Compound 4 can be purified by methods known to those skilled in the art.
[0273] In step 3 of Scheme 2, compound 4 is subjected to conditions that cleave the protecting group PG.
[0274] In the case of a BOC protecting group, the protecting group of compound 4 is removed under acidic conditions to give compound 5 of the present invention. Suitable acids include trifluoroacetic acid, hydrochloric acid, p-toluenesulfonic acid, and the like.
[0275] In the case of the FMOC protecting group, the protecting group of compound 4 is removed under basic conditions to give compound 5 of the present invention. Suitable bases include piperidine, triethylamine, and the like. Suitable solvents include DMF, NMP, dichloromethane, and the like. The FMOC group can also be removed under non-basic conditions, for example, by treatment with tetrabutylammonium fluoride trihydrate in a suitable solvent such as DMF. The FMOC group can also be removed by catalytic hydrogenation. Suitable catalysts for hydrogenation include 10% palladium on carbon and palladium(II) acetate. Suitable solvents for hydrogenation include DMF, ethanol, and the like.
[0276] In the case of a benzyloxycarbonyl or benzyl protecting group, the protecting group of compound 4 is removed by hydrogenation to give compound 5. Suitable catalysts for hydrogenation include 10% palladium on carbon and palladium acetate. Suitable solvents for hydrogenation include DMF, ethanol, methanol, ethyl acetate, and the like. The product, compound 5, can be purified by methods known to those skilled in the art.
[0277] Ester Preparation Strategy #3 (Acylation) [ka] In step 1 of scheme 3, compound 1, an acyl compound containing a functional group Y having a labile hydrogen that requires protection, is treated with a protecting reagent such as BOC anhydride, benzyloxycarbonyl chloride, FMOC chloride, benzyl bromide, etc., in a suitable solvent, optionally in the presence of a catalyst, to give compound 2, scheme 3. Compound 2 can be purified by methods known to those skilled in the art.
[0278] In step 2 of Scheme 3, compound 2 is treated with an activating reagent such as thionyl chloride, phosphorus oxychloride, EDC, or EEDQ to form activated acyl compound 3.
[0279] In step 3 of Scheme 3, polyphenol compound 4 is treated with activated acyl compound 3 in a suitable solvent, optionally in the presence of a catalyst. Suitable catalysts for producing compound 5 include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to compound 3. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. The activated acyl compound 3 can be used in an amount ranging from 0.5 to 15 equivalents relative to compound 4.
[0280] In step 4 of Scheme 3, compound 5 is subjected to conditions designed to cleave the protecting group PG shown above in Scheme 2. The product, compound 6, can be purified by methods known to those skilled in the art.
[0281] Ester Preparation Strategy #4 (Acylation) [ka] In step 1 of Scheme 4, compound 1, a polyol compound, is treated with compound 2, an acylating agent, in a suitable solvent, optionally in the presence of a catalyst. In the formula of compound 1, R represents a non-aromatic ring or acyclic moiety, and n represents an integer of 1 to 15. Suitable catalysts include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to compound 2. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. Suitable acylating agents include acyl chlorides, acyl fluorides, acyl bromides, and carboxylic acid anhydrides, regardless of whether they are symmetric or asymmetric. A suitable acylating agent may be generated in situ by pre-reacting a carboxylic acid with an activating agent such as EDC or EEDQ. The acylating agent may be used in an amount ranging from 0.5 to 15 equivalents relative to compound 1. The product, compound 3, may be purified by methods known to those skilled in the art.
[0282] Ester Preparation Strategy #5 (Baeyer-Villiger Oxidation) [ka] In step 1 of Scheme 5, ketone compound 1 (where R and R represent a non-aromatic cyclic or acyclic moiety) is treated with a peroxide or peroxyacid agent, such as meta-chloroperbenzoic acid, performic acid, peracetic acid, hydrogen peroxide, or tert-butyl hydroperoxide, in a suitable solvent, optionally in the presence of a catalyst. Suitable solvents include methylene chloride, diethyl ether, and combinations thereof. Suitable catalysts include BF3, carboxylic acids, and the like. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. The product, compound 2, can be purified by methods known to those skilled in the art.
[0283] The R and R groups of compound 1 in Scheme 5 may optionally contain an additional ketone functional group capable of undergoing reaction. Additionally, the R and R groups of compound 1 may form a ring.
[0284] Ester Preparation Strategy #6 (Mitsunobu Reaction) [ka] In step 1 of Scheme 6, a mixture of an alcohol compound, Compound 1, and a carboxylic acid, Compound 2, is treated with triphenylphosphine and a diazo compound, such as diethylazodicarboxylate (DEAD), in a suitable solvent. In the formula for Compound 1, R represents a non-aromatic cyclic or acyclic moiety. In the formula for Compound 2, R represents an alkanoyl group optionally substituted with one or more protected hydroxyl or oxo groups. Suitable solvents include methylene chloride, THF, acetonitrile, toluene, diethyl ether, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. The product, Compound 3, can be purified by methods known to those skilled in the art.
[0285] When compound 3 is optionally substituted with one or more protected alcohol groups, deprotection is achieved by the methods shown in Scheme 2 above.
[0286] Ester Preparation Strategy #7 (Nucleophilic Alkylation) [ka] In step 1 of Scheme 7, compound 1, a chloroformate, is treated with compound 2, an organometallic compound, in a suitable solvent. In the formula of compound 1, R represents an aromatic moiety, a non-aromatic cyclic moiety, or a non-aromatic acyclic moiety. In the formula of compound 2, R represents an alkyl group optionally substituted with one or more protected hydroxyl groups, and X represents a metal, such as Cu, Zn, or Mg, optionally coordinated with one or more counterions, such as chloride. Suitable solvents include methylene chloride, THF, acetonitrile, toluene, diethyl ether, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. The product, compound 3, can be purified by methods known to those skilled in the art.
[0287] Compound 1 can be prepared from the corresponding alcohol or polyol compounds by standard methods well known to those skilled in the art.
[0288] When compound 2 is optionally substituted with one or more protected alcohol groups, deprotection is achieved by the methods shown in Scheme 2 above.
[0289] The initial products may be further modified by methods known to those of skill in the art and illustrated in the examples below to prepare additional compounds of the present invention.
[0290] Ester Preparation Strategy #8 (Acylation) [ka] In step 1 of scheme 8, compound 1, an acyl compound containing a hydroxyl group to be acylated, is treated with a protecting reagent, such as benzyl bromide, in a suitable solvent, optionally in the presence of a catalyst, to give compound 2, scheme 8. Compound 2 can be purified by methods known to those skilled in the art.
[0291] In step 2 of Scheme 8, compound 2 is treated with an acylating agent in a suitable solvent, optionally in the presence of a catalyst. Suitable catalysts include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to compound 2. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. Suitable acylating agents include acyl chlorides, acyl fluorides, acyl bromides, and carboxylic anhydrides, regardless of symmetric or asymmetric reactions. Suitable acylating agents may be generated in situ by reacting a carboxylic acid with an activating reagent such as EDC or EEDQ. The acylating agent can be used in an amount ranging from 0.5 to 15 equivalents relative to compound 1.
[0292] In step 3 of Scheme 8, compound 3 is subjected to conditions that cleave the protecting group PG. In the case of a benzyl protecting group, the protecting group of compound 3 is removed by hydrogenation to give compound 4. Suitable catalysts for hydrogenation include 10% palladium on carbon and palladium acetate. Suitable solvents for hydrogenation include DMF, ethanol, methanol, ethyl acetate, and the like. The product, compound 4, can be purified by methods known to those skilled in the art.
[0293] In step 4 of scheme 8, compound 4 is treated with an activating reagent such as thionyl chloride, phosphorus oxychloride, EDC, or EEDQ to form activated acyl compound 5.
[0294] In step 5 of Scheme 8, compound 6, a polyhydroxyl compound, is treated with activated acyl compound 5 in a suitable solvent, optionally in the presence of a catalyst. In the formula of compound 6, R represents an aromatic or aliphatic cyclic or acyclic core. Suitable catalysts for producing compound 5 include pyridine, dimethylaminopyridine, trimethylamine, and the like. The catalyst can be used in an amount ranging from 0.01 to 1.1 equivalents relative to compound 3. Suitable solvents include methylene chloride, ethyl acetate, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, and combinations thereof. The reaction temperature ranges from -10°C to the boiling point of the solvent used, and the reaction completion time ranges from 1 to 96 hours. The activated acyl compound 5 can be used in an amount ranging from 0.5 to 15 equivalents relative to compound 6.
[0295] The product, compound 7, can be purified by methods known in the art.
[0296] The following examples are intended to illustrate the invention. They are not intended to limit the invention in any way. [Example]
[0297] Example 1. Preparation of exemplary acylated active agents [ka] Compound 1: [4-[(E)-2-[3,5-di(butanoyloxy)phenyl]vinyl]phenyl]butanoate To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (3 g, 13.14 mmol) and K2CO3 (4.54 g, 32.86 mmol) in acetonitrile (50 mL) was added butanoyl chloride (5.60 g, 52.58 mmol, 5.49 mL). The mixture was stirred at 20 °C for 10 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 10:1). Compound 1 was obtained as a white solid. LC / MS: (M+NH4 + ):456.2 [ka] Compound 2: [4-[(E)-2-[3,5-bis(4-phenylbutanoyloxy)phenyl]vinyl]phenyl]4-phenylbutanoate
[0298] Process 1 To a solution of 4-phenylbutanoic acid (5 g, 30.45 mmol) in dichloromethane (50 mL) was added SOCl (10.87 g, 91.35 mmol, 6.63 mL) at 0 °C. The mixture was stirred at 20 °C for 10 h. The reaction mixture was concentrated under reduced pressure to give a residue, which was dissolved in toluene (15 mL). The solution was concentrated under reduced pressure to give 4-phenylbutanoyl chloride (4.32 g, crude) as a yellow oil, which was used directly in the next step.
[0299] Process 2 To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.278 g, 1.22 mmol) and K2CO3 (420.89 mg, 3.05 mmol) in acetonitrile (30 mL) was added 4-phenylbutanoyl chloride (1.00 g, 5.48 mmol). The mixture was stirred at 20 °C for 10 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was mixed with another batch and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 8:1) to give compound 2 (367 mg) as a white solid. LC / MS (M+NH4 + ):684.3 [ka] Compound 3: [(2R,3R)-5,7-di(butanoyloxy)-2-[3,4,5-tri(butanoyloxy)phenyl]chroman-3-yl]3,4,5-tri(butanoyloxy)benzoate
[0300] Butyryl chloride (6.03 mL) was added to a stirred solution of epigallocatechin gallate (2.0 g) and pyridine (6.28 mL) in dichloromethane (20 mL) over 2 hours at −5° C. to 5° C. The resulting mixture was stirred overnight at room temperature. The reaction mixture was then diluted with dichloromethane (100 mL) and washed sequentially with water (50 mL), 2N HCl (50 mL), saturated sodium bicarbonate (50 mL), and brine. The organic layer was evaporated in vacuo, and the resulting crude material was purified by flash chromatography (30% ethyl acetate / heptane) to give compound 3 (800 mg, 18%). 1 H NMR (CDCl3): δ7.6(s, 2H), 7.22(s, 2H), 6.78(s, 1H), 6.6(s, 1H), 5.62(t, 1H), 5.18 (s, 1H), 2.98~3.02(m, 2H), 2.4~2.6(m, 16H), 1.6~1.8(m, 16H), 0.92~1.02(m, 24H). [ka] Compound 4: [(2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)chroman-3-yl]3,4,5-triacetoxybenzoate
[0301] Acetic anhydride (6.1 mL) was added dropwise to epigallocatechin gallate (2.0 g) in pyridine (20 mL) at 0° C., and the resulting mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the solid was filtered and washed with 1N HCl (10 mL) and aqueous heptane (20 mL). The solid was then dissolved in dichloromethane and passed through a silica gel filter column using dichloromethane as the mobile phase. The volatiles were evaporated to give compound 4 (1.0 g, 28%). 1 H NMR (CDCl3): δ7.6(s, 2H), 7.2(s, 2H), 6.75(s, 1H), 6.6(s, 1H), 5.6(t, 1H), 5.19(s, 1H), 2.98~3.02(m, 2H), 2.18~2.28(m, 24H). [ka] Compound 5: [(2R,3R)-5,7-bis(4-phenylbutanoyloxy)-2-[3,4,5-tris(4-phenylbutanoyloxy)phenyl]chroman-3-yl]3,4,5-tris(4-phenylbutanoyloxy)benzoate
[0302] Step 1: To a solution of 4-phenylbutanoic acid (3 g, 18.27 mmol) and SOCl (10.87 g, 91.35 mmol, 6.63 mL) in dichloromethane (50 mL), one drop of DMF was added, and the mixture was stirred at 20 °C for 5 h. The solvent was removed in vacuo, and toluene (20 mL) was added to the mixture. The mixture was concentrated in vacuo to give 4-phenylbutanoyl chloride (3.5 g, crude).
[0303] Step 2: To a solution of [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate (1 g, 2.18 mmol) and K2CO3 (4.52 g, 32.72 mmol) in acetonitrile (100 mL) was added a solution of 4-phenylbutanoyl chloride (7.97 g, 43.63 mmol) in acetonitrile (10 mL), and the mixture was stirred at 20 °C for 10 h. The mixture was filtered, and the filtrate was concentrated in vacuo. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate = 20:1 to 1:1) to give compound 5 (2.2 g, 1.28 mmol, 58.7% yield) as a white solid. LC / MS (M+H3O) + ):1645.1 [ka] Compound 6: [(2R,3R)-5,7-bis(3-hydroxybutanoyloxy)-2-[3,4,5-tris(3-hydroxybutanoyloxy)phenyl]chroman-3-yl]3,4,5-tris(3-hydroxybutanoyloxy)benzoate [ka] Compound 7: [4-[(E)-2-[3,5-bis[[(3R)-3-hydroxybutanoyl]oxy]phenyl]vinyl]phenyl](3R)-3-hydroxybutanoate [ka] Compound 8: [(2R,3R)-5,7-bis(3-oxobutanoyloxy)-2-[3,4,5-tris(3-oxobutanoyloxy)phenyl]chroman-3-yl]3,4,5-tris(3-oxobutanoyloxy)benzoate [ka] Compound 9: [4-[(E)-2-[3,5-di(propanoyloxy)phenyl]vinyl]phenyl]propanoic acid salt [ka] Compound 10: [4-[(E)-2-[3,5-bis(3-oxobutanoyloxy)phenyl]vinyl]phenyl]3-oxobutanoate [ka] Compound 11: [4-[(E)-2-[3,5-di(octanoyloxy)phenyl]vinyl]phenyl]octanoate
[0304] To a mixture of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (1 g) and K2CO3 (1.8 g) in ACN (30 mL) was added octanoyl chloride (2.14 g) at 25 °C. The mixture was stirred at 25 °C for 10 h. Additional octanoyl chloride (1.42 g) was added, and the mixture was stirred at 25 °C for 10 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse-phase preparative HPLC (C18, water (0.05% HCl)-ACN gradient) to give compound 11 (0.53 g, 20% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3). 7.481(m, 2H), 7.107~6.956(m, 6H), 6.809(m, 1H), 2.564(m, 6H), 1.781(m, 6H), 1.383(m, 24H), 0.894(m, 9H). [ka] Compound 12: [4-[(E)-2-[3,5-di(decanoyloxy)phenyl]vinyl]phenyl]decanoate
[0305] To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (1 g) and K2CO3 (3.0 g) in ACN (50 mL) was added dropwise decanoyl chloride (5.85 g). The mixture was then stirred at 25 °C for 16 h. The mixture was filtered and concentrated, and the residue was purified by silica gel chromatography (petroleum ether / EtOAc, 10:1) followed by preparative TLC (petroleum ether / EtOAc, 5:1) to give compound 12 (0.062 g, 2%) as a yellow oil. LCMS: 691.3 (M+H + ) 1 H NMR (400MHz, CDCl3). δ7.479(m, 2H), 7.110~6.954(m, 6H), 6.802(m, 1H), 2.562(m, 6H), 1.759(m, 6H), 1.422~1.322(m, 36H), 0.894(m, 9H). [ka] Compound 13: [4-[(E)-2-[3,5-bis[[(3R)-3-butanoyloxybutanoyl]oxy]phenyl]vinyl]phenyl](3R)-3-butanoyloxy-butanoate
[0306] Step 1: Benzyl (3R)-3-hydroxybutanoate To a solution of sodium (3R)-3-hydroxybutanoate (50 g) in DMF (500 mL) was added bromomethylbenzene (67.8 g) dropwise at 25 °C. The mixture was then stirred at 60 °C for 12 h. Water (800 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (550 mL). The organic layer was washed with brine (230 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash silica gel chromatography (petroleum ether / ethyl acetate = 100 / 1 to 40 / 1) to give benzyl (3R)-3-hydroxybutanoate (57 g, 66.6%) as a colorless oil, which was used directly in the next step.
[0307] Step 2: Benzyl (3R)-3-butanoyloxybutanoate To a solution of pyridine (55.7 g) in DCM (570 mL) was added benzyl (3R)-3-hydroxybutanoate (57 g) and DMAP (1.15 g) at 25 °C. Butanoyl chloride (43.8 g) was added dropwise to the mixture under N2, followed by stirring at 25 °C for 12 h. The mixture was concentrated, the residue was diluted with EtOAc (300 mL), and the organic layer was washed with HO (550 mL), brine (270 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash silica gel chromatography (petroleum ether / ethyl acetate, 100:1 to 70:1) to give benzyl (3R)-3-butanoyloxybutanoate (54 g, 62.6%) as a colorless oil. LCMS: 265.1 (M+H + )
[0308] Step 3: (3R)-3-butanoyloxybutanoic acid To a suspension of Pd / C 10% (9 g) in EtOAc (1300 mL) was added benzyl (3R)-3-butanoyloxybutanoate (54 g) at 25° C. The reaction mixture was stirred under H (15 Psi) at 25° C. for 4 h. The mixture was filtered and concentrated to give (3R)-3-butanoyloxybutanoic acid (30 g) as a colorless oil.
[0309] Step 4: [4-[(E)-2-[3,5-bis[[(3R)-3-butanoyloxybutanoyl]oxy]phenyl]vinyl]phenyl](3R)-3-butanoyloxy-butanoate To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.25 g) and (3R)-3-butanoyloxybutanoic acid (0.76 g) in DCM (7.5 mL) was added DCC (0.29 g) in DCM (5 mL). DMAP (0.040 g) was added to the mixture at 25 °C, and the mixture was stirred for 12 h. The mixture was cooled to 0 °C, petroleum ether (10 mL) was added, and the mixture was stirred for 15 min, then filtered and concentrated. The residue was dissolved in EtOAc (5 mL), washed with 0.5 N HCl (18 mL) and brine (8 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by reverse-phase preparative HPLC (C18; water (0.05% HCl)-ACN gradient) to give compound 13 (0.060 g, 7% yield) as a colorless oil. LCMS: 697.4 (M+H + ) 1 H NMR (400MHz, CDCl3). δ7.494(m, 2H), 7.12~7.042(m, 6H), 6.824(m, 1H), 5.428(m, 3H), 2.909~2.7 85(m, 6H), 2.303(m, 6H), 1.696~1.658(m, 6H), 1.527(d, 9H), 0.956(t, 9H). [ka] Compound 14: [2-acetoxy-4-(3,5,7-triacetoxy-4-oxo-chromen-2-yl)phenyl]acetic acid salt
[0310] To a mixture of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one (1 g) and acetic anhydride (2.36 g) in THF (40 mL) was added KCO (3.2 g) at 25 °C, and the mixture was then stirred at 55 °C for 12 h. Additional acetic anhydride was added (3 equivalents), and the mixture was stirred for an additional 3 h. The reaction mixture was concentrated in vacuo and purified by reverse-phase preparative HPLC (C18; water (0.05% HCl)-ACN gradient) to give compound 14 (0.837 g, 49%) as a white solid. LCMS: 513.2 (M+H + ) 1H NMR (400MHz, CDCl3). δ7.742~7.703(m, 2H), 7.373~7.346(m, 2H), 6.888(s, 1H), 2.443(s, 3H), 2.356(s, 6H), 2.350(s, 6H). [ka] Compound 15: [2-butanoyloxy-4-[3,5,7-tri(butanoyloxy)-4-oxo-chromen-2-yl]phenyl]butanoate
[0311] To a mixture of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one (1 g) and butanoyl chloride (3.53 g) in THF (40 mL) was added TEA (3.35 g) at 25 °C, and the mixture was then stirred at 55 °C for 12 h. The reaction mixture was concentrated in vacuo and purified by reverse-phase preparative HPLC (C18, water (0.05% HCl)-ACN gradient) to give compound 15 (1.13 g, 52% yield) as a colorless solid. LCMS: 653.3 (M+H + ) 1 H NMR (400MHz, CDCl3). δ7.666~7.608(m, 2H), 7.292~7.210(m, 2H), 6.880(s, 1H), 2.542(t, 2H), 2.535~2.484(m, 8H), 1.753(m, 10H), 1.020~0.997(m, 12H), 0.949(t, 3H). [ka] Compound 16: [2-octanoyloxy-4-[3,5,7-tri(octanoyloxy)-4-oxo-chromen-2-yl]phenyl]octanoate
[0312] To a mixture of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one (0.32 g) and octanoyl chloride (1.72 g) in THF (20 mL) was added TEA (1.07 g) at 25° C. The mixture was then stirred at 55° C. for 12 hours. Part of the solvent was removed in vacuo, and the precipitate was collected by filtration to give compound 16 (0.20 g, 20%) as a white solid. 1 H NMR (400MHz, CDCl3). δ7.709~7.655(m, 2H), 7.329~7.301(m, 2H), 6.837(s, 1H), 2.723(t, 2H), 2 .612~2.539(m, 8H), 1.751(m, 10H), 1.412~1.309(m, 40H), 0.896(m, 15H). [ka] Compound 17: [2-decanoyloxy-4-[3,5,7-tris(decanoyloxy)-4-oxo-chromen-2-yl]phenyl]decanoate
[0313] To a mixture of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one (1 g) and decanoyl chloride (6.31 g) in THF (50 mL) was added TEA (3.35 g) at 25° C., and the mixture was then stirred at 55° C. for 12 hours. Part of the solvent was removed in vacuo, and the precipitate was collected by filtration to give compound 17 (2.47 g, 69%) as a white solid. 1 H NMR (400MHz, CDCl3). δ7.772~7.669(m, 2H), 7.343~7.321(m, 2H), 6.685(s, 1H), 2.736(t, 2H), 2 .610~2.551(m, 8H), 1.762(m, 10H), 1.557~1.295(m, 50H), 0.899(m, 15H). [ka] Compound 18: [4-[(E)-2-(3,5-diacetoxyphenyl)vinyl]phenyl]acetate 1 H NMR (400MHz, DMSO-d6). δ7.635(d, 2H), 7.322~6.915(m, 6H), 6.910(s, 1H), 3.327(s, 3H), 2.291(s, 3H), 2.275(s, 3H). LCMS 355.0(MH+) [ka] Compound 19: [4-[(E)-2-[3,5-bis[[(2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoyl]oxy]phenyl]vinyl]phenyl](2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoate
[0314] To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.050 g), DCC (0.180 g), and DMAP (0.008 g) in THF (5 mL) was added (2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoic acid (0.479 g), and the mixture was stirred at 40 °C for 12 h. The reaction mixture was filtered and concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give compound 19 (0.080 g, 16% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3). δ7.529~7.481(m, 2H), 7.177~7.089(m, 5H), 6.669(m, 1H), 6.825(m, 1H) ), 5.781(m, 2H), 5.495~5.483(m, 2H), 5.341~5.305(m, 2H), 5.289~5.18 4(m, 2H), 5.053(d, 1H), 4.728(dd, 1H), 4.375(m, 2H), 4.156~3.989(m, 4H), 2.474~2.221(m, 30H), 1.597~1.566(m, 30H), 0.923~0.847(m, 45H) [ka] Compound 20: [4-(3,5,7-triacetoxy-4-oxo-chromen-2-yl)phenyl]acetic acid salt
[0315] To a mixture of 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one (2 g) in pyridine (15 mL) was added acetyl acetate (30 g), and the mixture was then stirred at 15° C. for 12 hours under a N atmosphere. The solvent was removed under reduced pressure, and the residue was poured into crushed ice with vigorous stirring. The solid precipitate was collected by filtration and washed with cold water and then with methanol. Compound 20 (2.1 g, 65% yield) was obtained as a white solid. LCMS: 455.0 (M+H + ) 1 H NMR (400MHz, CDCl3) δ7.858(d, 2H), 7.339(d, 1H), 7.278 7.257(m, 2H), 6.883(d, 1H), 2.447(s, 3H), 2.357(s, 6H), 2.333(s, 3H) [ka] Compound 21: (S)-2-(4-acetoxyphenyl)-4-oxochroman-5,7-diyl acetate
[0316] 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one (0.500 g) was dissolved in pyridine (10 mL), and then acetyl acetate (0.844 g) was added to the mixture. The reaction mixture was stirred at 15° C. for 12 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give compound 21 (0.300 g, 39% yield) as a white solid. LCMS: 416.1 (M+H2O + ) 1 H NMR (400MHz, CDCl3) δ7.468(d, 2H), 7.166(d, 2H), 6.793(d, 1H), 6.551(d, 1H), 5.49 7(dd, 1H), 3.039(dd, 1H), 2.783(dd, 1H), 2.393(s, 3H), 2.326(s, 3H), 2.308(s, 3H). [ka] Compound 22: (S)-2-(4-(butyryloxy)phenyl)-4-oxochroman-5,7-diyldibutyrate
[0317] To a solution of 5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one (0.500 g) in pyridine (10 mL) was added butanoyl butanoate (1.02 g). The reaction mixture was stirred at 15° C. for 12 hours. The mixture was concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give compound 22 (0.325 g, 34% yield) as a white solid. LCMS: 500.2 (M+H2O + ) 1 H NMR (400MHz, CDCl3) δ7.463(d, 2H), 7.158(d, 2H), 6.786(d, 1H), 6.536(d, 1H), 5.483(m, 1H) , 3.031(m, 1H), 2.662(m, 1H), 2.586~2.524(m, 6H), 1.837~1.785(m, 6H), 1.089~1.021(m, 9H) [ka] Compound 23: [3,5-diacetoxy-4-oxo-2-(3,4,5-triacetoxyphenyl)chromen-7-yl]acetate
[0318] To a solution of 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one (1 g) in pyridine (10 mL) was added acetyl acetate (15.26 g), and the mixture was stirred at 15° C. for 16 hours. The solvent was removed, and the mixture was poured into ice water with stirring. The solid was filtered, washed with water, and dried in vacuo to give compound 23 (1.1 g, 61% yield) as a gray solid. LCMS 571.1 (M+H + ) 1H NMR (400MHz, CDCl3) δ7.260(s, 2H), 7.349(d, 1H), 6.886(d, 1H), 2.441(s, 3H), 2.372(s, 3H), 2.353(s, 3H), 2.341(s, 3H), 2.333(s, 6H) [ka] Compound 24: [(3R)-3-[4-[(E)-2-[3,5-bis[[(1R)-3-acetoxy-1-methyl-propoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxybutyl]acetate
[0319] Step 1: To a solution of (3R)-butane-1,3-diol (2.4 g) in pyridine (20 mL), AcO (2.17 g) was added, and the mixture was stirred at 15 °C for 12 hours. The reaction mixture was concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give [(3R)-3-hydroxybutyl]acetate (1.4 g, 35.8% yield) as a colorless oil.
[0320] Step 2: To a solution of triphosgene (0.269 g) in THF (5 mL) was added a solution of [(3R)-3-hydroxybutyl]acetate (0.300 g) and TEA (0.230 g) in THF (5 mL) at 0° C., and the mixture was stirred at 15° C. for 1 hour. A ca. 0.23 M solution of [(3R)-3-chlorocarbonyloxybutyl]acetate (15 mL) was obtained. The reaction mixture was used directly in the next step.
[0321] Step 3: To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.090 g) and TEA (0.218 g) in THF (3 mL) was added a solution of [(3R)-3-chlorocarbonyloxybutyl]acetate (0.23 M, 10 mL) in THF. The reaction mixture was stirred at 15° C. for 5 hours. The reaction mixture was filtered and concentrated. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate, 4:1) to give compound 24 (0.085 g, 28.8% yield) as a colorless oil. LCMS: 725.1 (M+Na + ) 1 H NMR (400MHz, CDCl3) δ7.520(d, 2H), 7.244~7.192(m, 4H), 7.114(d, 1H), 7.036~6.979(m, 2 H), 5.019(m, 3H), 4.226(m, 6H), 2.099~1.995(m, 6H), 2.055(s, 6H), 1.442~1.422(m, 9H). [ka] Compound 25: [(1R)-3-[4-[(E)-2-[3,5-bis[[(3R)-3-acetoxybutoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxy-1-methyl-propyl]acetate
[0322] Step 1: To a solution of NaH (2.35 g, 60%) in THF (100 mL) was added (3R)-3-[tert-butyl(dimethyl)silyl]oxybutan-1-ol (10 g) at 0° C. The mixture was stirred at 15° C. for 1.5 h. Benzyl bromide (10.04 g) was added, and the mixture was stirred at 15° C. for 16 h. The reaction mixture was filtered and concentrated under reduced pressure, and the residue was purified by column chromatography (SiO, petroleum ether) to give [(1R)-3-benzyloxy-1-methyl-propoxy]-tert-butyl-dimethyl-silane (11 g, 55% yield) as a colorless oil.
[0323] Step 2: To a solution of [(1R)-3-benzyloxy-1-methyl-propoxy]-tert-butyl-dimethyl-silane (10 g) in THF (100 mL) was added pyridine hydrofluoride (8.41 g) at 15° C. The mixture was stirred at 50° C. for 2 hours. The reaction mixture was combined with another batch and concentrated under reduced pressure. The residue was diluted with HO (50 mL) and extracted four times with ethyl acetate (50 mL). The combined organic phases were washed with brine (50 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give (2R)-4-benzyloxybutan-2-ol (5.54 g) as a colorless oil.
[0324] Step 3: To a solution of (2R)-4-benzyloxybutan-2-ol (5.54 g) in pyridine (50 mL) was added AcO (4.71 g) at 15° C. The mixture was stirred at 15° C. for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give [(1R)-3-benzyloxy-1-methyl-propyl]acetate (4.7 g, 57% yield) as a colorless oil.
[0325] Step 4: To a solution of [(1R)-3-benzyloxy-1-methyl-propyl]acetate (2 g) in THF (20 mL) was added 10% Pd / C (0.027 g). The mixture was stirred under H (30 psi) at 30 °C for 16 h. The reaction mixture was filtered and concentrated under reduced pressure, and the residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give [(1R)-3-hydroxy-1-methyl-propyl]acetate (1.07 g, 65% yield) as a colorless oil.
[0326] Step 5: To a solution of [(1R)-3-hydroxy-1-methyl-propyl]acetate (0.300 g) in THF (5 mL) was added a solution of triphosgene (0.337 g) and TEA (0.230 g) in THF (5 mL) at 0° C. The mixture was stirred at 15° C. for 1 hour. The reaction mixture was filtered and used directly in the next step.
[0327] Step 6: To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.080 g) and TEA (0.194 g) in THF (3 mL) was added a solution of [(1R)-3-chlorocarbonyloxy-1-methyl-propyl]acetate (0.2 M, 10 mL) in THF. The reaction mixture was stirred at 15° C. for 5 hours. The reaction mixture was filtered and concentrated. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate, 4 / 1) to give compound 25 (0.056 g, 21% yield) as a colorless oil. LCMS: 703.1 (M+H + ) 1 H NMR (400MHz, CDCl3) δ7.513(d, 2H), 7.232~7.181(m, 4H), 7.154(d, 1H), 7.129~7.002(m, 2H), 5.106(m, 3H), 4.340(m, 6H), 2.072(s, 9H), 2.078~1.995(m, 6H), 1.323~1.282(m, 9H) [ka] Compound 26: [4-[4-oxo-5,7-di(propanoyloxy)chromen-2-yl]-2-propanoyloxy-phenyl]propanoic acid salt
[0328] Propionic anhydride (1.33 mL, 10.4 mmol) was added dropwise to a stirred solution of luteolin (0.3 g, 1.04 mmol) in anhydrous pyridine (2.5 mL, 31.2 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 30 mL of ethyl acetate and washed with HO (30 mL), 1 M HCl (30 mL), HO (30 mL), and saturated NaHCO (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–100% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 26 (0.073 g, 15% yield) as an off-white solid. 1H-NMR (DMSO-d6, 400MHz): δ12.75(s, 1H), 8.07(m, 2H), 7.5(m, 1H), 7.15(s, 1H), 7.12(d, 1H), 6.66(d, 1H), 2.59~2.66(m, 6H), 1.11~1.17(m, 9H) [ka] Compound 27: [4-oxo-3,5-di(propanoyloxy)-2-[3,4,5-tri(propanoyloxy)phenyl]chromen-7-yl]propanoic acid salt
[0329] Propionic anhydride (2 mL, 15.6 mmol) was added dropwise to a stirred solution of myricetin (0.5 g, 1.56 mmol) in anhydrous pyridine (2.78 mL, 47.1 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 30 mL of ethyl acetate and washed with HO (30 mL), 1 M HCl (30 mL), HO (30 mL), and saturated NaHCO (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–100% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 27 (0.31 g, 30% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ7.77(s, 2H), 7.64(d, 1H), 7.16(d, 1H), 2.60~2.70(m, 12H), 1.07~1.17(m, 18H) [ka] Compound 28: [4-[4-oxo-3,5,7-tri(propanoyloxy)chromen-2-yl]-2-propanoyloxy-phenyl]propanoic acid salt
[0330] Propionic anhydride (2.1 mL, 16.5 mmol) was added dropwise to a stirred solution of quercetin (0.5 g, 1.65 mmol) in anhydrous pyridine (3.98 mL, 49.5 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 30 mL of ethyl acetate and washed with HO (30 mL), 1 M HCl (30 mL), HO (30 mL), and saturated NaHCO (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–100% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 28 (0.1 g, 10% yield) as a white solid. 1 H NMR (DMSO-d6, 400MHz): δ7.85(m, 2H), 7.66(d, 1H), 7.54(d, 1H), 7.18(d, 1H), 2.62~2.89(m, 10H), 1.09~1.19(m, 20H) [ka] Compound 29: [(2R,3R)-5,7-di(propanoyloxy)-2-[3,4,5-tri(propanoyloxy)phenyl]chroman-3-yl]3,4,5-tri(propanoyloxy)benzoate
[0331] Propionic anhydride (2.78 mL, 21.8 mmol) was added dropwise to a stirred solution of epigallocatechin gallate (0.5 g, 1.09 mmol) in anhydrous pyridine (2.61 mL, 32.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 30 mL of ethyl acetate and washed with HO (30 mL), 1 M HCl (30 mL), HO (30 mL), and saturated NaHCO (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–100% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 29 (0.695 g, 70% yield) as a white solid. 1 H NMR (DMSO-d6, 400MHz): δ7.54(s, 2H), 7.38(s, 2H), 6.79(m, 1H), 6.66(m, 1H), 5.66(m, 1H), 5.54(s, 1H), 3.13~3.17(m, 1H), 2.96(d, 1H), 2.5~2.65(m, 16H), 1.0~1.2(m, 24H) [ka] Compound 30: [4-[(E)-2-[3,5-di(propanoyloxy)phenyl]vinyl]phenyl]propanoic acid salt
[0332] Propionic anhydride (0.56 mL, 4.4 mmol) was added dropwise to a stirred solution of resveratrol (0.1 g, 0.44 mmol) in anhydrous pyridine (1 mL, 12.4 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 30 mL of ethyl acetate and washed with HO (30 mL), 1 M HCl (30 mL), HO (30 mL), and saturated NaHCO (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–60% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 30 (0.075 g, 43% yield) as a white solid. 1 H-NMR (DMSO-d6, 400MHz): δ7.65(d, 2H), 7.2~7.3(m, 4H), 7.13(d, 2H), 6.92(t, 1H), 2.6(m, 6H), 1.1~1.3(m, 9H) [ka] Compound 31: 5-amino-2-butanoyloxy-benzoic acid hydrochloride
[0333] Step 1: To a mixture of 5-amino-2-hydroxy-benzoic acid (3 g, 19.59 mmol) in methanol (50 mL) was added BocO (4.28 g, 19.59 mmol, 4.50 mL) in one portion at 15 °C under N. The mixture was stirred at 15 °C for 5 h. The residue was poured into water (100 mL). The aqueous phase was extracted with EtOAc (100 mL) and the organic phase was dried over anhydrous NaSO, filtered and concentrated in vacuo. The residue was used in the next step without further purification. 5-(tert-Butoxycarbonylamino)-2-hydroxy-benzoic acid (4 g, crude) was obtained.
[0334] Step 2: To a solution of 5-(tert-butoxycarbonylamino)-2-hydroxy-benzoic acid (4 g, 15.79 mmol) and triethylamine (119.87 mg, 1.18 mmol, 164.88 μL) in THF (30 mL) was added butanoyl chloride (126.22 mg, 1.18 mmol, 123.74 μL) dropwise at 0 °C, maintaining the temperature below 0 °C. The reaction mixture was warmed to 15 °C and stirred for 2 h. The reaction was quenched by the slow addition of ice, and then the mixture was extracted with EtOAc (100 mL). The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by recrystallization with EtOAc (20 mL) to give pure 2-butanoyloxy-5-(tert-butoxycarbonylamino)benzoic acid (1.5 g, 4.64 mmol, 29% yield) as a white solid.
[0335] Step 3: A solution of 2-butanoyloxy-5-(tert-butoxycarbonylamino)benzoic acid (1.5 g, 4.64 mmol) in HCl-EtOAc (20 mL, 4 M) was stirred at 15° C. for 1 hour. The mixture was filtered to give the product, 5-amino-2-butanoyloxy-benzoic acid HCl salt, as an off-white solid (0.74 g, 2.76 mmol, 59.58% yield). LC / MS: (M+H + )224.1 [ka] Compound 32: 2-butanoyloxy-5-[(E)-(4-butanoyloxy-3-carboxy-phenyl)azo]benzoic acid
[0336] A solution of (E)-4,4'-(diazene-1,2-diyl)bis(2-carboxyphenolate) (2 g, 5.78 mmol), butanoyl chloride (2.46 g, 23.11 mmol, 2.41 mL), and NaOH (462 mg, 11.55 mmol) in DMF (100 mL) was stirred at 50°C for 0.5 h. The solid was filtered, water (150 mL) was added to the filtrate, and the mixture was filtered again. The resulting solid filter cake was dried in vacuo. 2-Butanoyloxy-5-[(E)-(4-butanoyloxy-3-carboxy-phenyl)azo]benzoic acid (0.8 g) was obtained as a brown solid. LC / MS: (M+H + ):443.1 [ka] Compound 33: 5-amino-2-[(2R,3R,4S,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid
[0337] This compound was prepared following a modified procedure described for the preparation of compound 34. [ka] Compound 34: 5-amino-2-[(2S,3R,4S,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid
[0338] Process 1 5-Aminosalicylic acid (10.0 g) was dissolved in a mixture of dioxane (100 mL), water (100 mL), and NaOH (2.60 g), and the resulting solution was cooled in an ice bath. Di-tert-butyl bicarbonate (Boc anhydride) (15.60 g) was added, and the mixture was warmed to room temperature and stirred for 1.0 h. The solution was concentrated to 60 mL, diluted with ethyl acetate (100 mL), and the resulting mixture was cooled in an ice bath. The mixture was acidified to pH 2-3 with aqueous KHSO4. The aqueous layer was extracted with EtOAc. The organic layer was washed with water, brine, dried over Na2SO4, filtered, and concentrated to give 5-(tert-butoxycarbonylamino)-2-hydroxybenzoic acid (7.0 g, 42%).
[0339] Process 2 5-(tert-Butoxycarbonylamino)-2-hydroxybenzoic acid (3 g) was dissolved in DMF, and the resulting solution was cooled to 0°C. 1,1'-Carbonyldiimidazole (CDI) was added, and the mixture was stirred at room temperature for 2 hours. Then, tert-butyl alcohol (1.7 g) and DBU (2.1 g) were added. The reaction was stirred at room temperature overnight. The reaction mixture was poured into ice water, and the solid product, tert-butyl 5(tert-butoxycarbonylamino)-2-hydroxybenzoate, was collected by filtration (3.0 g, 81.9%).
[0340] Process 3 To a mixture of tert-butyl 5-(tert-butoxycarbonylamino)-2-hydroxybenzoate, [(3R,4S,5R)-4,5-di(butanoyloxy)-6-hydroxytetrahydropyran-3-yl]butanoate (1.2 g), and triphenylphosphine (1.2 g) in THF (50 mL) was added di-t-butyl azodicarboxylate (DTAD) (1.1 g), and the mixture was stirred at room temperature overnight. The product was purified by reverse-phase chromatography using acetonitrile-water to give tert-butyl 5-(tert-butoxycarbonylamino)-2-[(3R,4S,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxybenzoate as a sticky solid (0.6 g, 30%).
[0341] Process 4 Tert-butyl 5-(tert-butoxycarbonylamino)-2-[(3R,4S,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxybenzoate (600 mg) was added to 4 M HCl in dioxane (15 mL) and stirred overnight at room temperature. After the starting material was consumed, the organic layer was evaporated, and the residue was co-evaporated twice more with heptane and dichloromethane. The resulting solid was dried under high vacuum to give the title product as a dark brown solid (200 mg, 43.8%). Product fractionation afforded two anomeric isomers (Example compounds 33 and 34). 1 H NMR(DMSO d6): Isomer 1: δ7.62(d, 1H), 7.45(dd, 1H), 7.38(d, 1H), 6(d, 1H), 5.6(t, 1H), 5.0~5.1(m, 1H), 4.7~4 .75(m, 1H), 3.6~3.8(m, 1H), 3.45~3.6(1H), 2.1~2.3(m, 6H), 1.4~1.6(m, 6H), 0.75~0.85(m, 9H). Isomer 2: δ7.82(d, 1H), 7.5(dd, 1H), 7.05(d, 1H), 5.5(d, 1H), 5.3(t, 1H), 5.1~5.15(m, 1H), 4.9~5. 0(m, 1H), 4.0~4.08(m, 1H), 3.7~3.8(1H), 2.1~2.3(m, 6H), 1.4~1.6(m, 6H), 0.75~0.85(m, 9H)ppm [ka] Compound 35: 5-[(E)-[3-carboxy-4-(3-oxobutanoyloxy)phenyl]azo]-2-(3-oxobutanoyloxy)benzoic acid [ka] Compound 36: 5-amino-2-(3-oxobutanoyloxy)benzoic acid [ka] Compound 37: 5-[(E)-[3-carboxy-4-[(3R)-3-hydroxybutanoyl]oxy-phenyl]azo]-2-[(3R)-3-hydroxybutanoyl]oxy-benzoic acid [ka] Compound 38: 5-amino-2-[(3R,4S,5R)-3,4,5-tri(3-oxobutanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid [ka] Compound 39: [(3R)-3-hydroxybutyl]5-amino-2-hydroxybenzoate
[0342] Step 1: (3R)-3-benzyloxybutan-1-ol To a suspension of LiAlH (0.313 g) in dry THF (20 mL) was added dropwise a solution of (3R)-3-benzyloxybutanoic acid (2 g) in THF (20 mL) at 0 °C, and the mixture was stirred at 0 °C for 2 h. The reaction mixture was added dropwise to HO (1 mL) and 15% aqueous NaOH (1 mL) and HO (3 mL), then dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate, 50:1 to 20:1 to 15:1 to 10:1) to give (3R)-3-benzyloxybutan-1-ol (0.90 g, 43%) as a brown oil. LCMS: 181.2 (M+H + )
[0343] Step 2: Benzyl 2-benzyloxy-5-nitro-benzoate To a solution of 2-hydroxy-5-nitro-benzoic acid (1 g) in DMF (16 mL) was added CsCO (4.45 g), followed by dropwise addition of benzyl bromide (2.10 g), and the reaction mixture was stirred at 80 °C for 10 h. Water (20 mL) was added, and the mixture was extracted three times with EtOAc (10 mL). The organic layer was washed three times with brine (10 mL), dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate, 80:1 to 20:1) to give benzyl 2-benzyloxy-5-nitro-benzoate (1.3 g, 59%) as a yellow solid.
[0344] Step 3: 2-Benzyloxy-5-nitro-benzoic acid To a solution of benzyl 2-benzyloxy-5-nitro-benzoate (0.800 g) in THF (50 mL) was added a solution of LiOH (0.527 g) in HO (50 mL). The mixture was stirred at 25° C. for 12 hours. The mixture was concentrated and the residue was acidified to pH 5 with 2 N HCl (30 mL). The yellow precipitate was collected by filtration, washed with petroleum ether / ethyl acetate (30 ml, 30:1), and dried under reduced pressure to give 2-benzyloxy-5-nitro-benzoic acid (0.600 g, 90%) as a yellow solid.
[0345] Step 4: [(3R)-3-benzyloxybutyl]2-benzyloxy-5-nitro-benzoate To a solution of (3R)-3-benzyloxybutan-1-ol (0.195 g), N,N'-dicyclohexylcarbodiimide (0.335 g), and 4-dimethylaminopyridine (0.039 g) in CHCl (4 mL) was added 2-benzyloxy-5-nitrobenzoic acid (0.591 g). The mixture was degassed and purged with N three times and stirred at 25 °C for 12 h. The reaction mixture was filtered and concentrated, and the residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate, 50:1 to 20:1) to give [(3R)-3-benzyloxybutyl] 2-benzyloxy-5-nitrobenzoate as a brown oil. LCMS: 458.2 (M+Na + ).
[0346] Step 5: [(3R)-3-hydroxybutyl]5-amino-2-hydroxy-benzoate To a solution of [(3R)-3-benzyloxybutyl] 2-benzyloxy-5-nitro-benzoate (0.450 g) in THF (20 mL) was added 10% Pd / C (0.200 g). The mixture was degassed and purged with H 3 times and stirred at 50 °C for 5 h at 50 psi. The reaction mixture was filtered and concentrated, and the residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate, 50:1 to 0:1) to give [(3R)-3-hydroxybutyl] 5-amino-2-hydroxy-benzoate (0.174 g, 71%) as a yellow solid. LCMS: 226.1 (M+H + ) 1 H NMR (400MHz, CDCl3): δ10.820(s, 1H), 7.448(m, 1H), 6.116(m, 1H), 5.986(m, 1 H), 4.591(m, 1H), 4.271(m, 2H), 3.769(m, 1H), 1.728(m, 2H), 1.106(d, 3H)ppm [ka] Compound 40: 5-(butanoylamino)-2-hydroxybenzoic acid
[0347] To a solution of 5-amino-2-hydroxybenzoic acid (1 g) and triethylamine (0.991 g) in dioxane (20 mL) and HO (10 mL) was added butyric anhydride (1.24 g), and the mixture was stirred at 20 °C for 16 h. Dioxane was removed under reduced pressure, and the pH was adjusted to 5-6 by adding 3N aqueous HCl at 0 °C. The solid was filtered, washed three times with water (20 mL), and concentrated in vacuo. The crude product was purified by reverse-phase preparative HPLC (C18, water (0.05% HCl)-acetonitrile gradient) to give 5-(butanoylamino)-2-hydroxybenzoic acid (0.3 g, 20%) as a light pink solid. LCMS: 224.1 (M+H + ) 1H NMR (400MHz, DMSO-d6): δ11.015(br, 1H), 9.807(s, 1H), 8.106(d, 1H), 7.652(dd, 1H), 6.893(d, 1H), 2.239(m, 2H), 1.604(m, 2H), 0.902(t, 3H)ppm [ka] Compound 41: 5-amino-2-(((2R,3R,4R,5R)-3,4,5-tris(butyryloxy)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid
[0348] Step 1. Tetrabutyric acid ribose To a stirred solution of D-(+)-ribose 1 (5 g) in anhydrous pyridine (24.2 mL) was added a solution of butyryl chloride (23.70 g) in dichloromethane (50 mL) at 0-5 °C. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was diluted with dichloromethane (100 mL) and washed sequentially with water (100 mL), 2N aqueous HCl (300 mL), saturated sodium bicarbonate solution (300 mL), and brine (100 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (5-10% EtOAc-hexane gradient) to give ribose tetrabutyrate as a colorless oil (7.5 g, 52%, mixture of α / β anomers).
[0349] Step 2. Ribose tributyrate Ammonium hydroxide (11 mL) was slowly added to a mixture of ribose tetrabutyrate 2 (7.5 g) in acetonitrile (60 mL) at room temperature, and the resulting reaction mixture was stirred for 5 h. The mixture was diluted with MTBE (75 mL) and stirred for 15 min. The organic layer was separated and concentrated under reduced pressure, and the residue was partitioned between MTBE (100 mL) and water (75 mL). The MTBE layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography [silica gel 100-200 mesh using 10-20% EtOAc-hexane as the eluent] to give ribose tributyrate (1.1 g, 17%) as a colorless oil.
[0350] Step 3. 5-tert-Butoxycarbonylamino-2-hydroxybenzoic acid To a stirred solution of 5-aminosalicylic acid 4 (5 g) in 1,4-dioxane and water (1:1; 100 mL) was added NaOH (1.3 g) and Boc-anhydride (7.83 g) at 0 °C, and the resulting reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc (50 mL), and the pH was adjusted to approximately 3–4 by the dropwise addition of 0.5 N aqueous HCl at 0 °C. The organic layer was separated, and the aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to give 5-tert-butoxycarbonylamino-2-hydroxybenzoic acid as an off-white solid (5.3 g, 64%).
[0351] Step 4. 5-tert-Butoxycarbonylmethyl-2-hydroxybenzoic acid tert-butyl ester To a stirred solution of 5-tert-butoxycarbonylamino-2-hydroxybenzoic acid 5 (5.3 g) in DMF (50 mL) was added CDI (3.39 g) at 0-5 °C, and the mixture was stirred for 2 h. tert-Butanol (4.025 mL) and DBU (2.54 mL) were then added, and the mixture was stirred at room temperature for 16 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (200 mL). The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography using silica gel [100-200 mesh; gradient elution with 5-10% EtOAc-hexane] to give 5-tert-butoxycarbonylmethyl-2-hydroxybenzoic acid tert-butyl ester as an off-white solid (2 g, 31%).
[0352] Step 5. (2R,3R,4R,5R)-2-(2-(tert-butoxycarbonyl)-4-((tert-butoxycarbonyl)amino)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl tributyrate To a stirred solution of hydroxybenzoic acid tert-butyl ester 6 (0.850 g) and tributyric acid ribose (1.04 g) in THF (5 mL) was added triphenylphosphine (1.03 g) and di-tert-butyl azodicarboxylate (0.948 g) sequentially at room temperature, and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel (5–18% EtOAc-hexane gradient) to give crude (2R,3R,4R,5R)-2-(2-(tert-butoxycarbonyl)-4-((tert-butoxycarbonyl)amino)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl tributyrate (1.3 g), which was used directly in the next step.
[0353] Step 6. 5-Amino-2-[(2R,3R,4R,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid To a stirred solution of crude (2R,3R,4R,5R)-2-(2-(tert-butoxycarbonyl)-4-((tert-butoxycarbonyl)amino)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl tributyrate (1.3 g, crude product from the above experiment) in 1,4-dioxane (7 mL) was added 4N HCl in 1,4-dioxane (10 mL) at 0° C., and the resulting reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then concentrated under reduced pressure, and the residue was purified by reverse-phase preparative HPLC to give 5-amino-2-[(2R,3R,4R,5R)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid (0.05 g). LCMS: 496.5 (M+H + ) 1 H NMR (400MHz, DMSO-d6): δ6.919~6.898(m, 2H), 6.658(m, 1H), 5.431(m, 1H), 5.350(m, 1H), 5.234(m, 1H), 5.161(m, 1H), 4.213(m 1H), 3.749(m, 1H), 2.497~2.268(m, 4H), 2.197(m, 1H), 1.620~1.487(m, 6H), 0.926~0.888(m, 9H)ppm [ka] Compound 42: 5-amino-2-[(2R,3R,4S,5S)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid
[0354] Step 1: 2-Hydroxy-4-nitro-benzoic acid (20 g) and KHCO3 (13.1 g) were suspended in DMF (100 mL). To this suspension, benzyl bromide (22.4 g) was added, and the reaction mixture was stirred at room temperature overnight. Water (150 mL) was added, and the resulting mixture was extracted with ethyl acetate (250 mL). The organic layer was separated, washed twice with water, brine, and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (hexane / ethyl acetate gradient). Recrystallization from 15% ethyl acetate in hexane gave benzyl 2-hydroxy-4-nitro-benzoate (10.5 g).
[0355] Step 2: Benzyl 2-hydroxy-4-nitro-benzoate (8.5 g), arabinose tributyrate (7.5 g), and triphenylphosphine (8.2 g) were dissolved in THF (150 mL) and stirred at 0° C. To this mixture was added di-t-butyl azodicarboxylate (7.2 g), and stirring was continued at 0° C. for 1 hour and then at room temperature overnight. The reaction mixture was concentrated and purified by column chromatography (hexane / ethyl acetate gradient) to give benzyl 5-nitro-2-[(2R,3R,4S,5S)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoate (1.78 g, 14%).
[0356] Step 3: 5-Nitro-2-[(2R,3R,4S,5S)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoate (0.095 g) was dissolved in methanol (15 mL) and stirred at room temperature. 10% Pd / C (0.05 g) was added to the mixture. The suspension was stirred overnight at room temperature under a hydrogen atmosphere. The reaction mixture was filtered through Celite and washed with methanol. The combined filtrate and washings were concentrated. The residue was purified by reverse-phase chromatography (C-18, 0.1% trifluoroacetic acid in acetonitrile and 0.1% trifluoroacetic acid in water) to give 5-amino-2-[(2R,3R,4S,5S)-3,4,5-tri(butanoyloxy)tetrahydropyran-2-yl]oxy-benzoic acid (0.045 g, 59%). MS 494.2(MH)NMR(DMSO d6): δ7.223(m, 1H), 7.139(m, 1H), 6.997(s, 1H), 7.851(d, 1H), 5.469(m, 1H), 5.350(m, 1H), 5.239(m , 1H)4.127(d, 1H), 3.672(d, 1H), 2.490~2.369(m, 6H), 1.596~1.485(m, 6H), 0.924~0.818(m, 9H)ppm [ka] Compound 43: (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-ene-1-carboxylic acid
[0357] Acetic anhydride (1.61 mL, 17.2 mmol) was added dropwise to a stirred solution of shikimic acid (0.300 g, 1.72 mmol) in anhydrous pyridine (1.38 mL, 17.2 mmol) under a N atmosphere at 0 °C. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% acetonitrile in water), and fractions were concentrated by rotary evaporation to give compound 43 (0.18 g, 34.8% yield) as a white solid. 1 H-NMR (DMSO-d6, 400MHz): δ12.90(s, 1H), 6.61(dt, 1H), 5.60(m, 1H), 5.18( dd, 1H), 5.12(dt, 1H), 2.76(m, 1H), 2.35(m, 1H), 2.04(s, 5H), 2.01(s, 3H). LC-MS:299.1(MH) - [ka] Compound 44: 3,4,5-triacetoxybenzoic acid
[0358] Acetic anhydride (1.65 mL, 17.6 mmol) was added dropwise to a stirred solution of gallic acid (0.300 g, 1.76 mmol) in anhydrous pyridine (1.41 mL, 17.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% acetonitrile in water), and fractions were concentrated by rotary evaporation to give compound 44 (0.259 g, 49.7% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ13.44 (s, 1H), 7.75 (s, 1H), 2.33 (s, 3H), 2.30 (s, 6H). LC-MS:319.0(M+Na) + [ka] Compound 45: (2R,3R,4S,5R)-2-(methoxytetrahydro)-2H-pyran-3,4,5-triyl triacetate
[0359] Acetic anhydride (2.28 mL, 24.2 mmol) was added dropwise to a stirred solution of (2R,3R,4S,5R)-2-methoxytetrahydropyran-3,4,5-triol (0.200 g, 1.21 mmol) in anhydrous pyridine (2.92 mL, 36.3 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 45 (0.217 g, 61.8% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ5.21 (t, 1H), 4.87 (m, 1H), 4.79 (dd, 1H), 4.62 (d, 1H) , 4.01(dd, 1H), 3.53(dd, 1H), 3.40(s, 3H), 2.04(s, 3H), 2.03(s, 3H), 2.01(s, 3H). LC-MS:313.0(M+Na)+ [ka] Compound 46: (2S,3R,4S,5R)-2-Methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0360] Acetic anhydride (2.28 mL, 24.2 mmol) was added dropwise to a stirred solution of (2S,3R,4S,5R)-2-methoxytetrahydropyran-3,4,5-triol (0.200 g, 1.21 mmol) in anhydrous pyridine (2.92 mL, 36.3 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 46 (0.216 g, 61.5% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ5.30 (t, 1H), 4.92 (m, 1H), 4.88 (d, 1H), 4.84 (dd, 1H) , 3.77(dd, 1H), 1.27(dd, 1H), 3.34(s, 3H), 2.03(s, 3H), 2.01(s, 3H), 2.00(s, 3H). LC-MS:313.0(M+Na)+ [ka] Compound 47: (2R,3S,4R,5R)-2-Methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0361] Acetic anhydride (378 μL, 4.02 mmol) was added dropwise to a stirred solution of (2R,3S,4R,5R)-2-methoxytetrahydropyran-3,4,5-triol (0.033 g, 201 μmol) in anhydrous pyridine (484 μL, 6.02 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 47 (0.0263 g, 45.1% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ5.25 (m, 1H), 5.22 (dd, 1H), 5.02 (dd, 1H), 4.91 (d, 1H) , 3.89(dd, 1H), 3.64(dd, 1H), 3.34(s, 3H), 2.12(s, 3H), 2.05(s, 3H), 1.97(s, 3H). LC-MS:313.0(M+Na) + [ka] Compound 48: (2S,3S,4R,5R,6R)-2-(acetoxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0362] Acetic anhydride (1.92 mL, 20.4 mmol) was added dropwise to a stirred solution of (2S,3R,4R,5R,6R)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol (0.200 g, 1.02 mmol) in anhydrous pyridine (2.46 mL, 30.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 48 (0.197 g, 53.3% yield) as a white solid. 1 H-NMR (DMSO-d6, 400MHz): δ5.12(m, 3H), 4.79(d, 1H), 4.18(dd, 1H), 4.08(dd, 1H), 3 .94~3.90(m, 1H), 3.36(s, 3H), 2.13(s, 3H), 2.05(s, 3H), 2.04(s, 3H), 1.95(s, 3H). LC-MS:385.1(M+Na) + [ka] Compound 49: (2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0363] Acetic anhydride (1.92 mL, 20.4 mmol) was added dropwise to a stirred solution of (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol (0.200 g, 1.02 mmol) in anhydrous pyridine (2.46 mL, 30.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 49 (0.153 g, 41.4% yield) as an oil. 1 H-NMR (DMSO-d6, 400MHz): δ5.28(dd, 1H), 5.17(dd, 1H), 4.95(dd, 1H), 4.63(d, 1H), 4.2 1(m, 1H), 4.09(m, 2H), 3.40(s, 3H), 2.13(s, 3H), 2.04(s, 3H), 2.03(s, 3H), 1.93(s, 3H). LC-MS:85.1(M+Na) + [ka] Compound 50: (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0364] Acetic anhydride (1.92 mL, 20.4 mmol) was added dropwise to a stirred solution of (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol (0.200 g, 1.02 mmol) in anhydrous pyridine (2.46 mL, 30.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 50 (0.148 g, 40.1% yield) as a white solid. 1 H-NMR (DMSO-d6, 400MHz): δ5.27(t, 1H), 4.91(t, 1H), 4.75(m, 2H), 4.20(dd, 1H), 4 .05~3.93(m, 2H), 3.39(s, 3H), 2.04(s, 3H), 2.01(s, 3H), 1.99(s, 3H), 1.95(s, 3H). LC-MS:385.1(M+Na) + [ka] Compound 51: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0365] Acetic anhydride (1.92 mL, 20.4 mmol) was added dropwise to a stirred solution of (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol (1:1) (0.200 g, 1.02 mmol) in anhydrous pyridine (2.46 mL, 30.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 51 (0.157 g, 42.5% yield) as a white solid. 1H-NMR (DMSO-d6, 400MHz): δ5.36 (dd, 1H), 5.22 (dd, 1H), 4.99 (m, 2H), 4.18 (m, 1H) ), 4.06(m, 2H), 3.34(s, 3H), 2.13(s, 3H), 2.04(s, 3H), 2.01(s, 3H), 1.95(s, 3H). LC-MS:385.1(M+Na) + [ka] Compound 52: (2S,3S,4R,5S,6R)-2-(acetoxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate
[0366] Acetic anhydride (1.92 mL, 20.4 mmol) was added dropwise to a stirred solution of (2S,3R,4R,5S,6R)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol (0.200 g, 1.02 mmol) in anhydrous pyridine (2.46 mL, 30.6 mmol) at 0 °C under a N atmosphere. The resulting stirred solution was allowed to warm to room temperature, and the reaction was monitored by LCMS until completion. The solution was diluted with 20 mL of ethyl acetate and washed with 1 M HCl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated by rotary evaporation. The crude residue was purified by flash chromatography (silica, 10–90% ethyl acetate in hexanes), and fractions were concentrated by rotary evaporation to give compound 52 (0.230 g, 62.3% yield) as a white solid. 1 H-NMR (DMSO-d6, 400MHz): δ5.29(dd, 1H), 4.96(dd, 1H), 4.92(d, 1H), 4.82(dd, 1H), 4.15(dd, 1H) ), 4.05(dd, 1H), 3.90(m, 1H), 3.34(s, 3H), 2.02(s, 3H), 2.01(s, 3H), 1.98(s, 3H), 1.96(s, 3H). LC-MS:385.2(M+Na) + [ka] Compound 53: (2R,3R,4S,5S)-Tetrahydro-2H-pyran-2,3,4,5-tetrayltetraacetic acid L-arabinose (50 g), N,N-dimethylpyridin-4-amine (6 g), and triethylamine (367 mL) were dissolved in 700 mL of DCM and stirred at 0 °C under N. Acetic anhydride (217 mL) was added dropwise over 30 min, and the reaction mixture was stirred overnight. The solvent was removed under reduced pressure, and the residue was redissolved in ethyl acetate, washed with 1 M HCl, HO, and brine, dried over MgSO, and evaporated. Normal phase purification using 0–100% ethyl acetate in hexanes afforded compound 53 as a waxy / amorphous solid (50% yield). 1H-NMR (DMSO-CDCl-3, 400MHz): δ6.35 (d, 1H), 5.37 (m, 3H), 4.06 (dd, 1H), 3.82 (dd, 1H), 2.155 (s, 3H) 2.15 (s, 3H), 2.02 (s, 6H). LC-MS:341.1(M+Na) + [ka] Compound 54: [(2R,3S,4S,5R)-2,3,4,5-tetraacetoxytetrahydropyran-2-yl]acetate methyl
[0367] To a solution of (3S,4S,5R)-2-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol (6 g, 33.3 mmol) in pyridine (50 mL) was added acetic anhydride (65.4 g, 640.6 mmol, 60.00 mL), and the mixture was stirred at 15 °C for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether / ethyl acetate = 50:1 to 1:1 gradient) to give methyl [(2R,3S,4S,5R)-2,3,4,5-tetraacetoxytetrahydropyran-2-yl]acetate (6 g, 14.60 mmol, 43.85% yield) as a yellow solid. 1H-NMR (CDCl-3, 400MHz): δ5.461 (d, 1H), 5.336 (dd, 1H), 5.250 (m, 1H), 4.797 (d, 1H), 4.415 (d, 1H), 4.102(d, 1H), 3.496(t, 1H), 2.165(s, 3H), 2.134(s, 3H), 2.050(s, 3H), 2.019(s, 3H), 1.999(s, 3H). LCMS:(M+Na + ):413.1 [ka] Compound 55: (2S,3R,4R,5S,6R)-6-(acetoxymethyl)-3-aminotetrahydro-2H-pyran-2,4,5-triyl triacetate HCl salt.
[0368] 1H-NMR (DMSO-d6, 400MHz): δ8.760~8.675(br m, 3H), 5.901(m, 1H), 5.346(t, 1H), 4.932(t, 1H), 4.190(m, 1H), 4.051~3.976( m, 3H), 3.582(m, 1H), 2.170(s, 3H), 2.028(s, 3H), 1.996(s, 3H), 1.977(s, 3H). LCMS:(M+Na + ):370.1 [ka] Compound 56: [(2R,3R)-5,7-di(butanoyloxy)-2-[3,4,5-tri(butanoyloxy)phenyl]chroman-3-yl]3,5-bis[(4-amino-2-hydroxybenzoyl)oxy]-4-hydroxybenzoate [ka] Compound 57: [(1S)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-acetoxy-2,6,6-trimethyl-3-oxo-cyclohexen-1-yl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxo-cyclohex-3-en-1-yl]acetate [ka] Compound 58: [(1S)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-butanoyloxy-2,6,6-trimethyl-3-oxo-cyclohexen-1-yl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxo-cyclohex-3-en-1-yl]butanoate [ka] Compound 59: [(1S)-3,5,5-trimethyl-2-oxo-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-[(4S)-2,6,6-trimethyl-3-oxo-4-(3-oxobutanoyloxy)cyclohexen-1-yl]octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-yl]3-oxobutanoate [ka] Compound 60: [(1S)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-[(3R)-3-hydroxybutanoyl]oxy-2,6,6-trimethyl-3-oxo-cyclohexen-1-yl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxo-cyclohex-3-en-1-yl](3R)-3-hydroxybutanoate [ka] Compound 61: [(1S)-3,5,5-trimethyl-2-oxo-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-[(4S)-2,6,6-trimethyl-4-octanoyloxy-3-oxo-cyclohexen-1-yl]octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-yl]octanoate [ka] Compound 62: [(1S)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-decanoyloxy-2,6,6-trimethyl-3-oxo-cyclohexen-1-yl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxo-cyclohex-3-en-1-yl]decanoate [ka] Compound 63: [(2R,3R,4S,5R,6S)-3,4,5-triacetoxy-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-2-yl]methyl acetate
[0369] Step 1: 3-Bromopyridin-2-ol (5 g) was added to aqueous NaOH (0.34 M, 84.52 mL) and aqueous AgNO (0.68 M, 42.26 mL) at 15 °C. The mixture was stirred for 10 min. The reaction mixture was filtered, and the solid was washed with HO (800 mL) and chilled methanol (200 mL) and dried under reduced pressure to give silver 3-bromopyridin-2-olate (6.5 g, 80.5% yield) as a white solid.
[0370] Step 2: To a solution of methyl [(1R,2R,3S,4R,5S)-2,3,4-triacetoxy-5-bromocyclohexyl]acetate (0.488 g) in toluene (10 mL) was added silver 3-bromopyridin-2-olate (1 g) at 15° C. The mixture was stirred at 120° C. for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure, and the residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate, 1:1) to give methyl [(1R,2R,3S,4S,5S)-2,3,4-triacetoxy-5-[(3-bromo-2-pyridyl)oxy]cyclohexyl]acetate (0.500 g, 75% yield) as a white solid.
[0371] Step 3: To a solution of methyl [(1R,2R,3S,4S,5S)-2,3,4-triacetoxy-5-[(3-bromo-2-pyridyl)oxy]cyclohexyl]acetate (0.350 g) and α-tocopherol (0.598 g) in DCM (5 mL) was added BF3.Et2O (47%, 0.629 g, 3 equiv.) at 15 °C. The mixture was stirred at 15 °C for 5 hours. The reaction mixture was quenched with sodium bicarbonate solution (5 mL) and extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate, 5:1) to give [(2R,3R,4S,5R,6S)-3,4,5-triacetoxy-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-2-yl]methyl acetate (0.400 g, 75.7% yield) as a white solid. 1 H NMR (400MHz, CDCl3) 5.362~5.179(m, 3H), 4.724(d, 1H), 4.191~4.049(m, 3H), 3.536(m, 1H), 2.568(m, 2H), 2.152(s, 3H), 2.12 0(s, 3H), 2.105(s, 3H), 2.082(s, 3H), 2.054~2.027(m, 9H), 1.838~1.737(m, 2H), 1.572~1.042(m, 24H), 0.882~0.842(m, 12H) [ka] Compound 64: [(2R,3R,4S,5R,6S)-3,4,5-tri(butanoyloxy)-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-2-yl]methylbutanoate
[0372] Step 1: To a solution of [(2R,3R,4S,5R,6S)-3,4,5-triacetoxy-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-2-yl]methyl acetate (2.7 g) in MeOH (30 mL) was added NaOMe (25%, 192 mg) in MeOH at 15° C. The mixture was stirred at 15° C. for 3 hours. The reaction mixture was neutralized with cation exchange resin, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate, 3:1 to ethyl acetate / MeOH, 20:1 gradient) to give (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-3,4,5-triol (1.3 g, 62% yield) as a yellow solid.
[0373] Step 2: To a solution of (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-3,4,5-triol in DCM (5 mL) was added pyridine (0.107 g) and butanoyl chloride (0.144 g) at 15° C. The mixture was stirred at 15° C. for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate, 4:1) to give [(2R,3R,4S,5R,6S)-3,4,5-tri(butanoyloxy)-6-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-tetrahydropyran-2-yl]methylbutanoate (0.075 g, 51% yield) as a white solid. 1H NMR (400MHz, CDCl3) 5.362(m, 1H), 5.284(m, 1H), 5.201(m, 1H), 4.733(d, 1H), 4.107(m, 2H), 3.529(m, 1H), 2.562 (m, 2H), 2.336(m, 2H), 2.28~2.21(m, 6H), 2.147(s, 3H), 2.100(s, 3H), 2.076(s, 3H), 1.852~1.01(m, 37H), 0.963 0.842(m, 24H) [ka] Compound 65: [4-[(E)-2-[3,5-bis[[(4R)-2,4-dimethyl-1,3-dioxane-2-carbonyl]oxy]phenyl]vinyl]phenyl](4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate
[0374] Step 1: To a solution of (3R)-butane-1,3-diol (2 g) and methyl 2-oxopropanoate (4.53 g) in ACN (100 mL) was added BF3.Et2O (47%, 13.40 g, 2 equiv.) dropwise, and the mixture was stirred at 15 °C for 16 h. The pH of the solution was adjusted to 7-8 with saturated NaHCO3, and the aqueous phase was extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate gradient) to afford methyl (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate (2.5 g, 64.7% yield) as a yellow oil.
[0375] Step 2: To a solution of methyl (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate (2.5 g) in MeOH (40 mL) and HO (10 mL), NaOH (1.15 g) was added and the mixture was stirred at 80 °C for 16 h. MeOH was removed, and the pH of the mixture was adjusted to pH = 2-3 with aqueous HCl (6 M). The aqueous phase was extracted four times with ethyl acetate (30 mL). The combined organic phase was washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylic acid (1.5 g, 65% yield) as a yellow oil.
[0376] Step 3: A solution of resveratrol (0.2 g), (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylic acid (0.561 g), DCC (0.723 g), and DMAP (0.054 g) in DCM (30 mL) was stirred at 15° C. for 16 hours. The solids were removed by filtration, and the solution was concentrated in vacuo. The crude product was purified by reverse-phase preparative HPLC (C18, [water (0.1% TFA)-AC]0) to give [4-[(E)-2-[3,5-bis[[(4R)-2,4-dimethyl-1,3-dioxane-2-carbonyl]oxy]phenyl]vinyl]phenyl](4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate (0.1 g, 17% yield) as a colorless oil. LCMS: 672.3 (M+18). 1 H NMR (400MHz, CDCl3) 7.552(d, 2H), 7.211(d, 2H), 7.170~7.104(m, 3H), 7.034(m, 1H), 6.9 44(m, 1H), 4.163~4.005(m, 9H), 1.975~1.709(m, 12H), 1.549~1.513(m, 3H), 1.318(d, 9H) [ka] Compound 66: [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl](4R)-4-methyl-1,3-dioxane-2-carboxylate
[0377] A solution of α-tocopherol (1 g), (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylic acid (0.169 g), EDCI (0.223 g), and DMAP (0.071 g) in DCM (10 mL) was stirred at 15° C. for 16 hours. The solvent was removed, and the crude product was purified by preparative TLC (petroleum ether / ethyl acetate, 5:1) to give [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl](4R)-4-methyl-1,3-dioxane-2-carboxylate (0.12 g, 9% yield) as a yellow oil. LCMS: 576.4 (M+18). 1 H NMR (400MHz, CDCl3) 5.297(s, 1H), 4.306(dd, 1H), 3.972~3.900(m, 2H), 2.575(t, 2H) , 2.075(s, 3H), 2.024(s, 3H), 1.983(s, 3H), 1.95~1.00(m, 32H), 0.874~0.835(m, 12H) [ka] Compound 67: [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexyl](2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoate
[0378] To a solution of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol (0.200 g) and (2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoic acid (0.341 g) in DCM (2 mL) was added DCC (0.129 g) and DMAP (0.013 g) at 15° C. The mixture was stirred at 15° C. for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure, and the residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate, 5:1) to give [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexel](2R,3S,4R,5R)-2,3,4,5,6-penta(butanoyloxy)hexanoate (0.300 g, 63% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) 6.231(d, 1H), 6.014(d, 1H), 5.641(dd, 1H), 5.511(m, 1H), 5.262(d, 1H), 5.121~5.066(m, 2H), 4.967(m, 1H), 4.847(d, 1H), 4 .317(dd, 1H), 4.111(m, 1H), 2.818(m, 1H), 2.597(m, 1H), 2.274~2.185(m , 13H), 2.055~1.955(m, 5H), 1.733~1.129(m, 29H), 1.001~0.870(m, 24H) [ka] Compound 68: [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexyl](2R,3S,4R,5R)-2,3,4,5,6-penta(propanoyloxy)hexanoate
[0379] To a solution of (2R,3S,4R,5R)-2,3,4,5,6-penta(propanoyloxy)hexanoic acid (0.5 g) in DCM (5 mL) was added (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol (0.484 g), DCC (0.433 g), and DMAP (0.038 g). The mixture was stirred at 15 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate gradient) to give [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene)-ethylidene-4-methylene-cyclohexyl](2R,3S,4R,5R)-2,3,4,5,6-penta(propanoyloxy)hexanoate (0.24 g, 25% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) 6.228(d, 1H), 6.104(d, 1H), 5.649(m, 1H), 5.523(m, 1H), 5.272(d, 1H), 5.123~5.068(m, 2H) , 4.989(m, 1H), 4.852(m, 1H), 4.299(m, 1H), 4.129(m, 1H), 2.834(m, 1H), 2.65~0.95(m, 68H), 0.94~0.869(m, 12H) [ka] Compound 69: [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexyl](4R)-4-methyl-1,3-dioxane-2-carboxylate
[0380] A solution of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol (0.3 g), (4R)-4-methyl-1,3-dioxane-2-carboxylic acid (0.228 g), DCC (0.322 g), and DMAP (0.095 g) in DCM (20 mL) was stirred for 16 hours at 15° C. The solids were filtered, and the filtrate was concentrated in vacuo. The crude product was purified by preparative TLC (petroleum ether / ethyl acetate, 5:1) to give [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexyl](4R)-4-methyl-1,3-dioxane-2-carboxylate (0.090 g, 21% yield) as a yellow solid. LCMS: 513.3 (M+H + ) 1 H NMR (400MHz, CDCl3) 6.230(d, 1H), 6.030(d, 1H), 5.068~5.035(m, 2H), 4.990(s, 1H), 4.844(s, 1H), 4.233(m, 1H), 3.868~3.801(m, 2H) , 2.798(m, 1H), 2.612(m, 1H), 2.442(m, 2H), 2.2(m, 1H), 2.050~0.095(m, 29H), 0.925(d, 3H), 0.875(d, 3H), 0.870(d, 3H), 0.546(s, 3H) [ka] Compound 70: [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexyl](4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate
[0381] A solution of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol (0.3 g), (4R)-2,4-dimethyl-1,3-dioxane-2-carboxylic acid (0.250 g), DCC (0.322 g), and DMAP (0.048 g) in DCM (20 mL) was stirred for 16 hours at 15° C. The solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate gradient) to give [(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexidyl](4R)-2,4-dimethyl-1,3-dioxane-2-carboxylate (0.050 g, 12% yield) was obtained as a yellow oil. LCMS: 549.4 (M+Na+) 1 H NMR (400MHz, CDCl3) 6.130(d, 1H), 5.938(d, 1H), 5.026~4.978(m, 2H), 4.784(d, 1H), 3.843~3.772 (m, 3H), 2.730(m, 1H), 2.552~0.995(35H), 0.848(d, 3H), 0.799(d, 3H), 0.795(d, 3H0, 0.469(s, 3H) [ka] Compound 71: (2R,3R,4S,5S)-tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate
[0382] To a solution of (3R,4S,5S)-tetrahydro-2H-pyran-2,3,4,5-tetraol (3 g, 19.98 mmol, 1 equiv.), TEA (16.18 g, 159.86 mmol, 22.25 mL, 8 equiv.), and DMAP (488.25 mg, 4.00 mmol, 0.2 equiv.) in DCM (30 mL) was added butyric anhydride (19.34 g, 122.25 mmol, 20 mL, 6.12 equiv.) at 0° C. The solution was then stirred at 0° C. for 1 h and then at 15° C. for an additional 15 h. LCMS indicated the reaction was complete. The solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography eluting with petroleum ether / ethyl acetate=1:0 to give (3R,4S,5S)-tetrahydro-2H-pyran-2,3,4,5-tetrayltetrabutyrate (8 g, 18.58 mmol, 93.00% yield, 100% purity) as a yellow oil. LCMS: (M+Na + ):453 1H-NMR (CDCl-3, 400MHz): δ6.3 (1H, d) 5.3 (2H, M). 3.8~4.0(dd, 2H), 2.2(m, 8H), 1.6(m, 8H), 0.97(m, 12H). [ka] Compound 72: (3R,4S,5S)-2-hydroxytetrahydro-2H-pyran-3,4,5-triyl tributyrate
[0383] To a solution of [(3S,4S,5R)-4,5,6-tri(butanoyloxy)tetrahydropyran-3-yl]butanoate (1 g) in THF (20 mL) and HO (1 mL) was added a solution of methanamine in THF (2 M, 1.51 mL), and the mixture was stirred at 15 °C for 24 h. The solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate gradient) to give [(3S,4S,5R)-4,5-di(butanoyloxy)-6-hydroxy-tetrahydropyran-3-yl]butanoate (0.15 g, 17.7% yield) as a yellow oil. LCMS: 383.1 (M+Na + ) 1H NMR (400 MHz, CDCl3) (mixture of anomers): δ 5.411 (d, 1H, major anomer), 5.370 (dd, 1H, major anomer), 5.300 (br, 1H, major anomer), 5.235 (br, 1H, minor anomer), 5.154 (dd, 1H, major anomer), 5.040 (m, 1H), 5.557 (br, 1H, minor anomer), 4.139 (d, 1H, major anomer), 3.959 (dd, 1H, minor anomer), 3.642 (dd, 1H, major anomer), 3.620 (d, 1H, minor anomer), 3.350 (br d, 1H, minor anomer), 2.619 (br, 2H, minor anomer), 2.330–2.116 (m, 6H, major and minor anomers), 1.666–1.496 (m, 6H, major and minor anomers), 0.931–0.834 (9H, major and minor anomers). [ka] Compound 73: (R)-3-(butyryloxy)butyl (R)-3-(butyryloxy)butanoate
[0384] To a solution of [(3R)-3-hydroxybutyl](3R)-3-hydroxybutanoate (0.400 g) and K2CO3 (0.784 g) in acetonitrile (5 mL) was added butanoyl chloride (0.532 g), and the mixture was stirred for 12 hours at 15° C. The reaction mixture was concentrated, and the residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate gradient) to give [(3R)-3-butanoyloxybutyl](3R)-3-butanoyloxybutanoate (0.220 g, 27.5% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3): δ5.197(m, 1H), 4.965(m, 1H), 4.045(m, 2H), 2.528(m, 1H), 2.449(m, 1H), 2.222~2.1 58(m, 4H), 1.799(m, 2H), 1.602~1.546(m, 4H), 1.222(d, 3H), 1.182(d, 3H), 0.884(t, 3H), 0.874(t, 3H)ppm [ka] Compound 74: (R)-Butane-1,3-diyldibutyrate
[0385] To a solution of (3R)-butane-1,3-diol (6 g) and K2CO3 (23.92 g) in acetonitrile (50 mL) was added butanoyl chloride (18.44 g), and the mixture was stirred at 15 °C for 12 hours. The reaction mixture was concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate gradient) to give [(3R)-3-butanoyloxybutyl]butanoate (11 g, 64.57% yield) as a colorless oil. LCMS: 248.1 (M+H3O + ) 1 H NMR (400MHz, CDCl3): δ5.022(m, 1H), 4.101(m, 2H), 2.300~2.247(m, 4H), 1.885(m, 2H), 1.679~1.594(m, 4H), 1.260(d, 3H), 0.949(t, 6H)ppm [ka] Compound 75: (2R,2'R)-((((5-((E)-4-((((R)-3-(butyryloxy)butoxy)carbonyl)oxy)styryl)-1,3-phenylene)bis(oxy))bis(carbonyl))bis(oxy))bis(butane-4,2-diyl)dibutyrate
[0386] To a solution of triphosgene (0.185 g, 0.624 mmol) in THF (10 mL) was added a solution of [(1R)-3-hydroxy-1-methyl-propyl]butanoate (0.200 g, 1.25 mmol) and TEA (0.189 g, 1.87 mmol) in THF (5 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. TLC showed that the starting reactant was consumed. The reaction mixture was filtered, concentrated, and used directly in the next step.
[0387] Process 2 To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.050 g, 0.219 mmol) and TEA (0.111 g, 1.10 mmol) in THF (5 mL) was added the above solution of [(1R)-3-chlorocarbonyloxy-1-methyl-propyl]butanoate in THF at 0 °C. The reaction was stirred at 20 °C for 2 h, then filtered and concentrated. The residue was purified by preparative TLC to give [(1R)-3-[4-[(E)-2-[3,5-bis[[(3R)-3-butanoyloxybutoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxy-1-methyl-propyl]butanoate (0.084 g, 41% yield) as a colorless oil. LCMS: (M+H2O + ):804.3 1 H NMR (400MHz, CDCl3): δ7.511(m, 2H), 7.270~6.970(m, 7H), 5.167~5.087(m, 3H), 4.360~4. 307(m, 6H), 2.299(t, 6H), 2.012(m, 6H), 1.703~1.647(m, 6H), 1.301(d, 9H), 0.965(t, 9H) [ka] Compound 76: (3R,3'R)-((((5-((E)-4-((((R)-4-(propionyloxy)butan-2-yl)oxy)carbonyl)oxy)styryl)-1,3-phenylene)bis(oxy))bis(carbonyl))bis(oxy))bis(butane-3,1-diyl)dipropionate
[0388] To a solution of (3R)-butane-1,3-diol (2 g, 22.2 mmol) and TEA (2.47 g, 24.4 mmol) in DCM (10 mL) was added propanoyl propanoate (3.18 g, 24.4 mmol), and the mixture was stirred at 25 °C for 12 h. The mixture was concentrated, and the residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10 / 1 to 5:1) to give [(3R)-3-hydroxybutyl]propanoate (1.8 g, 55% yield) as a colorless oil.
[0389] To a solution of triphosgene (0.203 g, 0.68 mmol) in THF (10 mL) was added a solution of [(3R)-3-hydroxybutyl]propanoate (0.20 g, 1.37 mmol) and TEA (0.21 g, 2.1 mmol) in THF (5 mL) at 0° C. The mixture was stirred at 0° C. for 1 h, then filtered and used directly in the next step. To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.050 g, 0.219 mmol) and TEA (0.111 g, 1.10 mmol) in THF (5 mL) was added the above THF solution of [(3R)-3-chlorocarbonyloxybutyl]propanoate at 0° C. The reaction mixture was stirred at 20° C. for 2 h, then filtered and concentrated. The residue was purified by preparative TLC to give [(3R)-3-[4-[(E)-2-[3,5-bis[[(1R)-1-methyl-3-propanoyloxy-propoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxybutyl]propanoate (0.060 g, 35% yield) as a colorless oil. LCMS: (M+Na + ):767.3 1 H NMR (400MHz, CDCl3): δ7.518(d, 2H), 7.270~6.976(m, 7H), 5.032~4.968(m, 3H), 4.267 ~4.189(m, 6H), 2.384~2.328(m, 6H), 2.066~1.980(m, 6H), 1.430(d, 9H), 1.555(t, 9H) [ka] Compound 77: (2R,2'R)-((((5-((E)-4-((((R)-3-(propionyloxy)butoxy)carbonyl)oxy)styryl)-1,3-phenylene)bis(oxy))bis(carbonyl))bis(oxy))bis(butane-4,2-diyl)dipropionate
[0390] Process 1 To a solution of pyridine (1.05 g, 13.3 mmol) in DCM (10 mL) was added (2R)-4-benzyloxybutan-2-ol (1 g, 5.6 mmol) and DMAP (0.022 g, 0.18 mmol) at 0 °C. Then, propanoyl chloride (0.719 g, 7.77 mmol) was added to the mixture at 0 °C, and the mixture was stirred at 25 °C under N for 3 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by flash silica gel chromatography (petroleum ether / ethyl acetate = 100 / 1 to 70 / 1) to give [(1R)-3-benzyloxy-1-methyl-propyl]propanoate (1.2 g, 4.6 mmol, 82% yield) as a colorless oil.
[0391] Process 2 To a solution of 10% Pd / C (0.4 g) in THF (200 mL) was added [(1R)-3-benzyloxy-1-methyl-propyl]propanoate (1.2 g, 5.1 mmol), and the mixture was degassed three times, purged with H2, and stirred under 15 Psi of H2 for 12 h at 40° C. The reaction mixture was filtered and concentrated to give [(1R)-3-hydroxy-1-methyl-propyl]propanoate (0.70 mg) as a colorless oil.
[0392] Process 3 To a solution of triphosgene (0.203 g, 0.684 mmol) in THF (10 mL) was added a solution of [(1R)-3-hydroxy-1-methyl-propyl]propanoate (0.200 g, 1.37 mmol) and TEA (0.208 g, 2.05 mmol) in THF (5 mL) at 0° C. The reaction was stirred at 0° C. for 1 h. The reaction mixture was filtered and concentrated and used directly in the next step.
[0393] Process 4 To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.050 g, 0.219 mmol) and TEA (0.111 g, 1.10 mmol) in THF (5 mL) was added the above THF solution of [(1R)-3-chlorocarbonyloxy-1-methyl-propyl]propanoate at 0 °C. The reaction was stirred at 20 °C for 2 h. The reaction mixture was filtered and concentrated, and the residue was purified by preparative TLC to give [(1R)-3-[4-[(E)-2-[3,5-bis[[(3R)-3-propanoyloxybutoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxy-1-methyl-propyl]propanoate (0.030 g, 14.71% yield) as a colorless oil. LCMS: (M+Na + ):767.3 1 H NMR (400MHz, CDCl3): δ7.506(d, 2H), 7.232~6.997(m, 7H), 5.149~5.070(m, 3H), 4.363 4.290(m, 6H), 2.368~2.312(m, 6H), 2.062~1.993(m, 6H), 1.308(d, 9H), 1.555(t, 9H) [ka] Compound 78: (3R,3'R)-((((5-((E)-4-(((((R)-4-(butyryloxy)butan-2-yl)oxy)carbonyl)oxy)styryl)-1,3-phenylene)bis(oxy))bis(carbonyl))bis(oxy))bis(butane-3,1-diyl)dibutyrate
[0394] To a solution of triphosgene (0.185 g, 0.62 mmol) in THF (5 mL) (10 mL) was added a solution of [(3R)-3-hydroxybutyl]butanoate (0.200 g, 1.25 mmol) and TEA (0.189 g, 1.87 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 h. The reaction mixture was filtered and used directly in the next step.
[0395] To a solution of 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol (0.050 g, 0.219 mmol) and TEA (0.111 g, 1.10 mmol) in THF (5 mL) was added the above THF solution of [(3R)-3-chlorocarbonyloxybutyl]butanoate at 0 °C. The mixture was stirred at 20 °C for 2 h. The reaction mixture was filtered and concentrated, and the residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 5 / 1) to give [(3R)-3-[4-[(E)-2-[3,5-bis[[(1R)-3-butanoyloxy-1-methyl-propoxy]carbonyloxy]phenyl]vinyl]phenoxy]carbonyloxybutyl]butanoate (0.080 mg, 45% yield) as a colorless oil. LCMS: (M+H2O + ):804.4 1 H NMR (400MHz, CDCl3): δ7.517(m, 2H), 7.270~7.018(m, 7H), 5.103(m, 3H), 4.260~4.203 (m, 6H), 2.313(m, 6H), 2.054(m, 6H), 1.698~1.643(m, 6H), 1.431(d, 9H), 0.957(t, 9H) [ka] Compound 79: (2S,3S,4S,5R,6R)-3,4,5,6-tetrakis(propanoyloxy)oxane-2-carboxylic acid [ka] Compound 80: (2S,3S,4S,5R,6S)-3,4,5,6-tetrakis(propanoyloxy)oxane-2-carboxylic acid [ka]
[0396] Process 1 To a solution of (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid (5 g, 25.75 mmol, 1 equiv.) in propionic anhydride (25 mL), I2 (653.68 mg, 2.58 mmol, 518.79 µL, 0.1 equiv.) was added. The mixture was stirred at 25 °C for 12 h. TLC showed complete consumption of (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid. The reaction mixture was concentrated under reduced pressure. The residue was then taken up in toluene and subsequently distilled in vacuo. The crude product, (2S,3S,4S,5R)-3,4,5,6-tetrakis(propionyloxy)tetrahydro-2H-pyran-2-carboxylic anhydride (7 g, crude), was obtained as a brown liquid.
[0397] Process 2 To a solution of (2S,3S,4S,5R)-3,4,5,6-tetrakis(propionyloxy)tetrahydro-2H-pyran-2-carboxylic anhydride (7 g, 16.73 mmol, 1 equiv.) in DCM (70 mL) was added BnOH (3.62 g, 33.46 mmol, 3.48 mL, 2 equiv.), and the mixture was stirred at 25° C. for 12 h. TLC showed that (2S,3S,4S,5R)-3,4,5,6-tetrakis(propionyloxy)tetrahydro-2H-pyran-2-carboxylic acid anhydride (propionic acid) was completely consumed, and a new major spot was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 6:1). Compound benzyl (2S,3S,4S,5R)-3,4,5,6-tetra(propanoyloxy)tetrahydropyran-2-carboxylate (1.5 g, crude) was obtained as a yellow oil. The residue was purified by preparative HPLC ([water (10 mM The product was purified by HCl (HCl, ...
[0398] Process 3 To a solution of benzyl (2S,3S,4S,5R,6R)-3,4,5,6-tetra(propanoyloxy)tetrahydropyran-2-carboxylate (30 mg, 59.00 μmol, 1 equiv.) in THF (5 mL) was added Pd / C (3 mg, 59.00 μmol, 10% purity, 1.00 equiv.). The suspension was degassed and purged with H2 three times. The mixture was stirred under H2 (15 Psi) at 25 °C for 12 h. LC-MS showed that the desired compound was detected. Filtration and concentration under reduced pressure gave the residue. The residue was purified by preparative HPLC ([water (0.1% TFA)-ACN]). (2S,3S,4S,5R,6R)-3,4,5,6-tetra(propanoyloxy)tetrahydropyran-2-carboxylic acid, compound 79 (5.3 mg, 12.67 μmol, 21.47% yield, 100% purity), was obtained as a yellow solid. Compound IDs were tentatively assigned. No further structure was confirmed by 2D NMR. LCMS: (M+18)+: 436.1 @ 3.215 min. 1 H NMR (400MHz, CDCl3): δ6.35(s, 1H), 5.49(t, J=9.6Hz, 1H), 5.22(t, J=9.8Hz, 1H), 5.07(d, J=10.1H) z, 1H), 4.42(s, 1H), 2.50~2.36(m, 2H), 2.34~2.14(m, 6H), 1.13(t, J=7.6Hz, 3H), 1.07~0.97(m, 9H)
[0399] Process 4 To a solution of benzyl (2S,3S,4S,5R,6S)-3,4,5,6-tetra(propanoyloxy)tetrahydropyran-2-carboxylate (50.00 mg, 98.33 μmol, 1 equiv.) in THF (5 mL) was added Pd / C (3 mg, 98.33 μmol, 10% purity, 1.00 equiv.). The suspension was degassed and purged with H2 three times. The mixture was stirred under H2 (15 Psi) at 25 °C for 12 h. LC-MS showed that the desired compound was detected. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC ([water (0.1% TFA)-ACN]). Compound 80, (2S,3S,4S,5R,6R)-3,4,5,6-tetra(propanoyloxy)tetrahydropyran-2-carboxylic acid (11 mg, 26.29 μmol, 26.74% yield, 100% purity), was obtained as a yellow oil. Compound IDs were tentatively assigned. No further structure was confirmed by 2D NMR. LCMS: (M+18)+: 436.1 @ 3.125 min. 1 H NMR (400MHz, CDCl3): δ5.84(d, J=7.6Hz, 1H), 5.42~5.27(m, 2H), 5.19(t, J=8.3Hz, 1H), 4.28(d, J=9.2Hz, 1H), 2.46~2.24(m, 8H), 1.18~1.06(m, 12H) [ka] Compound 81: (2S,3S,4S,5R,6R)-3,4,5,6-tetrakis(butanoyloxy)oxane-2-carboxylic acid
[0400] This compound was prepared following a modified procedure described for the preparation of compounds 79 and 80. LCMS: (M+Na + ):492.2. 1H-NMR (400MHz, CDCl3): δ6.26 (d, J=3.7Hz, 1H), 5.49 (t, J=9.9Hz, 1H), 5.16 (t, J=10.0Hz, 1H), 5.05 (dd, J=10.2, 3.7Hz, 1H) , 4.12(d, J=10.3Hz, 1H), 2.34(t, J=7.4Hz, 2H), 2.28~2.09(m, 6H), 1.69~1.58(m, 2H), 1.58~1.42(m, 6H), 0.95~0.78(m, 12H) [ka] Compound 82: (2S,3S,4S,5R,6S)-3,4,5,6-tetrakis({[3-(1H-indol-3-yl)propanoyl]oxy})oxane-2-carboxylic acid [ka]
[0401] To a mixture of (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid (0.2 g, 1.03 mmol, 1 equiv.) and 3-(1H-indol-3-yl)propanoic acid (1.17 g, 6.18 mmol, 6 equiv.) in DCM (10 mL), DIPEA (1.07 g, 8.24 mmol, 1.44 mL, 8 equiv.) and COMU (2.65 g, 6.18 mmol, 6 equiv.) were added in one portion at 25 °C under N2. The mixture was stirred at 50 °C for 12 h. LCMS showed that the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40 10u; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 30%-55%, 11 min) to give (2S,3S,4S,5R)-3,4,5,6-tetrakis[3-(1H-indol-3-yl)propanoyloxy]tetrahydropyran-2-carboxylic acid (88 mg, 8.77 umol, yield 8.51e-1%, purity 96.37%) as a white solid. LCMS: (MH +)877.2@1.375 minutes. LCMS:(M+18)896.3@2.832 minutes. 1 H NMR (400 MHz, methanol-d4): δ 7.5–6.8 (m, 20H), 5.8 (d, 1H), 5.4–5.3 (m, 1H), 5.3–5.2 (m, 1H), 5.2–5.1 (m, 1H), 4.1 (d, 1H), 3.0–2.0 (m, 16H) [ka] Compound 83: (2R,3R,4R,5R)-3,5-bis(butanoyloxy)-2-methoxyoxan-4-ylbutanoate
[0402] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0403] LCMS: (m+H+)=375.4. 1 H NMR (400MHz, DMSO-d6) δ5.28(t, 1H), 5.08(q, 1H), 4.90(td, 1H), 4.69(d, 1H), 3.92 (dd, 1H), 3.68(dd, 1H), 3.34(s, 3H), 2.39~2.16(m, 6H), 1.54(m, 6H), 0.88(m, 9H). [ka] Compound 84: (2R,3R,4R,5R)-2-methoxy-3,5-bis(propanoyloxy)oxan-4-ylpropanoic acid salt
[0404] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0405] LCMS: (m+H+)=355.3. 1H NMR (400MHz, DMSO-d6) δ5.26(t, 1H), 5.07(q, 1H), 4.94~4.84(m, 1H), 4.71(d, 1H), 3.92(dd, 1H), 3.69(dd, 1H), 3.35(s, 3H), 2.45~2.17(m, 6H), 1.02(dt, 9H) [ka] Compound 85: (2S,3R,4S,5S)-3,5-bis(butanoyloxy)-2-methoxyoxan-4-ylbutanoate
[0406] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0407] LCMS: (M+Na+) 397.3. 1 H NMR (400MHz, DMSO-d6) δ5.27(dt, 1H), 5.24(dd, 1H), 5.04(dd, 1H), 4.90(d, 1H), 3.89(dd, 1H), 3.61(dd, 1H), 3.32(s, 3H), 2.39~2.13(m, 6H), 1.65~1.42(m, 6H), 0.97~0.80(m, 9H). [ka] Compound 86: (2S,3R,4S,5S)-2-methoxy-3,5-bis(propanoyloxy)oxan-4-ylpropanoic acid salt
[0408] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0409] LCMS: (M+Na+) 355.3. 1 H NMR (400MHz, DMSO-d6) δ5.27(dt, 1H), 5.23(dd, 1H), 5.04(dd, 1H), 4.90(d, 1H), 3.89(dd, 1H), 3.62(dd, 1H), 3.32(s, 3H), 2.45~2.10(m, 6H), 1.12~0.91(m, 9H). [ka] Compound 87: [(2R,3R,4S,5R,6S)-3,4,5-tris(butanoyloxy)-6-methoxyoxan-2-yl]methylbutanoate
[0410] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0411] LCMS: (M+Na+) 497.2. 1 H NMR (400MHz, DMSO-d6) δ5.34(dd, 1H), 5.00(t, 1H), 4.92(d, 1H), 4.83(dd, 1H), 4.14(dd, 1H) ), 4.10~3.88(m, 2H), 3.34(s, 3H), 2.35~2.08(m, 8H), 1.60~1.40(m, 8H), 0.93~0.78(m, 12H) [ka] Compound 88: [(2R,3R,4S,5R,6S)-6-Methoxy-3,4,5-tris(propanoyloxy)oxan-2-yl]methylpropanoate
[0412] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0413] LCMS: (M+Na+) 441.2. 1 H NMR (400MHz, DMSO-d6) δ5.32(dd, 1H), 4.99(t, 1H), 4.92(d, 1H), 4.85(dd, 1H), 4.17(dd , 1H), 4.06(dd, 1H), 3.93(ddd, 1H), 3.34(s, 3H), 2.39~2.11(m, 8H), 1.09~0.92(m, 12H) [ka] Compound 89: [(2R,3S,4S,5R,6S)-3,4,5-tris(butanoyloxy)-6-methoxyoxan-2-yl]methylbutanoate
[0414] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0415] LCMS: (M+Na+) 497.2. 1 H NMR (400MHz, DMSO-d6) δ5.40(dd, 1H), 5.27(dd, 1H), 5.04(dd, 1H), 4.97(d, 1H), 4.22(t, 1H) ), 4.15~3.97(m, 2H), 3.35(s, 3H), 2.47~2.07(m, 8H), 1.69~1.38(m, 8H), 1.01~0.77(m, 12H) [ka] Compound 90: [(2R,3S,4S,5R,6S)-6-Methoxy-3,4,5-tris(propanoyloxy)oxan-2-yl]methylpropanoate
[0416] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0417] LCMS: (M+Na+): 441.1. 1 H NMR (400MHz, DMSO-d6) δ5.40(dd, 1H), 5.27(dd, 1H), 5.05(dd, 1H), 4.98(d, 1H), 4.22(ddd, 1H), 4.07(d, 2H), 3.36(s, 3H), 2.49~2.11(m, 8H), 1.15~0.94(m, 12H) [ka] Compound 91: [(2R,3R,4S,5R,6R)-3,4,5-tris(butanoyloxy)-6-methoxyoxan-2-yl]methylbutanoate
[0418] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0419] LCMS: (M+Na+): 497.1. 1 H NMR (400MHz, DMSO-d6) δ5.33(t, 1H), 4.96(t, 1H), 4.81(dd, 1H), 4.19(dd, 1H), 4.12 ~3.97(m, 2H), 3.39(s, 3H), 2.38~2.10(m, 8H), 1.64~1.38(m, 8H), 0.97~0.77(m, 12H) [ka] Compound 92: [(2R,3R,4S,5R,6R)-6-methoxy-3,4,5-tris(propanoyloxy)oxan-2-yl]methylpropanoate
[0420] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0421] LCMS: (M+Na+) 441.1. 1 H NMR (400MHz, DMSO-d6) δ5.31(t, 1H), 4.95(t, 1H), 4.80(dd, 1H), 4.74(d, 1H), 4.2 4(dd, 1H), 4.10~3.99(m, 2H), 3.39(s, 3H), 2.41~2.13(m, 8H), 1.09~0.91(m, 12H) [ka] Compound 93: [(2R,3S,4S,5R,6R)-3,4,5-tris(butanoyloxy)-6-methoxyoxan-2-yl]methylbutanoate
[0422] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0423] LCMS: (M+Na+) 497.1. 1H NMR (400MHz, DMSO-d6) δ5.30(dd, 1H), 5.22(dd, 1H), 4.99(dd, 1H), 4.64(d, 1H), 4.28~4.20(m , 1H), 4.15~3.96(m, 2H), 3.38(s, 3H), 2.43~2.06(m, 8H), 1.53(ddq, 8H), 0.99~0.79(m, 12H). [ka] Compound 94: [(2R,3S,4S,5R,6R)-6-Methoxy-3,4,5-tris(propanoyloxy)oxan-2-yl]methylpropanoate
[0424] This compound was prepared following a modified procedure described for the preparation of compound 53.
[0425] LCMS(M+Na): 441.1. 1 H NMR (400MHz, DMSO-d6) δ5.30(dd, 1H), 5.20(dd, 1H), 4.98(dd, 1H), 4.65(d, 1H), 4.24(td, 1H), 4.18~4.01(m, 2H), 3.39(s, 3H), 2.48~2.08(m, 8H), 1.03(ddt, 12H) [ka] Compound 95: (2S,3R,4R,5S)-6-hydroxy-4,5-bis({[3-(1H-indol-3-yl)propanoyl]oxy})-2-methyloxan-3-yl 3-(1H-indol-3-yl)propanoate
[0426] This compound was prepared according to the procedure described for compound 197, except that the synthesis was stopped after compound 95 was produced. LCMS: (MH): 676.3. 1H NMR (400 MHz, chloroform-d): δ 7.77–6.47 (m, 18H), 5.42–5.32 (m, 1H), 5.29–5.22 (m, 1H), 5.12–5.03 (m, 1H), 4.69–4.62 (m, 1H), 4.41–4.35 (m, 1H), 3.87–3.81 (m, 1H), 3.20–3.00 (m, 4H), 2.90–2.75 (m, 4H), 2.74–2.59 (m, 2H), 2.12–1.97 (m, 2H), 1.22–1.07 (m, 3H). [ka] Compound 96: (2S,3S,4S,5R,6S)-3,4,5,6-tetrakis({[2-(1H-indol-3-yl)acetyl]oxy})oxane-2-carboxylic acid [ka]
[0427] To a mixture of (2S,3S,4S,5R,6S)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid (200 mg, 1.03 mmol, 1 equiv.) and 2-(1H-indol-3-yl)acetic acid (1.08 g, 6.18 mmol, 6 equiv.) in DCM (10 mL), COMU (2.65 g, 6.18 mmol, 6 equiv.) and DIPEA (1.07 g, 8.24 mmol, 1.44 mL, 8 equiv.) were added in one portion at 25 °C under N2. The mixture was stirred at 50 °C for 12 h. LCMS showed that the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40 10u; mobile phase: [water (10mM NH4HCO3)-MeOH]; B%: 25%-45%, 11 min) to give compound 96, (2S,3S,4S,5R)-3,4,5,6-tetrakis(2-(1H-indol-3-yl)acetoxy)tetrahydro-2H-pyran-2-carboxylic acid (5 mg, 5.48 μmol, yield 0.532%, purity 90.23%) as a...
Claims
1. A composition comprising an active agent for use in modulating a metabolic marker or a non-alcoholic fatty liver disease marker in a subject in need thereof, said active agent having the following structure: The composition is a compound of the formula:
2. A composition comprising an active agent for use in ameliorating a metabolic disorder or non-alcoholic fatty liver disease in a subject in need thereof, said active agent having the following structure: The composition is a compound of the formula:
3. The composition described in claim 1, wherein the metabolic marker is for an obesity disorder.
4. The composition described in claim 2, wherein the metabolic disorder is an obesity disorder.
5. A composition described in any one of claims 1 to 4, wherein total fat percentage, cellular fat, body mass index, weight gain rate, abdominal fat mass, ratio of white fat to brown fat, level of lipid biosynthesis, or level of fat storage is reduced following administration of the composition.
6. The composition described in claim 5, wherein the total fat percentage, cellular fat, body mass index, abdominal fat mass, or ratio of white fat to brown fat is reduced after administration of the composition.
7. A composition described in any one of claims 1 to 6, wherein the subject is overweight or suffers from obesity, severe obesity, morbid obesity, or extreme obesity.
8. The method of claim 1, wherein the level of insulin, GLP-1, or PYY is increased following administration of the composition to the subject. blood glucose or hemoglobin A1c levels are reduced following administration of the composition to the subject; and / or glucose tolerance is increased following administration of the composition to the subject. The composition according to any one of claims 1 to 7.
9. The composition of claim 1, wherein the active agent is administered orally to the subject.
10. The composition of claim 9, wherein the active agent is cleavable in the gastrointestinal tract of the subject following oral administration to the subject.
Citation Information
Patent Citations
Agents for the treatment of tumors, especially ovarian and hematopoietic tumors, containing quercetin compounds as active substance
JP1995502009A
Xanthine oxidase inhibitor
JP2002145875A
Quercetin derivatives, their pharmaceutical composition and use
WO2013130020A1
